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Abstract 
The aim of this work was to screen the IL12p40 gene promoter for 
association with TB disease.  Initially a subcohort of children (TB cases and 
healthy controls) from a TB-endemic area was screened for DNA changes by 
the WAVE method.  Thereafter, the entire paediatric cohort and a cohort of 
healthy adult controls were screened by Amplification Refractory Mutation 
System PCR.  Functional testing was done by reporter assay and 
immunological phenotype was investigated by measurement of cytokines 
levels and cytokine receptor expression. 
WAVE screening identified two heterozygous SNPs, -1523 A/G and -1564 
C/T.  Statistical analysis showed that -1523 A/G may be protective against 
TB disease (p=0.02).  This possibility was supported by the location of -1523 
A/G occurring within a GTATA sequence reported to bind nuclear proteins.  
Specific ARMS-PCR assays were then designed for screening of additional 
paediatric subjects and healthy adult controls for these SNPs.  Analysis of the 
larger group, showed that -1564 C/T may contribute to susceptibility to TB 
disease (p=0.03)  Exploring functional relevance, normal and mutant 
promoter fragments were PCR amplified, using uniquely adapted primers that 
included restriction sites corresponding to those in the multiple cloning site of 
an expression vector, facilitating cloning.  A truncated promoter and one with 
essential regions deleted, were created as negative controls.  These five 
promoter fragments were cloned into the expression vector and functional 
differences tested by reporter.  No significant functional differences between 
variant and normal promoter fragments were observed.  A predictive immune 
phenotype was investigated by measurement of IFN, TNF and IL12p70 
cytokine levels and IL12R1 receptor expression.  While distinct patterns of 
cytokine responses were seen, these did not predict genotype.  These results 
show that the IL12p40 gene promoter is highly conserved and sequence 
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CHAPTER 1:  
An overview of the IL12/IL23/IFN pathway and 
genetic susceptibility to mycobacterial infection and 
Mycobacterium tuberculosis 
1.1 Introduction  
Tuberculosis (TB) has caused the death of more people than any other 
single infectious agent, making it the most successful pathogen known 
to man.  In Europe at the beginning of the nineteenth century the 
mortality was between 200 and 300 per 100 000 population. Today, 
the most optimistic global scenarios predict in excess of 80 million new 
cases and 20 million deaths in the next decade, 95% of which will 
occur in resource-poor countries. 
TB remains an important cause of morbidity and has only been 
displaced from the position of leading infectious cause of death by the 
arrival of the human immunodeficiency virus (HIV).  
Approximately one third of the human population is infected with 
Mycobacterium tuberculosis (M. tb), but the disease will only develop 
from latent infection to active disease in five - ten percent of 
immunocompetent individuals (WHO Report 2011: Global tuberculosis 
Control).  Estimated global TB incidence rates per 100 000 population 




Figure 1.1: Estimated global TB incidence rates 2011.   
Source:http://gamapserver.who.int/mapLibrary/Files/Maps/Global_TB_incidence_20
11.png 
There are many factors predisposing people to infection with 
mycobacterial species, including M. tb.  These include environmental 
factors like malnutrition and poor socio economic living conditions, 
Mendelian disorders affecting immune function, such as Severe 
Combined Immunodeficiency (Marchand et al. 2008), X-linked Chronic 
Granulomatous Disease (CGD) (Bustamante et al. 2007a, Lee at al 
2008) and cystic fibrosis (Giron et al. 2008), secondary 
immunodeficiencies such as HIV (Bekker and Wood 2010) and 
autoimmune disease (Harris and Keane 2010).   
Aside from HIV, the strong association between poverty and TB due to 
overcrowding, inadequate ventilation and malnutrition allow TB 
infection to be more readily transmitted.  Many of the poorest 
countries of the world have experienced massive population expansion 
that, together with limited resources for infrastructure development 
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and poor civic planning, have led to sprawling informal settlements.  It 
is estimated that about 80% of the urban population of these countries 
live in slums (UN-Habitat, 2013).  The poor socio-economic and 
environmental conditions characterizing these areas, facilitate the 
transmission of infectious diseases, including TB. 
Evidence suggests that there are genetic components responsible for a 
predisposition to mycobacterial infection.   
1.2 Approaches used in Genetic Studies 
Different approaches have been used for the identification of genes 
responsible for susceptibility or resistance to disease (Casanova and 
Abel 2002, Burgner et al. 2006).  
The Human Genome Project (HGP) opened up avenues for 
understanding the molecular basis of health and disease (Peltonen et 
al. 2001).  Prior to the HGP, understanding of the molecular basis of 
disease  evolved through family based linkage studies based on clinical 
data and association studies, to map the genes responsible for 
Mendelian disorders (Glazier et al. 2002).  Several methods can be 
used for each approach.  
Studies of inbred families with two or more affected siblings look for 
genetic linkage by searching for areas of the genome which have 
alleles that are homozygous in all affected family members (Newport 
et al. 1996).  Microsatellite markers can be used to scan an entire 
genome for alleles that are shared by only the affected family 
members.  Once a locus has been identified, further studies can be 
carried out to find the genetic variant.  This approach was often 
favoured as it avoided the need for a hypothesis about the candidate 
gene (Newport 2009).  It is however unlikely to detect any loci that 
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exert a moderate effect on disease susceptibility, so is best suited for 
study of single gene disorders.  
Affected sibling pair (ASP) methodology, which looks for genetic 
similarities in siblings who share a trait was often used, because, 
unlike other linkage approaches, the mode of inheritance (eg recessive 
or dominant) was not required to be known.  The ASP approach also 
avoids bias that could be introduced if healthy subjects were classified 
as resistant to disease when they were genetically susceptible, but not 
exposed to environmental trigger.  The main limitation of ASP studies 
is the lack of power for detecting genes with weak effects, likely to be 
the case with complex diseases like insulin-dependent diabetes 
(Davies et al. 1994, Kapur et al. 2012). 
Previously, association studies, searching for genetic differences 
between unrelated cases and controls in populations as opposed to 
families, had more power, but were limited to candidate genes, due to 
the large number of polymorphisms that would need to be typed for a 
genome- wide approach (Freimer et al. 2004).  Genome wide 
association studies have extended the scope of genetic studies and 
today are widely used in genetic susceptibility studies. 
Case control studies are often used in candidate gene association 
studies.  Once a candidate gene has been identified, the whole gene 
may be sequenced in a small cohort, looking for single nucleotide 
polymorphisms (SNPs).  The frequency of the variant allele is 
measured in cases and controls, looking for association.  As SNP 
frequencies can differ between populations, resulting in conflicting 
results, very large numbers of cases and controls are required for such 
studies to be valid.   
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As the HGP, progressed, parallel projects paved the way for genome 
wide association studies (GWAS) for multifactorial diseases.  These 
were the Single Nucleotide Polymorphism Consortium that reported 
1.42 million SNPs distributed throughout the human genome (The 
international SNP Map Working Group 2001), the International HapMap 
project and a second generation human haplotype map of over 3.1 
million SNPs from genotyping 270 individuals from four geographical 
diverse populations (The International HapMap Consortium 2003, 
International HapMap Consortium 2007). 
Genome wide association studies (GWAS) central provides a 
centralized database of genetic association studies, collating findings 
from studies and listing publications (Newport and Finan 2011, 
www.gwascentral.org ).  In this way, GWAS are able to identify 
common genetic factors that influence disease that could be targets for 
new vaccines and drugs.  The Wellcome Trust Case Control Consortium 
(WTCCC) conducted a GWAS study of 14 000 cases of seven common 
disorders and 3000 shared controls, demonstrating the feasibility of 
large scale studies (Wellcome Trust Case Control Consortium 2007).   
Animal studies have evaluated genetic susceptibility to infectious 
diseases, including tuberculosis.  A study done by Bekker et al. 2000, 
using a Tumour Necrosis Factor Alpha (TNF) knockout murine model 
looked at immunopathologic effects of mycobacterial infection. Tobin 
et al. 2010 carried out a genetic screen on zebrafish larvae and 
identified mutant classes showing susceptibility to Mycobacterium 
marinum.  A hypersusceptible mutant mapped to lta4h locus, encoding 
leukotriene A4 hydrolase, which catalyses the final step in the 
synthesis of leukotriene B4, a chemoattractant and proinflammatory 
eicosanoid.  The resultant anti-inflammatory state was shown to 
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permit mycobacterial infiltration by limiting production of TNF, a key 
anti-inflammatory molecule. This research group extended the animal 
work to humans, observing that significant protection from 
tuberculosis and leprosy were associated with heterozygosity for 
LTA4H polymorphisms in Vietnamese and Nepali cohorts respectively. 
Conversely, Curtis et al. 2010 genotyped six LT4AH gene 
polymorphisms in samples from 9115 Russian subjects (3703 patients 
with pulmonary tuberculosis and 5412 healthy controls) and found no 
evidence that these common polymorphisms provide protection 
against pulmonary tuberculosis. 
Today, many genes are being identified through microarray gene chip 
and gene expression technologies, allowing quicker and more efficient 
identification of candidate genes (Mistry et al. 2007, Berry et al. 2010, 
Lesho et al. 2011, Maertzdorf et al. 2012, Verhagen et al. 2012, 
Anderson et al. 2014).  Blood transcriptional profiling has improved 
diagnosis and understanding of TB.   
The different approaches used for genetic studies are summarized 




Requirements Advantages Disadvantages 
Family studies    
Genetic linkage 
2 or more affected 




Loci with moderate 
effect not detected 





Lack of power 
Association 
studies 
   
Case control 
studies 
2 or more affected 
siblings and matched 
controls 
More power 
Limited to candidate 
genes 
GWAS studies 
Large numbers of 
cases and controls 
























   
Exome capture 
Large numbers of 










Table 1.1: Approaches used in genetic studies 
1.3 Early association studies and identification of the 
Mendelian susceptibility genes of the IL12/IL23/IFN 
pathway 
Using technology available in the 1990s, the main candidate genes 
that appeared to be associated with mycobacterial disease were 
investigated by linkage analysis and association studies.  These studies 
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looked at significant associations between specific gene polymorphisms 
and phenotypes within families and populations. 
This led to the identification of Mendelian susceptibility genes of the 
IL12/IL23/IFN pathway that may be mutated in children and adults 
with a predisposition to mycobacterial disease. 
The IL12/IL23/IFN pathway, also known as the type I cytokine 
pathway, plays an important role in the protection of individuals 
against mycobacterial infection.  This pathway consists of several 
genes including interferon gamma receptor 1 (IFNR1), interferon 
gamma receptor 2 (IFNR2), interferon gamma (IFN), interleukin 12 
receptor beta 1 (IL12R1), (interleukin 12 receptor 2 (IL12R2), 
interleukin 12 (IL12) and signal transducer and activator of 
transcription 1 (STAT1) (Casanova 2001, Doffinger et al. 2001).  
Molecular analysis of patients with defects in the genes of this pathway 
has provided evidence of the genetic component and highlighted the 
importance of the IL12/IFN pathway in host defence against 
intracellular pathogens, including mycobacteria, Salmonella and some 
viruses (Casanova 2001).  About a third of patients with idiopathic 
disseminated poorly pathogenic mycobacteria and/or systemic 
salmonella infections have been found to have mutations in the genes 
of this pathway (Altare et al. 1998d).  Parental consanguinity and 
familial forms are frequently observed in affected individuals and this 
syndrome has subsequently been designated Mendelian Susceptibility 
to Mycobacterial Disease (MSMD). 
Patients with MSMD caused by single gene defects in the 
IL12/IL23/IFN pathway are primarily susceptible to non-tuberculous 
mycobacterial infections (NTM), but may also develop TB.  The study 
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of patients with NTM infections has added to our understanding of the 
mechanisms responsible for susceptibility to disease from M. tb. 
The following is a description of the major genes of the IL12/IL23/IFN 
pathway. 
1.3.1 Major genes of the IL12/IL23/IFN pathway associated 
with MSMD 
1.3.1.1 Interferon gamma receptor 1 and 2 (IFNR1 and R2) 
The gene loci for IFNR1 and IFNR2 are chromosomes 6q23-6q24 and 
21q22.1-22.2 and each gene has seven exons (Soh et al. 1994, Farrar 
and Schreiber 1993). 
Functional IFN receptors are composed of two 90 kDa IFNR1 (ligand 
binding chain) proteins and two 62 kDa IFNR2 (signal transducing 
chain) proteins.  Both IFNR1 and IFNR2 are expressed by phagocytic 
and dendritic cells (Pfizenmaier et al. 1988, Soh et al. 1994, Cook et 
al. 1994).  
The extracellular portion of IFNR1 contains the ligand binding domain 
and the intracellular portion contains domains necessary for signal 
transduction and receptor recycling (Farrar et al. 1991, Kotenko et al. 
1995, Bach et al. 1997). 
IFN signaling is an ordered, affinity driven process that derives its 
specificity from the specific binding site of a particular signal 
transducer and activator of transcription (STAT) protein to a defined, 
ligand-induced docking site on the activated receptor and the ability of 
the STAT1 homodimer to specifically activate IFN induced gene 
transcription (Bach et al. 1997). 
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Two IFN proteins bind as a homodimer to the two IFNR1 ligand 
binding chains that then dimerise and become associated with two 
IFNR2 signal transducing chains.   
The extracellular domain of IFNR2 interacts with the IFNR1/IFN 
complex (Bach et al. 1997). 
Receptor assembly leads to activation of the JAK1 and JAK2 and 
phosphorylation of a tyrosine residue on the intracellular domain of 
IFNR1.  The schematic sequence of these events is depicted in figure 




Figure 1.2: Schematic representation of the IFN signaling 
pathway. 
Source:  Newport 2003, modified figure reproduced from Bach et al. 1997   
Within the IFNR1/IFN complex, the IFNR1 and IFNR2 intracellular 
domains with their constitutively associated JAKs are brought into 
proximity.  Ligand binding results in reciprocal transphosphorylation of 
IFNR1 tyrosine 440 (Y440) (Bach et al. 1997, Igarashi et al. 1994). 
Through its SH2 domain, one latent STAT1 recognizes and binds to 
each tyrosine phosphorylated IFNR1 440tyrosine-aspartic acid-lysine-
proline-histidine444 (440YDKPH444) site.  The amino acid binding 
sites are depicted in figure 1.3. 
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Receptor associated STAT1 proteins are subsequently tyrosine 
phosphorylated, activated and form homodimers.  They are then 
phosphorylated and released into the cytosol as phosphorylated STAT1 
homodimers, forming gamma activating factors (GAFs) which are 
translocated to the nucleus.  GAFs bind gamma activating sequences 
(GASs) present in the promoters of target genes (Chen et al. 1998).  
After signaling, the ligand binding chains are internalized, dissociate 
and recycled to the cell surface (Shuai et al. 1992, Shuai et al. 1993).  
  
Figure 1.3: IFN signaling showing amino acids of binding sites. 
Source:  Bach et al. 1997 
1.3.1.2 Interferon gamma (IFN) 
Interferon family members have been segregated into two categories.  
Type I IFN is induced by cells as a result of viral infection and has been 
divided into two classes, based on cell origin.  IFN is a family of 17 
related proteins encoded by specific genes that are synthesized mainly 
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by leukocytes.  IFN is a single protein encoded by a specific gene 
produced mainly by fibroblasts. 
Type II IFN, commonly known as IFN is induced by immune and 
inflammatory stimuli and is synthesized predominantly by T 
lymphocytes and NK cells (Bach et al. 1997). 
The human IFN molecule is a non covalent homodimer consisting of 
two identical 17kD polypeptide chains (Gray et al. 1982) and was first 
identified on the basis of its in vitro antiviral activity (Wheelock 1965).  
The gene locus for IFN is chromosome 12q24.  There are four exons 
and a non-specific enhancer element in the first intron. 
IFN activates the transcription of many genes that play roles in 
antiviral activity, apoptosis, MHC protein expression, antigen 
processing and type I T helper cell (Th1) development.  IFN also 
activates macrophages to kill or restrict growth of microbial targets.  
This function appears to be important in host defense against 
mycobacteria.  In an inflammatory reaction, IFN is induced by IL12 
and IL18 secreted by macrophages and dendritic cells (Kobayashi et 
al. 1989, Seder et al. 1993, Micalief et al. 1996, Song et al. 2002).  
IFN stimulates the development and function of immune effector cells 
and also regulates the production of various other immunomodulatory 
or proinflammatory cytokines such as IL12 and TNF (Bach et al. 
1997).  As IFN plays such a major role in stimulating antimicrobial 
functions of monocytes and macrophages, people with defective 
receptors acquire disseminated infections with mycobacterial species 
of low virulence (Holland 2000). 
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1.3.1.3 Interleukin 12 receptor 1 and 2 (IL12R1 and 2) 
The IL12R is composed of two chains, IL12R1 and IL12R2, both of 
which have extensive homology to gp130, the common receptor  
chain of the IL6-like cytokine superfamily.  IL12R and IL23R share the 
same IL12R1 subunit.   
The gene locus for IL12R1 is chromosome 19p13.1 and there are 16 
exons.  The gene locus for IL12R2 is chromosome 1p31.2 and there 
are 15 exons (Yamamoto et al. 1997).  
The two receptor proteins are type 1 transmembrane glycoproteins. 
Functional IL12 receptors are expressed primarily on activated T and 
NK cells (Desai et al. 1992) and co-expression of the two receptor 
units is required for high affinity binding of IL12.  The IL12R2 subunit 
functions as the signal transducing component of the high affinity 
receptor complex (Presky et al. 1996), can be expressed at the cell 
surface in the absence of IL12R1 and can be upregulated by IFN 
(Verhagen et al. 2000). 
Signal transduction through IL12R induces tyrosine phosphorylation, 
primarily of JAK2 and TYK2, which in turn phosphorylate and activate 
STAT1, STAT3, STAT4 and STAT5.  The specific cellular effects of IL12 
are due mainly to its ability to induce activation of STAT4.  
Phosphorylated STAT4 molecules then dimerise and translocate to the 
nucleus, where IL12 inducible genes with an interleukin (IL) response 
element (IL12RE) are activated (Holland 2010).  The IL12 signaling is 




Figure 1.4: schematic representation of the IL12 signaling 
pathway. 
Source:  Newport 2003, modified figure reproduced from Lammas et al. 2000 
1.3.1.4 Interleukin 12 (IL12) 
IL12 is a heterodimer of 70 000 daltons (IL12p70) comprised of two 
covalently linked glycosylated subunits of 40 000 (IL12p40) and 35 
000 (IL12p35) daltons respectively (Kobayashi et al. 1989). 
The gene locus for heavy chain IL12p40, also known as IL12B is 
5q31.1-q33.1.  The gene has 7 exons, the first of which is un-
translated.  The gene locus for light chain IL12p35, also known as 
IL12A is 3p12-q13.2 and this gene also has 7 exons. 
In human peripheral blood, IL12 is mainly produced by phagocytes 
(monocytes/macrophages and neutrophils) and dendritic cells in 
response to pathogens (bacteria, fungi, intracellular parasites and 
viruses) as a result of soluble signals from activated T cells, NK cells 
and components of the inflammatory extracellular matrix (Cassatella 
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et al. 1995, D’Andrea et al. 1992, Trinchieri 2003).  The biology of 
these components is depicted in figure 1.5. 
 
Figure 1.5: Schematic representation of the biology of IL12. 
Source:  Trinchieri 2003 
IL12 plays an important role in promoting Th1 responses and 
subsequent cell mediated immunity (Hsieh et al. 1993, Manetti et al. 
1993, Afonso et al. 1994).  Production of IL12 stimulated by microbial 
lipoproteins, including a 19 kD M. tb lipoprotein is mediated by TLRs 
(Brightbill et al. 1999). 
IL12 enhances proliferation and cytotoxic activity of NK cells and T 
cells and stimulates their IFN production which together with other 
secondary and tertiary pro-inflammatory cytokines, have a direct toxic 
effect on tumour cells (Trinchieri 1994).    
In addition to the augmentation of cellular immune responses, IL12 
also augments the production of opsonizing and complement-fixing 
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classes of IgG antibodies that have been shown to have anti-tumour 
activity in vivo (Quaglino et al. 2002).   
IL12p40 associates not only with IL12p35 to form IL12p70, but also 
with p19 to form a heterodimeric cytokine IL23 (Oppmann et al. 
2000), shown in figure 1.6  Although IL23 and IL12p40 share the 
common p40 subunit, these cytokines have divergent activities 
(Oppmann et al. 2000, Langrish et al. 2005). 
 
Figure 1.6: The subunits of IL12 and IL23. 
Source:  Trinchieri 2003 
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Activated dendritic cells secrete detectable levels of IL23 which bind to 
IL12R1 and a second chain IL23R (Parham et al. 2002).   
IL23 induces the same JAK-STAT signaling molecules (JAK2, TYK2, 
STAT1, STAT3, STAT4 and STAT5) as does IL12, but it induces 
different DNA binding STAT dimers (Parham et al. 2002), possibly 
explaining the overlapping but not identical activities of the two 
cytokines.  Similar to IL12, human IL23 stimulates IFN production and 
proliferation in PHA blast T cells as well as in CD45RO memory T cells 
(Oppmann et al. 2000).  IL23 is an essential factor required for the 
expansion of a pathogenic CD4+ T cell population, which is 
characterized by the production of IL17, IL17F, IL6 and TNF.   
Humans lacking the common IL12p40 subunit are particularly 
susceptible to mycobacterial disease (Filipe-Santos et al. 2006) and 
this deficiency may reflect a role of both IL12 and IL23 in control of 
infection.   
IL12p40 and IL12R1 deficiencies also cause defects in IL23 and IL23R 
respectively.  As IL12 and IL23 share the p40 subunit, IL12p40 
deficiency should cause both defective IL12 and IL23 function.  
Likewise, as IL12R and IL23R use the IL12R1 subunit, IL12R1 
deficiency should cause defective IL12R and IL23R function (van de 
Vosse et al. 2004). 
Pedraza et al. 2010 reported two IL12Rβ1 deficiency patients affected 
with Klebsiella pneumoniae infections. They hypothesized that the 
infections could be due to a limited capacity to produce IL17.  This 
impaired IL23-dependent IL17 immunity in IL12p40 and IL12Rβ1 
deficiency patients may explain why Salmonella infection is 10X more 
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frequent in these patients than in IFNγR deficiency patients whose 
IL23/IL17 circuit is intact.   
In contrast to the protective role for IL23, there have also been 
reports of increased pathologic consequences related to IL23 (Cruz 
2010).  This highlights the fact that for chronic disease like TB, a 
balance in the level of IL23 is important.  High levels of the cytokine 
may be detrimental and with low levels, there is loss of protection 
against disease (Khader et al. 2011). 
1.3.1.5 Signal transducers and activators of transcription 
(STAT)s 
STATs serve as links between the cell surface and the nucleus and this 
requires their physical movement from the cytoplasm to the nucleus.   
STATs are DNA binding factors that are regulated directly by tyrosine 
phosphorylation (Shuai et al. 1993), which confers new properties to 
STAT factors by inducing dimerization via reciprocal phosphorylation 
and Src homology 2 (SH2) domain interactions.  This conformational 
change is essential for binding to specific DNA targets. 
The gene locus for STAT1 is 2q32.2, there are 23 exons, the first of 
which is untranslated.  STAT1 was originally identified as a latent 
cytosolic transcription factor involved in signaling of IFN for antiviral 
immunity and IFN for anti-mycobacterial immunity and has since 
been shown to be activated by a wide variety of cytokines and growth 
factors (Darnell et al. 1994).  In response to cytokines and growth 
factors, STAT1 family members are phosphorylated by the receptor 
kinases.  They then form homodimers or heterodimers that translocate 
to the cell nucleus, where they act as transcription factors.  The STAT 
proteins can be activated by various ligands, including IFN. 
20 
 
STAT1 signaling is shown in figure 1.7. 
 
Figure 1.7:  IFN and INF signaling showing antiviral immunity 
by IFN and anti-mycobacterial immunity by IFN. 
Source:  Haverkamp et al. 2006 
STAT4 has also been shown to be important for protection against 
mycobacterial disease.  A study done by Sabri et al. 2014 showed 
association between a STAT4 SNPs and pulmonary TB in a Moroccan 
population. 
STAT4 was initially cloned as a result of its homology with STAT1 
(Yamamoto et al. 1994), is widely expressed and is only tyrosine 
phosphorylated after stimulation of T cells with IL12.  Experiments 
with mice lacking STAT4 showed that all IL12 functions were 
disrupted, including the induction of IFN (Wang et al. 2014). 
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Kim et al. 2008 reported decreased phosphorylation of STAT1 and 
STAT4 in patients with multi drug resistant TB. 
Toyoda et al. 2004 have examined the immunological abnormality in a 
patient with recurrent Mycobacterium avium (M. avium) infection and 
the defect seemed likely to be impaired STAT4 nuclear translocation in 
IL12 stimulated T cells, leading to impairment of IFN production.     
1.3.1.6 IL12/IL23/IFN pathway interactions  
When macrophages are infected with mycobacteria, biologically active 
IL12p70 binds to the high affinity receptor IL12R on NK cells, CD4+T 
helper cells and cytotoxic T cells.  Binding of IL12 to the heterodimeric 
IL12R complex induces intracellular events, resulting in the activation 
of IL12 inducible genes including those encoding IFN.  The secretion 
of IFN by NK and T cells elicits a cell mediated immune response to 
intracellular pathogens within the infected macrophage by binding to 
the IFNRs on the macrophages.  As the ligand binding chains interact 
with the IFN, they dimerise and induce intracellular events that 
activate, via STAT1, a range of IFN responsive genes.  This sequence 




Figure 1.8: Overview of the IL12/IL23/IFN pathway, including 
signal transduction and transcription of IFN response genes, 
with stars denoting proteins that are encoded by mutated 
genes associated with MSMD. 
Source: Dr S. Anderson 2002 (personal communication) 
1.4 Reported Mutations of the IL12/IL23/IFN Pathway 
Causing MSMD 
The elucidation of the critical role of IFNR genes in control of 
mycobacterial infection came about with the identification of kindreds 
in whom affected individuals had severe infection with poorly virulent 
NTM in the absence of a known immunodeficiency (Uchiyama et al. 
1981, Newport and Levin 1994).  
IFNR1 deficiency was the first human mycobacterial susceptibility 
gene to be identified (Newport et al. 1996, Jouanguy et al. 1996). 
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Four children from the same small town in Malta where intermarriage 
between families is common, presented with disseminated atypical 
mycobacterial infection in the absence of any recognized 
immunodeficiency.  Each child was infected with a different species or 
strain of mycobacterium, viz M. fortuitum, M. avium and M. cheloni, as 
well as severe recurrent infections with Salmonella, suggesting a 
defect in host immunity. 
The partial consanguinity suggested a Mendelian disorder of autosomal 
recessive inheritance (Levin and Newport 1995). 
Immunologic investigation showed reduced TNF production in 
response to stimulation with IFNplus endotoxin in a whole blood 
assay (Levin et al. 1995).  A subsequent genome-wide search using 
microsatellite analysis identified a region on chromosome 6q for which 
all affected children in this family were homozygous (Newport et al. 
1996).  The gene encoding IFNR1 was known to map to that 
chromosomal region and this was further investigated.  Lymphocytes 
from patients were shown to lack expression of IFNR1 protein and 
DNA sequencing revealed that the affected patients were homozygous 
for a point mutation C395A that resulted in a premature termination 
codon S116X. 
At the same time, the report of a Tunisian infant with disseminated 
vaccine associated BCG infection and a different mutation 131delC in 
the IFNR1 gene, also resulting in premature termination TAA at 187-
189 (Jouanguy et al. 1996) firmly established the importance of IFN 
responsiveness in control of both vaccine associated BCG infection and 
environmentally acquired NTM infections. 
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Various IFNR mutations have since been described in individuals from 
many countries and in many ethnic groups.   
These patients with single gene defects in the IFNsignaling pathway 
are rare, but genetic, immunological and clinical study of the 
consequences of the defects has led to invaluable insight into human 
control of mycobacterial infection.  The molecular analyses of these 
first kindreds, assisted in the understanding of these inherited 
immunodeficiencies.   
Genetic defects continue to be reported on an ongoing basis.  The 
following is a description of some of the early ones identified that 
assisted in the understanding of these inherited immunodeficiencies. 
1.4.1 IFNR Deficiencies  
1.4.1.1 Complete IFNR1 Deficiency 
Reported mutations of complete IFNR1 deficiency are all autosomal 
recessive and two forms have been reported.  
In one form, the patients have been shown to harbour null mutations 
that prevent receptors from being expressed as in the first IFNR1 
mutations described, C395A/S116X (Newport et al. 1996) and 131delC 
(Jouanguy et al. 1996). 
In the other form of complete IFNR1 deficiency, patients were found 
to have normal cell surface expression of the receptor, but mutations 
in the extracellular ligand binding domain, prevented the surface 
receptors from binding the IFN.  The first mutations of this kind, 
295del12 and G230C/C77Y were reported by Jouanguy et al. 2000. 
25 
 
Patients with complete IFNR deficiencies have high plasma IFN levels 
(Fieschi et al. 2001).  
1.4.1.2 Partial IFNR1 Deficiencies 
Partial IFR1 deficiency presents with a milder phenotype and 
mutations can be autosomal recessive (ARIFNR1), resulting in later 
onset of infection or the dominant negative (ADIFNR1) form. 
Partial recessive IFNR1 deficiency was first reported, presenting with 
a clinically heterogenous disease (Jouanguy et al. 1997b, Remiszewski 
et al. 2006). 
A partial dominant form of IFNR1 deficiency was first identified 
independently in 12 unrelated kindreds, associated with a mutation 
hotspot in the IFNR1 gene (Jouanguy et al. 1999). 
These patients were found to have heterozygous frame shift small 
deletions in exon 6 of the IFNR1 gene.  The mutant alleles encode 
truncated receptors that bind IFN with normal affinity, but accumulate 
at the cell surface due to the lack of an intracellular recycling site, 
resulting in hyperexpression.   
The small deletions of 4 nucleotides, either AATT, ATTA, TTAA or TAAT 
at nucleotides 816, 817, 818 or 819 found in eleven families, were 
arbitrarily designated 818del4 and the 1 nucleotide deletion 818delT or 
819delT, found in one family was arbitrarily designated 818delT 
(Jouanguy et al. 1999) 
Nucleotide 818 of the IFNR1 gene was the first small deletion hotspot 
to be identified in the human genome (Doffinger et al. 2000b) and 
these overlapping small deletions at a single mutational site have been 
globally designated as 818 deletions. 
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A mutation hotspot is defined as a site at which at least two 
independent mutational events of the same type occur.  Small deletion 
mutational hotspots may have direct nucleotide repeats in flanking 
areas, which are thought to increase the risk of slipped mispairing 
during DNA replication.  Polypurine runs have also been shown to be 
associated with small deletions (Krawczak et al. 1991).  This model of 
slipped mispairing events and subsequent repair during replication has 
been proposed, based on the presence of two direct repeats in the 
vicinity of nucleotide 818. 
The IFNR1 818del4 is the most common mutation occurring in this 
gene and since this early report, it has been found in other families 
from many countries. 
Another hotspot in the IFNR1 gene was reported in an Argentinian 
patient by Rosenzweig et al. in 2002.  Due to the nucleotide sequences 
flanking the region, the deletion could be ACTC, CTCA or TCAC at 
nucleotides 561, 562 or 563, resulting in the same sequence ATACGC 
and was arbitrarily designated 561del4.  This 561del4 mutation occurs 
in the vicinity of direct AC repeats and a polypurine run.   
The 561del4 mutation had been previously identified in a German 
patient with a compound heterozygous mutation which included the 
maternally inherited 561del4 and a paternally inherited splice site 
mutation 373+1GT (Roesler et al. 1999).  Unlike the 818del4 which 
is dominantly inherited, the 561del4 mutation is recessive in both the 
Argentinian and German cases. 
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Table 1.2: Reported IFNR1 Deficiencies 
1.4.1.3 Complete IFNR2 Deficiency 
In 1998, Dorman and Holland reported the first child with complete 
IFNR2 deficiency, presenting with disseminated M. fortuitum and M. 
avium complex (MAC) infections.  The phenotype was caused by a 
homozygous recessive deletion 278del2 in the IFNR2 coding region, 
resulting in a premature stop codon upstream from the segment 
encoding the transmembrane domain.  No cell surface expression of 
IFNR2 was detected in this patient.   
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1.4.1.4 Partial IFNR2 Deficiency 
Partial IFNR2 deficiency has been described, presents with a milder 
phenotype and mutations are autosomal recessive.  Doffinger et al. 
2000a described the first partial IFNR2 deficiency in a 20 year old 
patient with a history of BCG and M. abscessus infection.  This 
C340T/R114C mutation did not prevent cell surface expression of the 
receptor. 
IFNR2 defects are less common than the IFNR1 defects.  This may be 
due to a diagnosis bias, as reagents for flow cytometry and 
immunoblotting for IFNR2 have been inferior to those of IFNR1 
(Holland 2001).  
Additional detailed IFNR2 gene mutations are listed in table 1.3. 
31 
 
































Doffinger et al. 
2000a, 
Doffinger et al. 
2001 

























Vogt et al. 
2005, 
















Not reported M. avium, 
disseminated 
BCG 




Loss of function Japan M.avium, M. 
fortuitum, M, 
porcium. 






expression of non 
functional 
receptor 
Not reported Not reported De Paus et al. 
2011, Kilic et 
al. 2012 
Table 1.3:  Reported IFNR2 Deficiencies 
1.4.2 IFN Deficiency 
Despite its critical role in intracellular infection, to date an MSMD 
phenotype due to a mutation in the human IFN gene has not been 
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described.  There exists the possibility that IFN deficiency could be 
extremely rare or fatal (Ottenhof et al. 2002).  Acquired IFN 
deficiency however, has been reported.   
1.4.2.1 874T/A SNP 
A functional polymorphism 874T/A has been identified in the IFN 
gene.  It correlates with decreased IFN production, but has not been 
conclusively linked to susceptibility to M. tb infection.  
1.4.2.2 Autoantibody mediated IFN Deficiency 
Anti-IFN  autoantibodies may be present naturally in certain clinical 
conditions, eg viral infections (Caruso et al. 1990) and African 
trypanosomiasis (Bonfanti et al. 1995, Madariaga et al. 1998). 
There have however been reports of anti-IFN autoantibodies causing 
acquired IFN deficiency, resulting in infections with NTM.   
In a report by Hoflich et al. 2004, a previously healthy female adult 
from Thailand presented with M. chelonae and Burkholderia 
cocovenenans infections.  Results of whole blood stimulation with 
concanalvin A showed no detection of IFN production, but stimulation 
of PBMCs showed normal levels of IFN production, suggesting an 
inhibitory factor in the patient’s plasma.  Plasma IgG depletion by 
protein A removed the anti IFN activity and the autoantibody was 
identified as an IgG4 isotype but the patient died before the inhibitory 
factor was identified. 
Doffinger et al. 2004 also reported an adult Filipino male with an 
autoantibody to IFN.  This patient had disseminated M. tb and M. 
chelonae infections.  Passing the patient’s serum through an affinity 
column coupled to IFN, removed the ability of the serum to inhibit the 
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biological activity of the IFN.  IgG antibodies specific for IFN, were 
eluted from the column. 
Three adult cases of acquired predisposition to mycobacterial disease 
due to autoantibodies to IFN were reported by Kampmann et al. 
2005.  Two females from the United Kingdom and one South African 
male affected with severe NTM infections, were described.  The two 
females had MAI, M. fortuitum and Aspergillus infections and the male 
had an MAI infection in the vertebra.  No IFN was detectable in 
patients’ plasma following stimulated whole blood assays.  However in 
the absence of autologous plasma, patients’ washed PBMCs produced 
IFN in response to stimulation with relevant antigens.  An IFN 
neutralizing factor, shown to be an autoantibdy against IFN was 
isolated from patients’ plasma by using affinity chromatography, 
surface-enhanced laser desorption/ionization (SELDI) mass 
spectrometry. 
High density cDNA microarray analysis showed that the anti-IFN 
antibodies were functional and blocked induction of IFN inducible 
genes.  Once the correct diagnosis had been made, the patients were 
successfully treated. 
A study by Patel et al. 2005 screened 35 patients with either 
disseminated or pulmonary NTM infection for whom no molecular 
defect was known.  They identified functional anti-IFN autoantibodies 
in a group of six East Asian women.  These autoantibodies were high 
titre, shown to block binding of native human IFN and inhibited IFN 
dependent up-regulation of TNF and IL12 production. 
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These studies show that acquired defects in the IFN pathway may 
also cause unusual susceptibility to intracellular pathogens in patients 
without genetically determined immunological defects. 
1.4.2.3 Genetic association with autoantibody mediated IFN 
deficiency 
Anti-IFN autoantibodies seen in a group of Taiwanese adults with NTM 
infections, have since been shown to be associated with two HLA-II 
alleles, HLA-DRB1*16:02 and HLA-DQB1*05:02 (Chi et al. 2013, Puel 
and Casanova 2013).  This is the first genetic evidence of anti-IFN 
autoantibody production in humans being the cause of MSMD. 
1.4.3 IL12R1 Deficiency 
IL12R1 deficiency is the most common form of MSMD (de 
Beaucoudrey et al. 2010). 
Mutations in the gene encoding the 1 subunit of the IL12 receptor 
were first identified in seven patients from six families with a mild 
phenotype (Altare et al. 1998c, de Jong et al. 1998). 
Impaired IFN secretion is also probably responsible for MSMD in 
patients with IL12R1 deficiency and residual IL12 independent IFN 
mediated immunity probably accounts for the milder clinical and 
histological phenotype.  
Because the IL23R contains the IL12R1 subunit, it is possible that 
patients with IL12R1 deficiency probably also have IL23R deficiency 
(Parham et al. 2002).  As IL12R1 deficiency may impair both IL12 
and IL23 signaling, Hoeve et al. 2003 investigated this by studying 
IL23 responses of four IL12R1 deficient patients.  In controls, IL23 
promoted IFN produced by CD3+ and CD8+ T cells, but IL12R1 
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deficient T cells lacked IL23 induced IFN secretion, showing that IL23 
cooperates with IL12 and IL18 in promoting IFN and that IL12R1 
deficiency may result in defective IL12 and IL23 mediated immunity. 
The IL12R1 deficiency has been renamed as IL12- and IL23R1 chain 
deficiency (Al-Herz et al. 2011) and this notation will be used 
forthwith. 
The IL12- and IL23R1 mutation database has been updated and 
described (van de Vosse et al. 2013). 
Additional detailed IL12- and IL23β1 gene mutations are listed in table 
1.4. 














BCG, S. enteriditis 
Altare et al. 
1998c, 
Boisson-











BCG, S.  
enteriditis 
Altare et al. 
1998c, Tanir 














Zghal et al. 
2002) 
Cyprus, Japan M. avium, S. 
enteriditis 
Altare et al. 
1998c, Sakai 
et al. 2001, 
Elloumi-Zghal 















M. avium, S. 
paratyphi 
de Jong et al. 
1998, Fieschi  
et al. 2003, 











B, S. dublin 
de Jong et al. 
1998, Fieschi 






BCG, S. typhi 
de Jong et al. 
1998 
C701T/R213W 
as reported by 









Japan, Morocco Disseminated M. 
avium 
Sakai et al. 
2001 
C637T/R213W  
as reported by 




























Aksu et al. 
2001, Fieschi 
et al. 2003, 
Kutukculer et 
al. 2006, 
Sanal et al. 
2006, de 















Tunisia Disseminated BCG Elloumi-Zghal 













Tunisia Disseminated BCG Elloumi-Zghal 











Turkey Disseminated BCG Lichtenauer-
Kaligis et al. 








Turkey Disseminated BCG Lichtenauer-






Turkey Disseminated BCG Lichtenauer-








Turkey Disseminated BCG Lichtenauer-






Turkey S. enteriditi, 
Candida 






Camaroon M. avium, M. 
triplex, S. dublin 






Saudi Arabia Salmonella 
species 




















Caragol et al. 
2003, Fiesci 
et al. 2003, 
Lee et al. 
2008, 






































Not reported Fieschi et al. 
2003 
1440_1447delins







Slovakia Not reported Fieschi et al. 
2003 
1007_1008delins










al protein  
Slovakia Disseminated BCG Fieschi et al. 
2003, Ulrichs 





Brazil S. typhi, 
Paracoccodioides 
brasiliensis 












Qatar S. group D Fieschi et al. 
2003, Ehlayel 







Germany M. avium, S, 
enteriditis 









exon 8 or 
exons 5 




Turkey S. enteriditis Fieschi et al. 
2003, Tanir 
et al. 2006, 














Iran Disseminated S. 
enteriditis 


















Haham et al. 
2003, Fieschi 
et al. 2004, 
Scheuerman 
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Not reported Filipe-Santos 
et al. 2006b, 
de 
Beaucoudrey 
et al. 2010 
1483+182_1619





Not reported Not reported Filipe-Santos 





Not reported Not reported Filipe-Santos 





Taiwan Not reported Filipe-Santos 
et al. 2006b, 
de 
Beaucoudrey 





Pakistan S. enteriditis Filipe-Santos 









Turkey S. group D Sanal et al. 
2006, Filipe-















Asilsoy et al. 
2007, 
Pedraza et al. 
2010a, de 
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Argentina Not reported Not reported Yancoski et 
al. 2009, de 
Beaucoudrey 


























Not reported de 
Beaucoudrey 


















Brazil Not reported de 
Beaucoudrey 











et al. 2010, 
Boisson-










Ukraine Salmonella de 
Beaucoudrey 





India, Iran Histoplasmosis de 
Beaucoudrey 










Chile Not reported de 
Beaucoudrey 





China Not reported de 
Beaucoudrey 









Argentinia Not reported de 
Beaucoudrey 













































Turkey Candida de 
Beaucoudrey 














Iran M. tb de 
Beaucoudrey 





Argentina Not reported de 
Beaucoudrey 









China Not reported de 
Beaucoudrey 





Tunisia Not reported de 
Beaucoudrey 
et al. 2010 
1623_1624insTT 







Argentinia Not reported de 
Beaucoudrey 





Iran Not reported de 
Beaucoudrey 









































Table 1.4: Reported IL12- and IL23R1 deficiencies 
1.4.4 IL12R2 Deficiency 
Kondo et al. 2001a and Kondo et al. 2001b reported reduced IFN 
production in response to stimulation with IL12 in atopic Japanese 
subjects with mutations in the IL12R2 gene but no associations were 
found with mycobacterial disease.  Bassumy et al. 2003 did a study 
looking at associations between type I diabetes and asthma and 
IL12R2 gene mutations in the Japanese population and again, no 
associations were found with mycobacterial disease.  
A possible reason why no IL12R2 defects have been found to be 
associated with mycobacterial disease may be because IL23R signaling 
can compensate for an IL12R2 defect   (van de Vosse et al. 2004). 
1.4.5 IL12p40 Deficiency 
In 1998 a child born to consanguineous Pakistani parents presented 
with a mild histopathological and clinical phenotype and a recessive 
mutation in the IL12p40 gene was reported.  This first mutation was a 
reported as a homozygous frameshift deletion of 4.4 kilobases 
(482del373), encompassing two coding exons 5 and 6 (Altare et al. 
1998a, Altare et al. 1998d).   
The same 482del373 mutation was also found in an Indian family in 
which it caused fatal disseminated BCG infection in one child and 
repeated infections of Salmonella enteriditis in a second affected child 
(Picard et al. 2002).  The mutation was reported as a 4.6 kilobase 
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deletion designated 482+82_856-854 del (deletion from 482+82 in 
intron 4 donor site and 856 or 854 in exon 6) resulting in a loss of 167 
of original 328 amino acids and addition of 45 new amino acids. 
These two descriptions differ slightly in the two literature reports, but 
have been quoted as the same deletion. 
Mycobacterial infections in these deficiencies occur primarily because 
IFN mediated immunity is impaired and residual IL12 dependent 
secretion of IFN is probably responsible for the milder clinical 
phenotype.  Patients with mutations in the IL12p40 gene are 
susceptible to infections with Salmonella species. 
Additional detailed IL12p40 gene mutations are listed in table 1.5. 
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Saudi Arabia Disseminated 
BCG, Salmonella 
species 
Picard et al. 
2002 
482+82_856-







Pakistan, India Disseminated 
BCG, Salmonella 
species 
Altare et al. 
1998a, Altare 
et al. 1998d, 
Picard et al. 
2002  






Tunisia Disseminated BCG Elloumi-Zghal 









































India Not reported Prando et al. 
2013 
Table 1.5:  Reported IL12p40 deficiencies 
1.4.6 STAT1 Deficiencies 
1.4.6.1 Partial STAT1 Deficiency   
The first STAT1 defect T2116C/L706S reported was a partial deficiency 
(Dupuis et al. in 2001), with a clinical phenotype similar to that of the 
partial IFNR deficiencies (Jouanguy et al. 1997b, Jouanguy et al. 
1999, Doffinger et al. 2000a).  This type of deficiency results in 




1.4.6.2 Complete STAT1 Deficiency 
Complete recessive STAT1 deficiency results in impairment of both 
IFN mediated anti-mycobacterial immunity and IFN mediated anti-
viral immunity, resulting in a severe phenotype. 
In 2003, the first cases of complete STAT1 deficiency were reported in 
two unrelated Saudi Arabian infants born to consanguineous kindreds.  
These were a 2 nucleotide deletion at position 1754, 1755, 1756 or 
1757 arbitrarily designated 1757-1758delAG, generating a premature 
stop codon at position 603 and a homozygous nucleotide substitution 
of T to C in exon 20, resulting in an amino acid change L600P.  The 
parents of both infants were healthy and heterozygous for each 
mutation (Dupuis et al. 2003). 
Additional detailed STAT1 gene mutations are listed in table 1.6. 
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no protein expression, 





























No DNA binding, 
impaired anti-
mycobacterial immunity 






Skipping of exon 3, 
reduced 
phosphorylation, no DNA 
binding, expression of 
lower MW protein, 





living in Italy 
M. kansasii, 
viral infections 
Vairo et al. 
2011 
Table 1.6: Reported STAT1 deficiencies 
The molecular analyses of these genetic defects identified from 1996 
onwards, have led to a better understanding of the importance of the 
IFN pathway in protection against TB.  Identification of new genetic 
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defects is ongoing, but the foundation of understanding was laid from 
these early reports resulting in important diagnostic and therapeutic 
implications. 
Reference sources for mutations were www.ncbi.nlm.nih.gov/pubmed,  
www.google.com, UCT libraries database and the time frame was to 
July 2013. 
1.5 MSMD Caused by Mutations in Genes Outside of the 
IL12/IL23/IFN Pathway 
Mutations in certain genes outside of the IL12/IL23/IFN pathway can 
also cause MSMD. 
There were early reports of X-linked modes of inheritance associated 
with mycobacterial disease (Nedorost et al. 1991, Holland et al. 1994,    
Frucht and Holland 1996, Frucht et al. 1999). 
1.5.1 X linked NFkB essential modulator (NEMO) deficiciency 
(XR-MSMD-1) 
Nuclear factor kappa B (NFkB) is a collective name for a heterologous 
group of dimeric transcription factors composed of members of the Rel 
family of DNA binding proteins that recognize a common sequence 
motif (Karin and Ben-Neriah 2000).   
The NFkB dimers are ubiquitously expressed and their interaction with 
the inhibitor of NFkB (IkB) regulates NFkB activity.  The IkBs in 
mammals include IkB, IkB and IkB.  The IkB kinase complex IKK 
regulates IkB phosphorylation resulting in its ubiquitination and 
proteosome degradation, releasing NFkB into the nucleus to initiate 
the process of gene transcription. 
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IKK is composed of 3 subunits, IKK and IKK acting as catalytic 
components and IKK, also known as NFkB essential modulator 
(NEMO) which acts as the structural scaffolding supporting the IKK 
complex (Karin et al. 2000, Rosenzweig and Holland 2005).  The gene 
that encodes NEMO is required for activation of NFkB transcription.  It 
is located on the X chromosome and has 10 exons.  The NEMO protein 
is a 419 amino acid regulatory protein (Aradhya et al. 2001). 
X – linked recessive NEMO mutations cause anhidrotic ectodermal 
dysplasia with immunodeficiency (EDA-ID), a developmental and 
immunologic disorder (Zonana et al. 2000).  NEMO deficiency can 
impair B cell function, T cell development and survival, NK cell 
cytotoxicity and TLR immune responses.  Patients with NEMO 
mutations can also have increased susceptibility to mycobacterial 
disease (Hanson et al. 2008) as well as other infections (Orange et al. 
2004).   
In 2006, an X-linked recessive MSMD syndrome caused by NEMO 
mutations was reported (Filipe-Santos et al. 2006).  This group 
reported on mutations in the leucine zipper domain of the NEMO gene 
in three unrelated kindreds from the USA, France and Germany, with 
this syndrome.  Mutations were found in the coding regions of the 
NEMO genes in all three probands.  One NEMO mutation identified in 
the American kindred was A944C/E315A and a second mutation 
G956A/319Q was identified in both the French and German kindreds.  
These two mutations did not affect NFkB activation in response to 
most of the classical activators tested, but were found to selectively 
impair the CD40 triggered and NFkB/c-Rel-mediated induction of IL12 
production by monocytes and dendritic cells, accounting for the 
susceptibility to mycobacterial infections. 
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Impaired secretion of IL12 by PHA stimulated monocytes and T cells 
was observed in patients with the NEMO mutations, possibly affecting  
CD40 signaling within monocytes, resulting in low levels of IL12 
secretion upon T cell stimulation. 
Imamura et al. 2011 reported a Japanese child with disseminated BCG 
infection caused by a C913G/D311E NEMO mutation.  This mutation 
was located in the NEMO ubiquitin-binding domain.  Flow cytometry 
showed that NEMO expression was not detected in the patient’s B 
cells, monocytes or NK cells as measured by expression on CD19+, 
CD14+ or CD56+ cells by anti NEMO monoclonal antibodies.  
B cell responses to CD40L as measured by flow cytometry were found 
to be severely impaired.  Both IFN secretion induced by stimulation 
with IL18 and IL12 and TNF secretion in response to LPS stimulation 
in the absence or presence of IFNγ were severely impaired. 
1.5.2 XR-MSMD-2 deficiency 
Bustamante et al. 2007b also studied a large kindred with four male 
maternal relatives affected with mycobacterial disease.  Three of the 
subjects had recurrent disease after BCG vaccination and the fourth 
had recurrent TB.  Screening by whole blood assays excluded all 
known forms of autosomal recessive and dominant disorders of the 
IL12/IL23-IFN pathway.  There was abnormal CD40-dependent IL12 
production by monocytes in the presence of autologous and 
heterologous PHA activated T cells.   
In this kindred, no NEMO mutations were found, NEMO expression was 
normal in an EBV-B cell line and fresh blood cells as shown by Western 
blotting and flow cytometry showed normal NEMO expression on all 
leukocyte subsets.  
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This work excluded the NEMO gene as the cause of disease using 
clinical observations (lack of ectodermal dysplasia), immunological 
results (normal IL12 production by monocytes), genetic analysis 
(normal sequence of NEMO coding region), biochemical data (normal 
NEMO protein production) and linkage analysis (NEMO encompassing 
region excluded by X scan). 
As a result of this finding, a new form of X-linked recessive MSMD, 
designated XR-MSMD-2 was reported, but the genetic defect was not 
identified. 
1.5.3 X-linked Chronic Granulomatous Disease (CGD) (CYBB 
deficiency) predisposing to TB disease 
Patients with CGD are susceptible to TB and BCG complications.  About 
70% of cases are transmitted by X-linked mode of inheritance, arising 
from mutations in the gp91-phox subunit of the phagocyte NADPH 
oxidase, the protein encoded by the CYBB gene, localized on 
chromosome Xp21.1 (Bustamante et al. 2007a, Lee et al. 2008).   
MSMD caused by X-linked Chronic Granulomatous Disease (CGD) has 
been reported.  Two kindreds in which male adults with previously 
unknown mutations in the CYBB gene, resulting in an impaired 
respiratory burst in macrophages, but not monocytes or granulocytes, 
developed MSMD (Bustamante et al. 2011).  The mutations identified 
in the two kindreds were A231C/Q231P and A178C/T178P in the gp91-
phox subunit.  Affected males in both kindreds were heterozygous for 
the mutations. 
1.5.4 IRF-8 deficiency 
MSMD due to interferon regulatory factor 8 (IRF8), a protein essential 
for the development of dendritic cells and the differentiation of 
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macrophages and granulocytes has been documented.  Mutations in 
the IRF8 gene, localized on chromosome 16q24.1, impair IL12 
secretion by monocytes and dendritic cells.  One case of autosomal 
recessive IRF8 deficiency caused by a K108E mutation is associated 
with severe disease and complete depletion of monocytes and 
dendritic cells and two unrelated cases of autosomal dominant IRF8 
deficiency caused by a T80A mutation, presenting with a milder 
phenotype, have been reported (Hambleton et al. 2011, Salem et al. 
2103). 
1.5.5 ISG15 deficiency 
MSMD due to mutations in the ISG15 gene, encoding an IFN /β 
inducible, ubiquitin-like intracellular protein, have been reported.  Two 
unrelated patients with homozygous mutations G379T/Q127Q and 
336_337insG had impaired but not abolished IFN immunity and mild 
MSMD (Bogunovic et al. 2012). 
1.6 MSMD Phenotype 
MSMD is a phenotypically heterogeneous syndrome and many of these 
patients present with a variable array of atypical clinical symptoms 
(Dupuis et al. 2000).  The disorders are genetically different but 
immunologically similar, impaired IFN mediated immunity being the 
common pathogenic mechanism accounting for the mycobacterial 
infection.   
1.6.1 Clinical features 
Individuals with impaired cell mediated immunity due to MSMD exhibit 
increased susceptibility to opportunistic infections caused by NTM, BCG 
and Salmonella species, M. avium being the most common 
opportunistic infection (Casanova et al. 1995, Kumararatne 1997, 
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Doffinger et al. 1999).  Salmonella infection is more common among 
individuals with IL12 or IL12- and IL23R1 receptor deficiency (de 
Jong et al. 1998, Altare et al. 1998c) while this infection occurred in a 
minority of patients with IFN receptor deficiency (Jouanguy et al. 
1996, Casanova et al. 1996, Newport et al. 1996, Haverkamp et al. 
2006).  Additional infectious organisms found in MSMD patients are 
listed in tables 1.2-1.6. 
There is correlation between the genotype (null or mild mutation), the 
cellular phenotype (complete or partial defect), the histological 
phenotype (immature or mature granulomas) and clinical phenotype 
(poor or favourable outcome). 
Children with lepromatous like granulomas that are poorly delimited, 
multibacillary with no epithelioid or giant cells generally die of 
overwhelming infection (Emile et al. 1997). 
Complete IFNR1 and IFNR2 deficiencies predispose patients to this 
type of overwhelming infection with impaired granuloma formation in 
infancy or early childhood. 
Children presenting with tuberculoid granulomas that are well 
delimited and paucibacillary with epithelioid and giant cells have a 
more favourable outcome and are associated with survival. 
These are seen in patients with partial IFNR1, partial IFNR2, partial 
STAT1, IL12p40 and IL12R1 deficiencies predisposing them to curable 
infection with mature granulomas at various ages. 
The categories of mutations causing MSMD can result in defective 
response to IFN, defective response to IL12, defective production of 
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IL12, defective production of IFN, resulting in impairment of anti-
mycobacterial immunity and anti-viral immunity.  
These are summarized in table 1.7. 
Deficiency Phenotype Laboratory diagnostics 
IFNR1   
Complete recessive Severe, early onset NTM, 
Salmonella infections, 
disseminated BCG 
No response to IFN in WBAs 
*.  High serum IFN levels. 
Absence of receptor 
expression or overexpression 
of nonfunctional receptor seen 
by flow cytometry. 
Partial recessive Milder, later onset NTM 
infection, disseminated 
BCG 
Partial response to IFN in 
WBAs*. Response can be 
increased by using high 
concentrations of IFN. 
Partial dominant Milder, later onset NTM, 
osteomyelitis common 
Partial response to IFN in 
WBAs*. Response can be 
increased by using high 
concentrations of IFN. 
IFNR2   
Complete autosomal 
recessive 
Severe, early onset NTM, 
Salmonella infections, 
disseminated BCG 
No response to IFN in WBAs*.  
Partial autosomal 
recessive 
Milder, later onset NTM 
infection, disseminated 
BCG 
Partial response to IFN in 
WBAs*. Response can be 
increased by using high 
concentrations of IFN. 
IFN   
Acquired autoantibodies Severe, NTM infections, 
disseminated BCG. 
Undetectable IFN in WBAs*.  
In absence of autologous 
plasma, detectable, IFN levels 
secreted by PBMCs, measured 
in WBAs*. 
IL12- and IL23Rβ1   
Complete autosomal 
recessive 
Severe, early onset NTM 
infections, disseminated 
BCG.  Salmonella 
infections common. 
No response to IL12 in WBAs*. 
Absence of receptor 




Milder, later onset NTM 
infection, disseminated 
BCG. 
Partial response to IL12 in 
WBAs*. 





Milder, NTM infections, 
disseminated BCG.  
Salmonella infections 
common. 
Undetectable or low IL12 
levels in WBAs*. 







Undetectable or low IFN 
levels in WBAs*. 
Immunity analyzed by EMSA, 








Low IFN levels in WBAs*. 
Immunity analyzed by EMSA, 
nuclear binding assays. 
NEMO   
Partial X-linked 
recessive 
Disseminated BCG, M. 
avium, mycobacterial 
infections, S. pneumonia. 
Impaired B cell, T cell, NK cell 
function, CD40-IL12 signaling. 
Undetectable or low IFN and 
IL12 levels in WBAs. Absence 
of protein detected by Western 
blotting. 
CYBB   
Partial X-linked 
recessive 
Disseminated BCG, TB. Impaired CYBB dependent 
NADPH respiratory burst. 





Depletion of dendritic cells, 






Depletion of monocytes and 
dendritic cells, impaired IL12 
production. 







Low IFN levels produced by 
PBMCs and NK cells in WBAs*. 
 
Table 1.7: Phenotype and laboratory diagnostics for 




When considering diagnosis of MSMD, the following clinical features, in 
the absence of other identifiable causes of immunodeficiency are 
important to note: 
 Patients with disseminated or recurrent infection due to poorly 
pathogenic mycobacteria (BCG or NTM).  
 Disseminated MAC infection is an indication of manifestation of 
an immunological defect (Holland 2001). 
 Patients with systemic infections caused by non-typhi Salmonella 
species that are persistent and recurrent despite antibiotic 
treatment. 
 Patients with M. tb infections who are treatment compliant, have 
drug sensitive organisms but develop recurrent or disseminated 
disease. 
 Diagnostic clues for identifying partial dominant IFNR1 
deficiencies can be slow healing of BCG scars, family history of 
infections with NTM, Salmonella infections and lack of response 
to Langerhans’  Cell histiocytosis (LCH) therapy (Edgar et al. 
2001). 
 Children with Histiocytosis-X, unresponsive to treatment, or with 
atypical pathological features (Lammas et al. 2001). 
 Patients with severe unexplained viral infections including CMV, 
HSV, Varicella zoster virus, RSV, Parainfluenza virus type 3, 
because a subset of patients with MSMD may manifest 
unexplained viral infections (Dorman et al. 1999). 
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1.6.2 Laboratory screening 
Diagnosis remains challenging, but as a start a few standard assays 
may be done as an initial screening process.  These tests include 
whole blood up-regulation assays followed by ELISAs to detect 
secretion ofF, IL12 and IFNcytokines and cellular responses to 
IFN and IL12.  The measurement of IFN and IL12 receptors may be 
done by flow cytometry.  This is depicted in figure 1.9. 
 
Figure 1.9: Algorithm showing laboratory screening for defects 
in IL12/IL23/IFN pathway. 
These are more fully discussed in Chapter 5 (Immune testing). 
The discovery of these genetic disorders has had important diagnostic 
and therapeutic implications with respect to bone marrow 
transplantation, IFN treatment and anti-mycobacterial drugs.  A 
better understanding of the critical elements of these cytokine 
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pathways has also aided in ways to circumvent genetic defects through 
treatment with complementary cytokines (Holland 2000). 
1.6.3 Treatment 
Complete recessive IFNR deficiency patients have a poor prognosis, 
responding less well to anti-mycobacterial chemotherapy and bone 
marrow transplantation is challenging (Dorman et al. 2004).  
Transplant engraftment has been shown to be suboptimal in complete 
IFNR1 deficient patients, possibly due to the high levels of circulating 
IFN in these patients and active mycobacterial infection impairs 
success in Haematopoietic Stem Cell Transplantation (HSCT) (Roessler 
et al. 2006). 
Partial deficiencies are good candidates for successful cytokine 
prophylaxis and therapy (Holland 2000), showing a favourable 
response to anti-mycobacterial chemotherapy and treatment with 
exogenous IFN.  It is important to identify and describe mutations as 
it then becomes possible to choose appropriate treatment.  For 
example the T832G/E278X mutation causing partial dominant IFNR1 
deficiency allows some cell surface expression of IFNR1 receptors. 
This made it possible to administer exogenous IFN to flood existing 
functional and non-functional receptor sites during episodes of 
osteomyelitis to ensure immunological response from patient’s cells.  
Dose escalation of IFN is necessary, possibly to achieve saturation of 
the nonfunctional cell surface IFNR1 chains.  Treatment of IL12R1 
deficient patients with high doses of IFN has also been shown to have 
positive clinical effects (Alangari et al. 2011). 
Obtaining an accurate molecular diagnosis is therefore crucial for 
determining optimal treatment strategy.   
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1.7 Human Genetic Susceptibility to Infection with 
Mycobacterium tuberculosis 
Differences in susceptibility to M. tb reported in different racial and 
ethnic groups (Stead et al. 1990), as well as twins studies (Comstock 
1978, van der Eijk et al. 2007) are indicators of genetic susceptibility 
to TB.  In support of this hypothesis was also the report of a tragic 
incident in Lubeck in 1923 when a single virulent viable M. tb strain 
was inadvertently used to immunize 249 infants (Smith FB 1988).  
Responses ranged from recovery to death from overwhelming TB 
disease with 173 infants surviving, arguing for a genetic basis for 
resistance to TB. 
Major gene loci important for controlling TB infection are being 
identified on an ongoing basis and studies are revealing a Mendelian 
susceptibility to infection with M. tb (Baghdadi et al. 2013). 
1.7.1 MSMD patients affected with M. tb 
The importance of the IL12/IL23/IFN pathway was elucidated by the 
incidence of NTM infections seen in MSMD patients, but susceptibility 
to infection with M. tb was also seen. 
A small subset of MSMD patients become infected solely with M. tb 
(Altare et al. 2001, Caragol et al. 2003, Ozbek et al. 2005, Tabarsi et 
al. 2011).  Following is a description of some cases. 
Altare et al. 2001 reported clinical heterogeneity in a family affected 
with IL12R1 deficiency.  Two siblings were homozygous for the 
C637T/R213W mutation, preventing receptor expression and 
abolishing cellular responses to IL12.  One sibling had disseminated 
BCG infection in early childhood.  The second sibling was unaffected by 
BCG immunization, receiving 3 innoculations of live BCG, but 
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developed abdominal TB at the age of 18 years.  Neither sibling had 
clinical disease caused by NTM. 
There was a report of a family with 1L12R1 deficiency affected with 
M. tb infection but no infectious diseases caused by BCG or NTM 
infection.  Three siblings in this family with the splice site mutation 
1791+2TG showed different clinical phenotypes.  One child had 
disseminated TB, the second had Salmonella sepsis and pulmonary TB 
and the third was asymptomatic (Caragol et al. 2003). 
Ozek at al 2005 reported a child with 1L12R1 deficiency caused by 
the 1021+1GC splice site mutation, affected with disseminated TB. 
An adult male with 1L12R1 deficiency caused by the 355delT 
mutation was diagnosed with TB resistant to isoniazid and rifampicin.  
The TB disseminated into lymph nodes and the colon, with a fatal 
outcome.  This is the first report of IL12R1 deficiency presenting with 
disseminated TB in an adult (Tabarsi et al. 2011). 
A child with inherited IL12p40 deficiency caused by the 4.6kb deletion 
(Altare et al. 1998a, Altare et al. 1998d, Picard et al. 2002) was 
reported to have disseminated mycobacterial disease following BCG 
vaccination, followed by infection with M. tb. (Pulickal et al. 2008). 
Picard et al. 2002 reported a case of IL12p40 deficiency in a child with 
the 315insA mutation who developed virulent M. tb infection. 
1.8 Genetics in M. tb Infection 
An oligenic pattern of inheritance implies that phenotype is dependent 
on two or a few major genes, whereas a polygenic pattern of 
inheritance implies that the phenotype results from the effect of a 
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large number of genetic loci, each having a small effect (Alcais et al. 
2009).   
Many genes may be important in susceptibility to M. tb including Toll 
like receptors, NRAMP, IL1 and ILRa, NEMO, Vitamin D, Vitamin D 
receptor, Vitamin D binding protein and NOS2A.  These are discussed 
below. 
1.8.1 Toll like receptors (TLR)s 
Microbial lipoproteins are potent stimulators of IL12 production by 
human macrophages.  Induction is mediated by the TLRs, known to be 
important for initiation and coordination of host response to M. tb.  
There have been many studies demonstrating the importance of TLRs 
with respect to TB.  Following is a description of some reports. 
Liu et al. 2006 reported that TLR activation of human macrophages 
up-regulates expression of the vitamin D receptor and the vitamin D-1 
hydroxylase genes, resulting in production of the antimicrobial peptide 
cathelcidin and killing of intracellular mycobacteria.  This data supports 
the link between TLRs and Vitamin D-mediated innate immunity which 
is important in mycobacterial immunity. 
Ma et al. 2007 did a study on TLR variants that contributed to 
susceptibility to TB.  They carried out a population-based-case-control 
study on 1312 adults from three ethnic groups, African Americans, 
European Americans and Hispanics.  Results suggested that variant 
TLRs in TLR 1, 6, 10 contribute to human susceptibility to TB disease.   
Hawn et al. 2007 reported that a TLR1 SNP I602S regulates the innate 
immune responses to extracts of mycobacteria.  It has also been 
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reported by Yim et al. 2008 that shorter GT repeats in intron II of the 
TLR2 gene were significantly associated with TB in a Korean cohort. 
Davila et al. 2008 carried out an association study in an Indonesian 
cohort and found four polymorphisms in the TLR8 gene on the X 
chromosome, three in the promoter region, showing evidence of 
association with susceptibility to TB in males.  They then screened a 
Russian cohort for these polymorphisms and confirmed this 
association.   
Dalgic et al. 2011 reported on the Arg753Gln SNP in TLR2 in a 
paediatric Turkish cohort with TB.  The heterozygous genotype was 
significantly higher in patients with pulmonary TB and pulmonary and 
extrapulmonary TB than in patients with LTBI. 
A meta-analysis has also reported TLR1, TLR2 and TLR6 
polymorphisms associated with pulmonary tuberculosis in different 
geographical regions.  The G1805T polymorphism in TLR1 was shown 
to increase susceptibility to TB in Africans and American Hispanic 
subjects, the G2258A polymorphism in TLR2 was associated with 
increased TB risk in Asians and Europeans and the C745T 
polymorphism in TLR6 was associated with decreased TB risk (Zhang 
et al. 2013). 
1.8.2 Natural resistance-associated macrophage protein 
(NRAMP) 
Studies of an inbred strain of mice with increased susceptibility to 
mycobacteria, salmonella and leishmania infections led to the 
identification of the Nramp1 gene located on chromosome 1, 
designated Bcg, Ity or Lsh (Bellamy and Hill 1998, Bellamy 2003, Plant 
and Glynn 1979, Crocker et al. 1984, Blackwell 1989). 
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Gruenheld et al. in 1994, isolated the mouse Nramp2 gene and it was 
mapped to chromosome 15. 
The human homologue of Nramp1, designated NRAMP1 or SLC11A1 
(solute carrier family 11, member 1) was mapped to chromosome 
2q35 (Cellier et al. 1994).    
In 1995, Vidal et al. reported the isolation and characterization of the 
human NRAMP2 (SLC11A2) gene, localized on chromosome 12q13.   
Liu et al. in 1995 identified nine sequence variants in NRAMP1 and 
linked two highly polymorphic microsatellite markers to NRAMP1.   
After a study done on a Brazilian population, Shaw et al. 1997 
concluded that the NRAMP1 gene is not a major gene involved in 
susceptibility to TB in these subjects.  However, a number of other 
studies completed on different ethnic groups have shown an 
association of polymorphisms in the NRAMP1 gene with susceptibility 
to TB. 
Bellamy et al. 1998 reported on the variations in the NRAMP1 gene 
and susceptibility to TB in West Africans.  An association was found 
with four polymorphisms, a microsatellite  polymorphism  5’(CA)n, a 
SNP in intron 4 (469+14G/C) reported as INT4, D543N and a deletion 
in the 3’ untranslated region 1729+55del4. 
In a study done on aboriginal Canadians, an association between 
susceptibility to TB and NRAMP intragenic variants was found 
(Greenwood et al. 2000). 
A study on a Japanese population has reported on NRAMP1 
polymorphisms, clinical features of TB and susceptibility to disease 
(Abe et al. 2003).  While no association was observed between 
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susceptibility and human NRAMP1 polymorphisms, the genetic 
variation in this gene may be associated with cavitation in patients 
with TB. 
The 5’ allele [(GT)9] in the promoter of SLC11A1 has been associated 
with higher expression and resistance to tuberculosis and the 120bp 
allele  [(GT)10] has been associated with lower promoter activity and 
susceptibility to TB (Awomoyi et al. 2002, Hoal et al. 2004). 
A more recent review and meta-analysis done by Li et al. 2011 looking 
at widely studied polymorphisms for 3’ UTR, D543N, INT4 and 5’ 
(GT)n, reported that NRAMP1 may play an important role in host 
defence against development  of TB.   
These varied reports indicate that NRAMP is involved in susceptibility 
to mycobacterial infections in humans, but the effect is too weak to be 
the sole gene involved. 
1.8.3 Interluekin 1 and interleukin 1 receptor agonist (IL-1 
and IL-Ra) 
The genes encoding the proinflammatory cytokine interleukin 1 (IL-
1) and its antagonist receptor interleukin 1 Ra (IL-Ra)(IL1 receptor 
agonist) are both located on chromosome 2.   
They are strongly induced by M. tb and are secreted by monocytes, 
macrophages and dendritic cells.  IL-1 is expressed in excess at the 
site of disease in patients with TB (Law et al. 1996).  A study done on 
Gujarati Asians in west London showed that a proinflammatory 
haplotype of IL-1 and IL-1Ra was significantly more common in 
patients with TB pleurisy than in those with other types of TB or 
healthy M. tb sensitized healthy controls (Wilkinson et al. 1999). 
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1.8.4 Vitamin D and Vitamin D receptor 
During the 19th century, cod liver oil and sunlight were widely used to 
treat patients with TB.  Today, epidemiological evidence links vitamin 
D deficiency and TB.   
Vitamin D is synthesized in the skin during exposure to sunlight and is 
metabolized by the liver to 25-hydroxyvitamin D [25(OH)D], the major 
circulating vitamin D metabolite and standard measure of vitamin D 
status.  25(OH)D undergoes further hydroxylation to 1 alpha, 25 
dihydroxy vitamin D3 [1,25(OH)2D3], the hormonal form of vitamin D 
and immunomodulatory metabolite that enhances antimycobacterial 
activity (Liu et al. 2006, Martineau et al. 2007). 
Early studies had shown that in vitro 1,25(OH)2D3 enhances the ability 
of human monocytes to restrict growth of M. tb (Rook et al. 1986) and 
that vitamin D exerts its effect via the Vitamin D receptor (VDR) which 
is present activated lymphocytes (Reichel et al. 1987). 
In a study done by Martineau et al. in 2007, it was shown that 
1,25(OH)2D3 reduced transcription and secretion of IFN, IL12p40 and 
TNF in PBMCs and macrophages infected with mycobacteria (BCG and 
H37RV).  Results showed that 1,25(OH)2D3 also suppressed BCG and 
M. tb in culture.   
VDR polymorphisms were typed in the Gambian case-control study, 
previously discussed in section 1.9.2, in which NRAMP1 had been 
found to be associated with TB (Bellamy et al. 1998).  Genetic 
variation in bone mineral density has been shown to be associated 
with SNPs in the VDR gene.  These include an exon 9, codon 352, 
synonymous change, ATT to ATC creating a Taq1, restriction site 
(Morrison et al. 1994).  Alleles were designated t and T, the presence 
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or absence of the restriction site denoted by t or T respectively.  
Analyzing the respective genotypes TT, Tt and tt, results suggested 
that tt homozygotes may be resistant to clinical TB, as subjects with 
the codon 352 tt genotype were significantly underrepresented among 
TB patients (Bellamy et al. 1999). 
The prevalence of both vitamin D deficiency and TB is high among 
Asian immigrants in the United Kingdom (Bellamy 2003).  A report by 
Martineau et al. 2007 showed by using the BCG lux assay, that a 
single dose of vitamin D enhances immunity to mycobacteria 
Wilkinson et al. 2000 investigated the interaction between serum 
vitamin D (25-hydroxycholecalciferol) concentrations and VDR 
genotype with respect to susceptibility to TB.  They typed three VDR 
polymorphisms defined by the presence of restriction endonuclease 
sites for Taq1, Bsm1 and Fok1.  There was no significant association 
between VDR genotype and TB, but the combination of codon 352 
genotype TT/Tt and 25-hydroxycholecalciferol was associated with 
disease and the genotype ff or undetectable 25-hydroxycholecalciferol 
was strongly associated with disease.  The tt genotype was also found 
to be less frequent among Gujarati Asian patients affected with TB in 
west London, compared to controls.  In the Wilkinson study, the f 
allele containing the Fok1 site was found to be associated with 
extrapulmonary disease. 
Gao et al. 2010 did a meta-analysis on associations of the FokI, TaqI, 
ApaI and BsmI VDR polymorphisms with risk of TB infection and 
results supported the hypothesis that Vitamin D deficiency may play a 
role as risk factor during development of clinical disease. 
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Rathored et al. 2012 did a study in northern India, enrolling 897 
participants as three groups (354 MDR-TB, 338 DS-PTB, 205 controls 
205).  Genotypic and allelic frequencies of FokI, BsmI and TaqI VDR 
polymorphisms and concentrations of 25(OH)D were analyzed.  The 
FokI Ff genotype and TaqI t allele correlated positively with MDR-TB.  
The ff genotype and f allele of FokI frequency were higher in MDR-TB 
and drug sensitive TB groups.  BsmI Bb genotype correlated inversely 
with MDR-TB.  Serum 25(OD)D concentrations were significantly 
lowest in MDR-TB, correlating inversely with time to sputum smear 
conversion.  This study concluded that VDR gene polymorphisms and 
hypovitaminosis D may predispose to MDR-TB and lower serum 
25(OD)D may increase time to MDR-TB sputum negativity. 
1.8.5 Vitamin D binding protein 
The polymorphic system known as the group specific component (GC) 
was identified as the vitamin-binding protein (DBP) of human plasma.  
Vitamin D metabolites in the circulation are bound to vitamin D binding 
protein (DBP).  Double–band variants were called GC1 and single-band 
variants were named GC2 according to nomenclature adopted in 1978. 
(Cleve and Constans 1988).  Two common polymorphisms at codons 
416 (GAT to GAG, Asp to Glu) and 420 (ACG to AAG, Thr to Lys) of 
exon 11 of this gene give rise to three major electrophoretic variants, 
Gc1F (fast), Gc1S(slow) and Gc2.  These Gc variants of the DBP differ 
in affinity for vitamin D metabolites that modulate antimycobacterial 
immunity (Martineau et al. 2010).   
In a study using TB patients and healthy controls from Brazil, South 
Africa and Gujarati Asians in the UK, it was shown that an association 
between Gc genotype and susceptibility to TB is dependent on vitamin 
D status.  The Gc2/2 genotype was strongly associated with 
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susceptibility to active disease in Gujarati Asians.  This association was 
preserved if serum 25(OH)D was <20 nmol/l, but not if it was higher.  
No association was observed in the other ethnic groups (Martineau et 
al. 2010). 
1.8.6 NOS2A 
The nitric oxide synthase 2A gene (NOS2A) is induced in response to 
infections and cytokines, generating nitric oxide (Kun et al. 2001).  
Studies have shown NOS2A to be associated with TB.   
Gomez et al. 2007 evaluated the influence of two NOS2A SNPs on the 
risk of developing pulmonary TB in a Northwestern Colombian 
population and found influence with one SNP. 
In another study, a mixed case control association study of individuals 
with TB, relatives or close contacts was carried out.  Ten NOS2A SNPs 
in African-Americans were associated with TB, three SNPs interacted 
with a SNP in TLR4 and five others interacted with a SNP in IFNR1, 
showing that variants may contribute to TB susceptibility and act 
synergistically with SNPs in other genes (Velez et al. 2009). 
In a South African coloured population, association was found with 
NOS2A haplotypes consisting of two promoter polymorphisms reported 
(Moller et al. 2009). 
1.8.7 Immunity related GTPase M (IRGM) 
IRGM has been shown to be critical in regulatory autophagy as a 
means of disposing cystolic cellular structures and reducing the growth 
of intracellular pathogens, including M. tb.  IRGM gene variants were 
studied in 2010 patients with pulmonary TB and 2346 unaffected 
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controls.  The IRGM genotype -261TT was negatively associated with 
M.tb disease (Intemann et al. 2009). 
1.9 Additional Association Studies 
Today, microarray technology is used for identification of RNA 
expression signatures.  Some reported studies are tabulated in table 
1.8. 
Study findings Country  Reference 
Whole blood RNA expression: distinct gene 
expression patterns identified in patients with active, 
recurrent, latent and cured TB (South African adults) 
South Africa Mistry et al. 
2007 
PBMC RNA expression: differential gene expression 
patterns identified in TB patients and healthy 
controls (German adults) 
Germany Jacobsen et al. 
2007 
Whole blood RNA expression: 393 gene transcript 
identified, differentiating between active TB, latent 
TB and healthy controls; 86 gene transcript 
identified, differentiating active TB from other 
inflammatory conditions and infectious diseases 
(South African and British adults) 
Multiple Berry et al. 
2010 
Whole blood RNA expression: 127 probeset 
representing 77 genes differentiated between active 
TB, latent TB, BCG vaccinated individuals and 
healthy controls (Brazilian adults) 
Brazil Lesho et al. 
2011 
PBMC RNA expression: 506 differentially expressed 
genes identified, distinguished between active TB, 
latent TB and healthy controls (Chinese adults) 
China Lu et al. 2011 
PBMC RNA expression: 17 microRNAs differentially 
expressed, distinguished between active TB, latent 
TB and healthy controls (Chinese adults) 
China Wang et al. 
2011 
Whole blood RNA expression: different gene 
expression patterns identified in individuals with 
active TB and sarcoidosis (German adults) 
Germany Maertzdorf et 
al. 2012 
Whole blood RNA expression: innate immune type 1 
interferon signaling cascade may be used for 
monitoring active TB disease (Indonesian adults) 
Netherlands Ottenhof et al. 
2012 
Whole blood RNA expression: 116 gene expression 
pattern identified, distinguishing between active TB, 
latent TB and healthy controls (Warao Amerindian 
children) 
Netherlands Verhagen et 
al. 2012 




Several GWAS have been carried out on different cohorts in several 
countries, identifying chromosomal regions associated with TB (Moller 
et al. 2012).   
These are tabulated in table 1.9. 
Genetic region Country  Reference 
15q11-13 South Africa Bellamy et al. 2000 
Xg The Gambia Bellamy et al. 2000 
10q26-13, 11q12.3, 
20p12.1 
Brazil Miller et al. 2004 
8q12-q13 Morocco Baghdadi et al. 2006 
6p21-q23 South Africa Cooke et al. 2008 




Uganda Stein et al. 2008 
18q11.2 Ghana, The 
Gambia, Malawi 











Indonesia Png et al. 2012 
Table 1.9: Reported GWAS associated with TB 
These GWAS have added to the understanding of the molecular 
mechanisms of TB disease.  However, many of the genetic associations 
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reported by the early candidate gene studies cannot be replicated by 
GWAS Qu et al. 2013.   
This emphasizes the importance of both types of investigations. 
Advancement of technology, genomic capture, including exome 
capture, is allowing for investigation of complete coding regions of the 
genome (Teer and Mullikin 2010). 
As genetic regions shown to be important for immunity to TB are 
identified, relevant genes are being targeted. 
A functional promoter polymorphism has now been identified in the 
IFITM3 gene on chromosome 11p15, a susceptibility locus for 
tuberculosis in a Han Chinese population.  IFITM3 encodes for 
interferon inducible transmembrane protein 3, acting as an effector 
molecule for IFN.  A case control study has shown a significant 
association between the rs3888188 polymorphism and susceptibility to 
TB.  The rs3888188 G allele was found to be more frequent in TB 
patients and functional assays showed reduced promoter activity. 
The genetic effect of TB susceptibility is further complicated by 
confounding effects of environmental factors and exposure to TB. 
1.10 Concluding statement 
In this chapter I have provided an overview of selected known genetic 
factors within and outside of the IL12/IL23/IFNpathway that are 




1.11 This study 
The work done for this thesis was part of a large Burroughs-Wellcome 
funded collaborative study that started in 2000 to look at the 
immunogenetics of susceptibility to mycobacterial infection.  At that 
time, the greatest evidence to support an underlying genetic basis for 
TB had come from studies on patients with single gene defects which 
showed that up-regulation of the macrophage through the 
IL12/IL23/IFN pathway was a fundamental step in the containment of 
infection with mycobacteria.  The majority of subjects with MSMD are 
susceptible to infections with NTM, but a small subset of this group, 
have been reported to be susceptible exclusively to M. tb. 
Observations from patients with MSMD also raise the possibility that a 
substantial proportion of children with disseminated TB have a 
Mendelian predisposition to disease.  
The IL12p40 promoter had not been extensively screened and was a 
potential candidate gene for study. The IL12p40 promoter and the 
IFN genes were thus chosen for genetic screening in this study. 
1.11.1 Hypothesis 
Susceptibility to primary progressive TB of childhood may result from 
polymorphisms and mutations in genes within the IL12/IL23/IFN 
pathway.  IL12p40 promoter genotype may be predictive of an 
immune phenotype that determines susceptibility to TB disease.   
1.11.2 Aims 
The aim of the work for this thesis was to investigate the genetic 




1. To screen selected paediatric and adult cohorts in the Western 
Cape, South Africa, for DNA changes in the IL12p40 promoter.  
2. To evaluate the functional relevance of IL12p40 promoter SNPs 
identified by a luciferase reporter assay. 
3. To investigate the immunological phenotype in the paediatric 
cohort of TB cases screened by measurement of secreted 
cytokines, TNF, IL12, IFN and the cytokine receptor IL12R1.   
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CHAPTER 2: The IL12 p40 gene promoter 
2.1 Introduction 
As IL12 is an important component of the IL12/IL23/IFN pathway, it 
was postulated that any mutations in the IL12p40 gene promoter 
would have the potential to be of clinical relevance.  Promoter sites are 
important for gene function and mutations in these regions can be 
beneficial or detrimental. 
The major focus of the genetic component of the work for my thesis 
was the screening of the IL12p40 gene promoter for DNA changes. 
In this chapter I review the human IL12p40 gene promoter. 
In 2004 there was a comprehensive screening of promoters in 1% of 
the human genome that was chosen for intensive study analysis in the 
first phase of the ENCODE (ENCyclopaedia Of DNA Elements) project 
(Encode Project Consortium 2004).  The availability of genomic 
sequences of many eukaryotes has enabled the development of 
methods designed to analyse gene boundaries. 
Various technologies have been used for inferring transcription start 
sites (TSS)s, including methods based on sequencing of cDNAs and 
those that use hybrization of RNA or cDNA to DNA probes.  Some of 
the methods allow for targeting to a specific genomic region or gene 
and others are applied to whole genomes (Sandelin et al. 2007). 
The integration of TSS, transcription factor binding data and 
phylogenetic information from multiple mammalian genomic 
sequences has the potential to identify new classes of genomic 
regulatory elements currently regarded as intergenic and it is likely 
that more promoter motifs are yet to be discovered. 
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2.1.1 Promoter types 
The promoters of genes may be focused or dispersed and are 
comprised of the initiation site for the start of transcription and gene 
sequences upstream from the initiation site.   
2.1.1.1 Core promoters 
Core promoters which encompass the minimal portion of promoter 
sequence required to initiate transcription may exhibit combined 
properties of focused and dispersed promoters, having multiple 
dispersed start sites with one particularly strong start site (Juven-
Gershon and Kadonaga 2010).  Genome wide detection of TSSs has 
revealed that RNA polymerase II transcription initiates at millions of 
positions in mammalian genomes.  Most core promoters do not have a 
single TSS but an array of closely located TSSs with different rates of 
initiation.  Frith et al. 2008 showed that initiation events are clustered 
on the chromosomes.  They showed that the TSSs can be predicted 
with high accuracy by sequence. 
Studies have demonstrated that core promoters are diverse and 
complex and that specific DNA sequence elements and patterns are 
associated with them.  These elements are not universal, each is 
present in only a subset of core promoters and some core promoters 
appear to lack all the known core promoter elements.  These patterns 
have important characteristics that are linked to the expression of 
downstream genes.  Different elements can co-occur in the same 
promoter, but some combinations are more likely than others. 
2.1.1.2  Focused promoters 
Focused promoters, also known as a single peak promoters or sharp 
promoters contain either a single TSS or a cluster of start sites over a 
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narrow region of several nucleotides and are usually associated with 
regulated genes (Juven-Gershon et al. 2008, Juven-Gershon and 
Kadonaga 2010).  Most eukaryotic core promoters appear to be 
focused promoters, but in vertebrates, only about a third or less are 
focused promoters, present in a small group of biologically important 
genes.  Focused promoter properties in vertebrates are dependent on 
the presence or absence of sequence motifs which serve as binding 
sites for transcription factors (Juven-Gershon and Kadonaga 2010).  
The analysis of focused core promoters led to the discovery of 
sequence motifs such as the TATAbox, BREu (upstream transcription 
initiator factor IIB [TBIIB] recognition element), BREd (downtream 
TBIIB recognition element), Inr (initiator), MTE (motif ten element), 
DPE (downstream promoter element), DCE (downstream core 
element), and XCPEI (X core promoter element I) (Sandelin et al. 
2007, Juven-Gershon and Kadonaga 2010).  The focused core 
promoter typically encompasses -40 to +40 nucleotides, which span 
relative to the +1 TSS and is the location at which the RNA 
polymerase II machinery initiates transcription (Juven-Gershon and 
Kadonaga 2010). 
2.1.1.3  Dispersed promoters 
Dispersed promoters are also known as broad promoters.  In dispersed 
initiation there are multiple weak start sites over a broad region of 
about 50 – 100 nucleotides and this type of promoter is usually 
present in constitutive genes. In vertebrates, 70% of genes have 
dispersed promoters which are typically found in CpG islands (Juven-
Gershon and Kadonaga 2010).  Dispersed promoters generally lack 
BRE, TATA, DPE and MTE sequence motifs (Sandelin et al. 2007). 
75 
 
2.1.1.4  Bidirectional promoters 
Genome wide analysis has also shown that there are genes with 
bidirectional promoters that are usually broad, with TSSs on opposite 
strands of DNA separated by less than 1kb, (Trinkelein et al. 2004. 
2.1.1.5  Alternative exonic promoters 
Some genes have more than one promoter region used in different 
contexts or tissues or to produce different protein products.  These 
alternative promoters contribute to the complexity of the human 
proteome (Carninci et al. 2006).  Weak alternative exonic promoters 
have also been identified.  These exonic TSSs tend to be more 
prevalent in tissue specific genes (Carninci et al. 2006). 
2.2  Reported promoter mutations 
Promoter mutations have been described in many genes and may have 
major, subtle or negligible effects on gene expression. 
Promoter mutations having clinical relevance have been reported. 
An example of a promoter mutation having a major, beneficial effect is 
the C-46T mutation in the gene encoding the Duffy blood group 
antigen, the erythrocyte receptor for Plasmodium vivax malaria 
parasite, lying within a GATA motif.  The mutation disrupts the binding 
site of the GATA1 erythroid transcription factor, impairing promoter 
activity.  This causes resistance to infection and disease (Tournamille 
et al. 1995). 
Several beneficial mutations have been identified in the IFNR1 gene 
promoter, an important component of the IL12/IL23/IFN pathway.   
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A paediatric case control study in the Mandinka ethnic group in The 
Gambia, looking at four promoter polymorphisms at +95, -56, -270 
and -470 in the IFNR1 gene, showed that subjects heterozygous for 
the C-56T mutation appeared to be protected against cerebral malaria. 
The -470delTT was associated with protection against severe malaria 
in general.  The subjects with these polymorphisms all had an 
additional A-611G polymorphism (Koch et al. 2002).   
An adult study showed no association between promoter mutations at 
+95, -56, -270, -470, -611 and pulmonary TB in a Gambian cohort 
(Awomoyi et al. 2004).   
Another study tested functionality of IFNR1 promoter mutations at -
56, -72, -169, -255, -470 and -611 in African American, Caucasian 
and Korean subjects but found no association with mycobacterial 
disease, including pulmonary tuberculosis and NTM infections 
(Rosenzweig et al. 2004). 
In the work for her thesis, Dr Suzanne Anderson identified five SNPs, -
470/471 TTdel, C-255T, T-181G, T-72C, C-56T in the IFNR1 gene 
promoter in the cohort of cases and controls screened.  The T-181G 
mutation was novel.  The relatively small size of the cohorts studied, 
resulted in insufficient power to detect any effect on TB susceptibility 
(Anderson 2007). 
2.3 The IL12p40 gene promoter 
I will now describe the structure of the IL12p40 promoter, from its 




2.3.1  Murine studies 
In 1995, Murphy et al. defined the genomic organization and promoter 
sequence of the murine IL12p40 promoter, working with a 4.3kb 
proximal promoter region consisting of proximal 5’ sequence, 1st exon 
and 1st intron.  The aim of the study was to understand IL12 induction 
by bacterial products and IFN and they demonstrated several 
important features of the IL12p40 gene regulation in macrophages.  
They focused on the regulation of the IL12p40 subunit because it is 
induced by bacterial stimulation whereas the IL12p35 is constitutive. 
By stimulating murine cells from peritoneal exudates with LPS, in the 
absence and presence of IFN, they measured IL12 production by 
ELISA and demonstrated that IFN caused a twenty-fold increase in 
the level of IL12 produced by LPS alone.  Based on these results, the 
J774 murine macrophage cell line was used for transfection 
experiments with luciferase based murine IL12p40 promoter 
constructs.  Cells transfected with constructs containing 4.3kb of 
proximal 5’ sequence, first exon and first intron, showed LPS inducible 
and IFN regulated luciferase activity, with 13-fold increase above 
background with LPS and 21-fold above background with addition of 
IFN.  Elements were determined using deletion mutants, restriction 
mapping, hybridization to IL12p40 specific oligonucleotides, PCR and 
sequencing. 
To map the elements, various luciferase based deletion mutant 
reporter constructs from 40 to 4300bp of the 5’ promoter sequence 
were prepared and the activity examined.  No loss of promoter activity 
was seen from -703 to the TSS, but a deletion of 7bp between -132 
and -125 markedly reduced the activity, suggesting the location of a 
cis acting element, which regulates expression of a gene located on 
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the same molecule of DNA, usually upstream of the coding sequence it 
controls. 
These results suggested that the murine IL12p40 promoter sequence 
between -132 and -125 conferred LPS inducibility and IFN 
augmentation. 
To identify factors contributing to inducible activity, overlapping 
oligonucleotide probes were used.  The -131AAAATTCCCC-121 sequence 
from -131 to -121 had 8 of 10 nucleotides that make up the identity of 
an NFkB consensus sequence.  
This suggested the presence of a potential half site as a target for 
NFkB binding in which two adenine residues (-131 to -130) replace two 
conserved guanine residues common to reported functional NFkB sites 
(Baeuerie and Henkel 1994). 
Using electrophoretic mobility shift assays (EMSA) and anti-sera to Rel 
transcription factors, this group localized a novel sequence that bound 
the rel family of transcription factors.  They also localized inducible 
activity of the promoter to the sequence GGGAATTTA from -132 to -
122.  To test the functional role of the NFkB site for IL12p40 promoter 
activity, luciferase constructs with 2bp mutations were prepared.  The 
native sequence conferred 15-fold inducibility without IFN 
pretreatment and 28- fold LPS inducibility with IFN pretreatment.  
Altering the -131AA-130 to a -131GG-130 mutation, converting the sequence 
to a full NFkB site, markedly increased the promoter activity. 
NFkB mediates the induction of several proinflammatory molecules.  
Previous studies have described authentic NFkB binding sites with 
mismatches at one of these terminal residues, but this study was the 
first to show a site with both residues as mismatches. 
79 
 
A consensus sequence GAGGAA from -143 to -138 for B cell and 
macrophage specific transcription factor PU.1 lies immediately 
upstream of the NFkB site.  After conducting EMSA experiments and 
comparing activities of IL12p40 luciferase reporter constructs which 
differed in regions containing PU.1 consensus sequences, they 
concluded that this site contributed to the activity of the murine 
IL12p40 promoter, but was not critical for induced promoter activity. 
The work done by this group was novel in that they identified 
functional promoter regions that confer LPS inducibility and IFN 
augmentation and that transcription of IL12p40 was shown to be 
induced via a NFkB half site. 
2.3.2 Human studies 
IL12p40 gene activation is the result of a complex interplay between 
multiple inducible transcription factors.  A number of detailed studies 
on isolated PBMC and macrophage cell lines have teased out this 
interplay and are described in the this section. 
Early studies of the human IL12p40 gene promoter, identified 
important binding factors and repressor elements (Ma et al. 1996, Ma 
et al. 1997, Gri et al. 1998, Becker et al. 2001).   
Ma et al. in 1997 did additional work, showing the comparison of 
genetic organization of the human and murine IL12p40 gene 
promoters.  Several putative sequence motifs are highly conserved 
between the two IL12p40 promoters, suggesting their functional 
significance.  Both promoters show a fairly high degree of homology up 
to approximately -400 with respect to the TSS.  After this, the 




In 1996 Ma et al. did experiments showing that IFN enhances IL12 
production by priming phagocytic cells for LPS induced transcription of 
the IL12p40 gene.  They studied the production and quantitation of 
IL12 by radio immunoassay (RIA) and ELISA after stimulation of 
PBMCs with IFN and LPS.  In PBMCs, IFN alone did not induce 
significant IL12p40 production, LPS alone did induce a five-fold 
increase over unstimulated cells and IFN pretreatment resulted in a 
75- fold stimulation of IL12p40.  Cells treated simultaneously with IFN 
and LPS, produced marginally increased IL12p40 production compared 
to those pretreated with IFN, followed by LPS.  
This group also did experiments with a 3.3kb human IL12p40 
promoter reporter construct from +56 to the 5’ end of the 3.3 kb.  This 
was linked to a fruit fly luciferase reporter construct pXP2 at the PstI 
site which was used for transient transfections in a number of myeloid 
and lymphocytic cell lines.  Transfection was done by electroporation. 
The cloned promoter construct was shown to be silent in two human T 
cell lines, constitutively active in two human EBV+ B lymphoblastoid 
cell lines and LPS-inducible in the human THP-1 and mouse RAW264.7 
monocytic cell lines.  As the RAW264.7 cell line is easily transfectable 
and regulates the endogenous IL12p40 gene in response to IFN and 
LPS similarly to that in human monocytes, it was used for analysis of 
regulation of the cloned human promoter. 
Luciferase activity was measured and values normalized against the 
internal control  galactosidase, to correct for transfection efficiency.  
Effects of folds increase induced by IFN and LPS were replicated by 
these luciferase assays.      
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This showed that the cloned 3.3kb fragment of the IL12p40 promoter 
could mimic the behaviour of the endogenous IL12p40 promoter in 
transient transfection assays in terms of cell type specificity and 
responsiveness to IFN and LPS. 
Deletion mutant constructs generated by PCR were tested for their 
ability to induce transcription of the reporter-luciferase gene in 
response to IFN and LPS.  Promoter regions truncated at -222 showed 
that 50% reduction in expression when compared to the 3.3kb 
sections.  This indicated that upstream elements enhanced 
transcription.  A more severely truncated region at residue -204 
showed a substantial reduction of inducibility by IFN and LPS.  A 
potential motif TTTCCT was located between -204 and -222.  A GGAA 
motif has been established as the consensus motif for the ets family of 
transcription factors.  A 5bp deletion of this sequence resulted in 
complete unresponsiveness to IFN and LPS.  Additional experiments 
with an ets-2 expression vector indicated that ets-2 was mediated by 
this element.  The construct truncated at -222 was active in monocytic 
cells and B cells, but silent when transfected into T cell lines, indicating 
regulation in a tissue specific manner as was observed in the 3.3kb 
promoter.  The construct truncated at -204 showed low, but 
consistent, inducibility by IFN and LPS, indicating that a downstream 
element may be responsible for this persistent inducibility.  It was 
thought that the NFkB site was responsible for this, as it bound to a 
consensus site CCCTTAAAGT located at -116 to -107 in response to 
LPS. 
Two other elements, interferon regulatory factor 1 (IRF-1), important 
for gene induction, located at -730 to -719 and nuclear factor for IL6 
(NF-IL6), a transcription factor, at -520 to -512 were studied by 
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deletion analysis.  Experiments showed that these elements did not 
result in decreased response to IFN and LPS stimulation. 
In a further study, Ma et al. 1997 showed that within the -400 
proximal promoter region, several putative transcription factor binding 
sites, the ets-2, PU.1 and NFkB-like elements were very well 
conserved and that the ets-2 element at -211 to -207 was a 
functionally critical site.  It reacted with nuclear complex termed F1 
which was highly inducible by IFN treatment for 16 hours or LPS 
stimulation for 8 hours. 
Ets-2 and a novel, antigenically related protein with approximate 
molecular mass of 109kDa, plus additional components including IRF1 
and cRel were shown to be part of the F1 complex.  This novel protein 
was designated GL109, a nuclear factor inducible by IFN and LPS.  It 
is part of a complex including IRF1 and possibly NFkB c-Rel that 
interacts with the ets element in the IL12p40 promoter.  The NFkB and 
ets sites appeared to be equally critical for inducible promoter activity 
in macrophage cell lines, the NFkB having a more dominant role in 
constitutive IL12p40 promoter activity in EBV+ B cells.  Ets-2 and c-
Rel are transiently expressed in B, T and monocytic cell lines, 
synergistically activated with the IL12p40 promoter, indicating a lack 
of requirement for cell type or stimulant specific transcription factors. 
In 1998, Gri et al. also worked with the 3.3kb human IL12p40 
promoter reporter construct, from +108 to -3300, using various cell 
lines including human EBV transformed B lymphoblastoid cell line, 
RPMI-8866, EBV-Burkitt’s lymphoma cell line BJAB, T cell line Jurkat 
and the murine macrophage cell line RAW 264.7.  The promoter 
fragment was cloned into a luciferase reporter construct pXP2 at the 
PstI site and transaction was done by electroporation, using BJAB 
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cells, Jurkat cells, RPMI 8866 cells and RAW 264.7 cells.  Luciferase 
activity was corrected for transfection efficiency by normalizing to the 
measured CMV  galactosidase internal control level.  Activity was 
expressed as fold induction above the background of cells transfected 
with the promoterless plasmid.  Luciferase activity of the +108 to -
3300 construct and a series of nested 5’ deletion constructs was 
measured.  Luciferase activity of the full construct was 65-fold that of 
the promoterless vector and measurement of the deletion mutant 
constructs in EBV+BCL suggests that the region between -222 and -28 
is most crucial for constitutive promoter activity on the BJAB 
(EBV+BCL) cells.  Two essential cis elements, an NFkB site and an ets 
site have been localized within the promoter.  By preparing a series of 
promoters with defined mutations, the functional roles of the NFkB and 
ets sites at -117 and -212 was evaluated.  Analysis of the activity of 
the constructs in transiently transfected EBV+BCL showed a marked 
increase in the luciferase activity of promoter constructs mutated at 
the NFkB site, but only a 50% decrease for the ets-2 deletion mutants.  
In contrast, analysis of constructs in the RAW 264.7 cells showed that 
mutations at both these sites almost completely abolished the 
inducubility of the IL12p40 promoter by INF and LPS.  These results 
suggest that B cells use the same cis elements and transcription 
factors as macrophages do, but the relative role of each may vary.  
Using EMSA experiments, the NFkB site was shown to interact with 
p50 and c-Rel, members of the NFkB family and the ets site 
constitutively bound an ets-2 containing complex.  This showed that 
full activation of the human IL12p40 promoter is a result of interplay 
between NFkB and Ets family members. 
In 2001 Becker et al. also studied regulation of the human IL12p40 
promoter construct from +66 to -747.  This 800bp promoter fragment 
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was cloned into the luciferase pXP1 vector and RAW 264.7 cells 
transfected by the diethylaminoethyl (DEAE) method.  The promoter 
was synergistically induced in RAW 264.7 cells upon stimulation with 
LPS plus IFN, showing a 9.5-fold induction compared with 
unstimulated cells. 
In vivo footprinting in resting and activated human CD14+ monocytes 
was studied.  Footprints for trans-activating proteins C/EBP, NFkB, and 
ets were only found on stimulation with LPS and IFN.  In contrast, 
footprinting over a purine rich sequence at -155, termed GA-12, a 
GATA sequence in the IL12 promoter, was observed in resting but not 
activated cells.  Mutagenesis within the GA-12 sequence caused 
upregulation of inducible IL12p40 promoter, suggesting a repressor 
function at this site.  The binding activity of the GA-12 binding protein 
GAP-12 was increased by IL4 and Prostaglandin 2 (PGE2), inhibitors of 
IL12 expression, suggesting that GAP-12 binding may modulate 
IL12p40 gene expression. 
These findings suggest that in unstimulated human monocytes, GAP-
12 binds to the IL12p40 promoter, suppressing gene expression.  
Upon stimulation, GAP12 is displaced from the promoter and NFkB 
p50/p65, C/EBP and PU.1 promote the induction of IL12p40 gene 
expression. 
These studies identified important binding and transcription factors in 
the IL12p40 gene promoter. 
2.3.3 The human IL12p40 gene promoter 
The genetic organization of the proximal region of the human IL12p40 





Figure 2.1: Schematic representation of the genetic 
organization of the proximal region of the human IL12p40 gene 
promoter showing TSS and transcription factors TATAbox, 
CCAAT/enhancer binding protein (c/EBP), nuclear factor kappa 
B (NFkB), PU.1, GA-12, epithelium specific transcription factor 
2 (ets2), activator protein 1 (AP-1), specificity protein 1 (SP1), 
NF-IL6, interferon regulatory factor 1 (IRF-1). 
Regulation of the IL12p40 gene is complex and involves various 
transcription factors and binding sites in the IL12p40 gene promoter.  
These are described in the following section. 
2.3.3.1 TATAbox  
The TATAbox, the most ancient and widely used core promoter motif 
throughout nature, was the first eukaryotic core promoter element to 
be identified (Michael L Goldberg PhD thesis Stanford University 1979, 
Smale and Kadonaga 2003).  It has been conserved from archaea to 
humans (Reeve 2003) is also present in plants (Molina and Grotewold 
2005, Yamamoto et al. 2007), but is only present in 10%-15% of 
mammalian core promoters (Carninci et al. 2006).  The TATAbox 
assists in directing RNA polymerase II to the initiation site downstream 
on the DNA, ensuring that RNA polymerase II is correctly positioned.  
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The metazoan TATAbox consensus sequence is TATAWAAR where the 
upstream T is usually located at -31 or -30 relative to the A+1 (or 
G+1) position in the Inr (Carninci et al. 2006, Ponjavic et al. 2006). 
TATAbox is recognized and bound by TATAbox binding protein (TBP) 
which is a subunit of transcription initiation factor IID (TFIID) complex 
in eukaryotes.  
Statistical analysis (Ponjavic et al. 2006) and structural studies (Hahn 
2004) show that the TATAbox position can vary by 28-34 bp from the 
first T in TATAA consensus to the major initiation peak with a distance 
of 30-31 bp being preferred. 
As previously discussed, the presence of a TATAbox is associated with 
promoters that have a sharply defined TSS.  However, not all sharp 
promoters have a TATAbox.   
Ponjavic et al. 2006 showed that tissue specificity is strongest if the 
TATAbox is -30 bp or -31 bp relative to dominant TSS and that the 
initiation site consensus varies with the TATA-TSS distance.  Studies 
show that the longer TATA-TSS distances (32-34 bp) are used more 
frequently than the shorter distances (28-29 bp) (Molina and 
Grotewald 2005, Ponjavic et al. 2006). 
Precise transcription initiation in TATAbox containing promoters 
generally requires both the TATAbox and Inr like element (O’Shea-
Greenfield and Smale 1992). 
Most promoters regardless of class, lack the Inr consensus sequence 
but even in its absence, the precise start point of RNA polymerase II 
mediated transcription is not random, but specific. 
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2.3.3.2 CCAAT/enhancer binding protein (c/EBP)  
Maehara et al. 1999 showed that NFkB and c/EBP act synergistically to 
enhance gene transcription induced by LPS and IFN (Maehara et al. 
1999). 
2.3.3.3 Nuclear factor kappa B (NFkB)  
Nuclear factor kappa B (NFkB) dimers are ubiquitously expressed and 
their release into the nucleus initiates the process of gene 
transcription.  This is discussed in chapter 1. 
2.3.3.4 PU.1 
Transcription factor PU.1 is tissue specific and expressed in cells of the 
haematopoietic lineage, including macrophages, B lymphocytes and 
granulocytes (Celada et al. 1996). 
2.3.3.5 GA-12  
GA-12 (GATA sequence in the IL12p40 promoter) is a repressor 
element of IL12p40.  Saito et al. 2006 reported impairment of IL12p40 
production by the mouse macrophage cell line RAW264.7 in response 
to LPS.  Activation of GA-12 was detected, rather than suppression of 
promoter elements such as NFkB, AP-1 and IRF-1.  This was 
accompanied by hyperactivation of the extracellular signal-related 
kinase (ERK).  When the ERK activation was suppressed by the UO126 
inhibitor, the IL12p40 production increased and GA-12 activation 
decreased. 
2.3.3.6 Epithelium Specific Transcription factor 2 (ets2)  
The first member of the ets (E twenty six) family of transcription 
factors was identified as a gene transduced by the leukaemia virus 
E26.  All ets family members are identified by a highly conserved DNA 
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binding domain, the ets domain.  Ets factors may act as repressors or 
activators of transcription. (Sharrocks 2001). 
2.3.3.7 Activator Protein 1 (AP-1) 
AP-1 is a heterodimeric protein made of proteins belonging to the c-
Fos, c-Jun, ATF (activity transcription factor) and JDP (Jun 
dimerization protein) families.  It regulates gene expression in 
response to a variety of stimuli, including normal development and 
neoplastic tansformation, functioning within the complexity of many 
cell pathways (Hess et al. 2004). 
2.3.3.8 Specificity Protein 1 (SP1)  
SP1 is a human transcription factor, belonging to the Sp/KLF family of 
transcription factors and is involved in gene expression in the early 
development of an organism (Paonessa et al. 2013). 
 2.3.3.9 NF-IL6 (nuclear factor for IL6) 
Identification of the NF-IL6 trancriptional regulator has been important 
in recogizing the importance of its potential role in multi drug resistant 
1 (MDR1) gene induction (Combates et al. 1994).  Single binding sites 
for NF-IL6 and NFkB are present in the promoter of the IFN gene and 
they act synergistically (Matsusaka et al. 1993). 
2.3.3.10 Interferon-Regulatory Factor Transcription Factor 1 
(IRF1) 
The IRF family of transcription factors is part of the winged helix-turn-
helix DNA-binding domain superfamily.  Members of this family share a 
highly conserved 120 amino acid DNA-binding domain that recognizes 
ISRE consensus DNA sequences.  The ISREs are found in promoters of 
type I IFNs and many genes including type I IFN-induced genes as 
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discussed in chapter 1, section 1.3.1.2.  IRFS are involved in many 
immune processes. 
The complex interplay of transcription factors and binding sites is 
illustrated in figure 2.2. 
 
Figure 2.2: Transcriptional regulation of the gene encoding 
IL12p40. 
Source: Trinchieri 2003  
2.4 Reported mutations in the human IL12p40 promoter 
There have been several publications reporting mutations in the 
IL12p40 (IL12B) promoter (Pravica et al. in 2000, Morahan et al. 
2001, Morahan et al. 2002a, Morahan et al. 2002b, Khoo et al. 2004, 
Muller-Bergaus et al. 2004, Marquet et al. 2008, Morris et al. 2011).  
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Pravica et al. in 2000 reported a G to T change at position -1287 in a 
single individual in a study of adults in the UK, but no clinical data 
were given and therefore, it is not known if this had any functional 
effect. 
There have been several publications about a microinsertion event 
(GC)del(CTCTAA)ins 3kb upstream of the transcription start site.  The 
normal, shorter allele was notated IL12Bpro2 and the mutated allele 
IL12Bpro1.   
Morahan et al. in 2002a studied the genetics of this microinsertion 
event in conjunction with a polymorphism A16974C in the IL12B 3’ 
untranslated region (UTR).  The A16974C polymorphism had been 
found to be associated with development of Type I Diabetes and 
expression of higher levels of IL12 in vitro.  The A allele was notated 
IL12B 3’UTR1 and the C allele notated IL12B 3’UTR2 (Morahan et al. 
2001).  Examining the four haplotypes, the outcome of malaria was 
studied with respect to the various polymorphisms.  An association 
was found between the microinsertion event genotype and cerebral 
malaria in Tanzanian children.  IL12Bpro1 homozygosity was 
functionally associated with lower nitrous oxide production and 
therefore it was found that homozygosity for the IL12Bpro1/3’UTR2 
haplotype conferred greater susceptibility to death from cerebral 
malaria in Tanzanian children, but not in Kenyan children. 
Morahan et al. in 2002b also linked this microinsertion event with the 
severity of atopic and non atopic asthma in children in Australia.  The 
children who were heterozygous for this polymorphism were at the 
greatest risk for progression to severe asthma. However, another 
study done by Khoo et al. in 2004 found no association with asthma or 
atopy and the microinsertion event in Australian children and adults. 
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Muller-Bergaus et al. in 2004 published work on the microinsertion 
event in a cohort of Australian adults linking it to the secretion of IL12.  
They observed that homozygotes for the longer IL12Bpro1 allele were 
unable to secrete IL12.  
This microinsertion event was also found to correlate with secretion of 
IL12, having an impact on the clinical course of disease in patients 
with melanoma (Schadendorf et al. 2006). 
A study done on a cohort of families in Mali by Marquet et al. in 2008 
observed that the heterozygous genotype GC/CTCTAA was 
overtransmitted in children with cerebral malaria. 
Morris et al. 2011 investigated whether polymorphisms in the IL12p40 
promoter were associated with susceptibility to pulmonary TB in two 
West African populations, The Gambia and Guinea-Bissau and in two 
independent populations from North and South America.  Nine 
polymorphisms were identified including a 3 bp insertion in the 
promoter, reported as position 158692783 with rs 17860508.  No 
association was found with this promoter polymorphism. 
A summary of these reported mutations in the human IL12p40 
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Table 2.1: Reported mutations in the human IL12p40 promoter 
These studies report mutations in the IL12p40 promoter, many far 
upstream of the documented transcription and binding sites (Pravicia 
et al. 2000, Morahan et al. 2002a, Morahan 2002b, Khoo et al. 2004, 
Muller-Berghaus et al. 2004, Schadendorf et al. 2006, Marquet et al. 
2008). 
These studies also indicate that the heterozygous genotype is often 
functionally significant and that conducting studies on different ethnic 
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groups and populations is important, as variable effects can be 
observed between different populations. 
In chapter 3, I describe the methodology used for promoter screening 




CHAPTER 3: IL12p40 promoter screening  
and SNP frequencies 
3.1 Introduction and Ethics statement 
This chapter describes the cohort screened, methodology and work 
carried out to identify sequence changes in the IL12p40 promoter.   
This study was conducted according to the principles expressed in the 
Declaration of Helsinki.  The study was approved by the Research 
Ethics Committee, University of Cape Town (Reference number: 
013/2000).  All patients and controls provided written, informed 
consent for the collection of samples and subsequent analysis.   
3.2 Study group 
3.2.1 Paediatric cases 
3.2.1.1 Recruitment of TB cases 
A group of children of Xhosa origin and a group of children from the 
heterogeneous Coloured group were recruited to the study. The  
Coloureds are the predominant population in the Western Cape and 
are a mixed ethnic group of Malay origin mixed with either European 
or the indigenous Khoi and San people (Salmon and Martell 1994).   
Recruitment of all TB cases was made mainly at Red Cross War 
Memorial Children’s Hospital (RCWMCH) and local community clinics 
within two health districts of the City of Cape Town.  These were firstly 
the predominantly Xhosa, formal urban settlements of Langa and 
Guguletu within the City of Cape Town and the informal Xhosa 
settlement of Khayelitsha.  In addition, a smaller number of children 
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were recruited from Coloured settlements within Cape Town Central 
and the South Peninsula. 
3.2.1.2 Method of recruitment 
TB cases suitable for recruitment were identified by Dr Suzanne 
Anderson (SA) using three main sources of information: 
 Past and current admissions to the RCWMCH and associated 
University of Cape Town Teaching Hospitals. 
 Past and current TB culture results from the microbiology 
laboratory at the RCWMCH where, on average, 100-120 culture 
positive cases are identified annually. 
 Official TB notification records from the City of Cape Town Health 
Department.  The name, address, age and type of TB of each 
notified case is provided on their database.  The majority of 
cases came from local community clinics and day hospitals and 
confirmatory microbiology was therefore only available in a 
minority of cases. 
Children who had either active TB or a past history of TB disease 
based on hospital records were recruited to the study.  Newly 
diagnosed active TB cases were recruited at the time of hospital 
admission and commencement of anti-TB chemotherapy, while past 
history cases were enrolled at least one year after initial diagnosis.  
The rationale for not recruiting past history cases until this time was to 
ensure that the in vitro functional studies of cytokine responses were 
unaffected by the acute disease process itself. 
Exclusion criteria were: age over 14 years, HIV seropositivity, any 
other underlying immunodeficiency, children treated with 
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glucocorticosteroids or other immunosuppressive drugs for a prolonged 
time period. 
3.2.1.3 Diagnostic classification 
TB cases were classified as active or past history in the following 
categories: 
 Definite TB - diagnosis confirmed by culture of M. tb from 
sputum, gastric aspirate, CSF, other body fluids or biopsy 
material. 
 Highly Probable TB – acid fast bacilli identified in sputum, 
gastric aspirate, CSF, other body fluids or on histological 
examination of biopsy material. 
 Probable TB  
– adapted from World Health Organisation criteria (WHO 1983 Report 
No EPI/GEN/83/4.  Provisional guidelines for the diagnosis and 
classification of the EPI target diseases for primary healthcare, 
surveillance and special studies) as  
An ill child with a history of contact with suspected or confirmed case 
of pulmonary TB  
plus any one of the following criteria: 
 A history of contact with a confirmed adult pulmonary TB case. 
 Suggestive changes of active TB on chest X-Ray. 
 Loss of weight, or cough for 2 weeks, or no response to 




 Suggestive histological findings in biopsy material. 
 A Mantoux response of ≥15mm*.   
*Note, in this study the cut-off point for a positive Mantoux was set at 
15mm which is well above the WHO recommended value of >10mm. 
This is in keeping with recruitment in a high TB prevalence 
environment (Donald 1999). 
At the time of this study, classification of Probable TB was defined by 
this WHO 1983 report.  Subsequently, the definition of Probable TB 
has become tighter and more specific (Graham et al. 2011).  
 Possible TB - Symptoms of TB for more than two weeks 
(cough, fever, weight loss) and one of either: 
o a suggestive chest x-ray 
o a household contact 
o no alternative diagnosis established.  
 Where an alternative diagnosis became apparent after 
recruitment, patients were re-categorised and excluded from 
further analysis in the study. 
 Past History of TB – children were classified as past history 
cases if recruited 12 months or more after the initial diagnosis of 
TB and commencement of treatment.   
A total of 252 paediatric TB cases were recruited comprising 90% 
Xhosa and 10% Coloured subjects.  The clinical features and of 
paediatric cases and controls are summarized in tables 3.1 and 3.2. 
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 Active TB Past History TB Total 
Definite 39 36 75 
Highly Probable 6 3 9 
Probable 90 18 108 
Possible 33 27 60 
Total 168 84 252 
Table 3.1: Categories of paediatric TB cases 
All active TB cases were seen and bled on three different occasions: at 
enrolment, six months into treatment and one year after enrolment. 
Clinical data were collected from all cases and blood collected for 
functional assays and DNA extraction on all enrolled subjects on every 
visit.  
Past history cases were bled on two occasions, two to four weeks apart 




Cases Controls p value 
 N Median 
Age (IQR) 
N Median Age 
(IQR) 
 
All TB Cases 252 40 (20-87) 145 55 (30.5-91.5) P=0.15** 
PTB Cases 105 33(15-65)    
EPTB Cases 145 48(24-112)    
Categorical Outcomes 
 Cases Controls p value 
 N % N %  
Sex 252  145  p = 0.005** 
Female 117 46 77 53  
Male 135 58 67 47  
BCG 
vaccination 
     
Yes 119 47 63 43 p =0.91** 
No 77 31 42 29  
Not recorded on 
RTHC* 
56 22 40 28  
Mantoux      
0-14mm 41 10(0-11) 94 0(0-0) p = 0.00** 
≥15mm 94 20(16-22) 38 18.5(15-20)  
No result**** 117 46 13 9  
Table 3.2: Clinical features of of paediatric cases and 
controls*RTHC: Road to Health Card 
** Pearson chi square 




3.2.2 Paediatric Controls 
A cohort of healthy, age matched children from the same 
neighbourhood, living within three streets of, but not in the same 
household as a TB case, was recruited as a control group.  All control 
children were Mantoux skin tested and results documented.  Any child 
with an induration diameter of 15mm or greater was referred to the 
local TB clinic for a chest X ray and assessment to determine whether 
or not active TB was present, in accordance with national guidelines 
and excluded from the study if diagnosed with TB. 
The cohort of healthy children was recruited to the study for two main 
purposes: 
 To enable comparison of the functional immunological phenotype 
in healthy children with that measured in past history TB cases  
 To provide a cohort of healthy children for future use in case-
control studies testing newly identified polymorphisms in 
candidate genes for their role in TB susceptibility 
All controls were seen and bled twice at an interval of 2 to 4 weeks to 
check for stability of the functional immunological phenotype. 
3.2.3 Adult Controls 
A further cohort of 756 healthy adult controls with no history of TB 
disease, from the Xhosa and Coloured communities were recruited 
from the same environment as the paediatric controls and cases.  
Local church communities and factory workers were invited to donate 
a 10ml sample of blood after screening to exclude prior TB disease or 
treatment for latent TB infection.  Because no functional phenotype 
was measured and a prior history of TB was excluded, no screening for 
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HIV infection was considered necessary.  It was assumed that all adult 
controls living in a TB endemic environment had been exposed to and 
infected with M. tb. 
The healthy adult controls consisted of 82.4% Xhosa, 17.6% Coloured 
subjects. 
3.3 Screening the promoter region of the IL12p40 in cases 
and controls  
Sequence variations in genes of the IFN pathway were identified using 
two different techniques.  The Imperial College London group used the 
technique of Mutation Detection Gel Analysis (MDGA) from 
Laboratoires Ellios Biotec for screening the IFNR1, IL12p40, IL12p35, 
IL12R2 genes.   For the work in this thesis I used the WAVE 
technique for screening of the IL12p40 promoter, as apparatus for 
MDGA was not available in Cape Town. These two methods enabled 
large scale, mutation screening of candidate genes to be completed.  
To ensure that the two methods were comparable, a validation of the 
WAVE technique was done (see section 3.4.1 below). 
3.3.1 Methodology 
3.3.1.1 MDGA 
MDGA is a combination of two electrophoretic DNA separation 
techniques: single stranded conformation polymorphism (SSCP) and 
heteroduplex mobility analysis (HMA), using PCR amplicons (Crepin et 
al. 2003).  During electrophoresis, double stranded DNA moves 
through a gel at a rate that is determined by its nature and length.  
Single strands in contrast are affected by any base change, as without 
a complementary strand complimentary nucleotides will pair with each 
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other, forming a unique structure of loops and folds dependent on the 
sequence.  The presence of SNPs results in different secondary 
structures, which on electrophoresis show different migration patterns. 
SSCP utilizes this latter property to identify mutations and 
polymorphisms in PCR amplified DNA.  In this technique, double 
stranded DNA is denatured and immediately cooled on ice, preventing 
reannealing of the double strands and allowing folding of the single 
strands into their secondary structures.   
HMA is similar to SSCP but the test sample and wild type are mixed, 
denatured and allowed to reanneal to form a heteroduplex.  A 
mutation in one of the strands will cause a mismatch in the 
heteroduplex, with an alteration in conformation and electrophoretic 
migration pattern. 
MDGA has the advantage of combining electrophoretic discrimination 
of both single stranded DNA secondary structure and double stranded 
homoduplex/heteroduplex. Thus it has the potential to improve on 
resolution of SSCP and HMA used individually.  This is shown in figure 





Figure 3.1: Principles of SSCP and HMA techniques that are 
combined in the MDGA technique. 
In example 1 (SSCP) a mutation in strand b is shown to result in 
different secondary structure and migration pattern. 
In example 2 (HMA) a homozygous mutant results in the formation of 
a bubble in the heteroduplex when the strands are allowed to re-
anneal, retarding migration on the gel. 
3.3.1.2 WAVE  
WAVE utilizes the properties of MDGA with denaturing high 
performance liquid chromatography (DHPLC) and is able to distinguish 
between two or more DNA sequences. 
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Heteroduplexes are prepared by mixing the PCR amplified “normal” 
DNA from a healthy control and “test” DNA samples for each test 
mutation.  If the normal and patient PCR product sequences are 
identical, a homoduplex forms.  If the patient DNA sequence is 
different to the normal, a heteroduplex forms.  These heteroduplexes 
are run on the WAVE instrument, allowing for the detection of 
mutations by the differential retention of homoduplex and 
heteroduplex amplicons on reversed-phase chromatography supports.  
These supports are housed in heated columns where the operational 
temperatures are derived by computational analysis of the DNA 
sequence (Oefner PJ et al. 2000, Xiao et al. 2001).     
When running the samples on the WAVE instrument, a normal control 
homoduplex sample is always included with test samples, for 
comparison of elution patterns.  Any migration pattern different from 
the normal sample is considered as a possible sequence change and 
the genomic DNA of that region of the gene is sequenced.  This is 




Figure 3.2: Flow diagram of procedure for WAVE screening for 
DNA changes. 
The WAVE and MDGA techniques are very similar as regards their 
underlying DNA chemistries, cost requirements, mutation detection 
sensitivities and the use of 96 well plates.  However, the main 
technical difference is that while MDGA uses a single electrophoretic 
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temperature for one sample, WAVE may use more than one 
temperature for each sample, depending of the nature of the DNA 
sequence.  Different sequences of DNA fragments result in individual 
conformations which shape uniquely at different temperatures.  Thus, 
for all amplicons run on the WAVE instrument, the melting domains of 
the PCR product fragments are calculated by sequence computation 
prior to running the samples.   
A comparison of the MDGE and WAVE mutation detection methods is 
summarized in table 3.3. 
MDGA technique WAVE technique 
PCR product run on ABI 377 
sequencer using Elliomut gelTM 
PCR products run on WAVE Nucleic Acid 
Fragment Analysis System 
 
DNA amplicons run on gel, with 
molecular weight markers, 
detected by fluorescence 
DNA amplicons bound to column, eluted and 
detected by UV after Denaturing High 
Performance Liquid Chromatography 
Fluorescent dCTPS used 
(yellow, green, blue)  
Standard dNTPS used 
Fluorescent PCR products fade 
with time 
PCR products stable 
Single injection of sample, 
single electrophoretic 
temperature 
Melting profiles of amplicons   calculated 
before running, sometimes more than one 
injection required if more than one DNA 
domain 
Amplicons with mutations 
migrate at different rates to 
those of normal sequences 
Amplicons with mutations forming 
heteroduplexes elute at different times to 
homoduplexes of normal sequences. 
Table 3.3: Comparison of the WAVE and MDGA techniques 
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3.4 Methods and Results 
3.4.1 WAVE validation 
To ensure that the two methods were comparable, a validation of the 
WAVE technique was completed using three genomic DNA samples 
with known mutations previously identified by the MDGA technique in 
London. 
Genomic DNA from three samples with known mutations in the IFNR1 
promoter (TT deletion), IL12R2 (CT SNP) and TNFR1 (CT SNP) 
genes, previously identified using MDGA, were screened by WAVE. In 
addition DNA from a healthy donor was PCR amplified with appropriate 
primers.  Heteroduplexes were prepared by mixing the normal and 
mutant DNA samples for each test mutation and run on the WAVE 
instrument. 
All three test mutations were successfully detected by WAVE.  Results 




Figure 3.3: Heteroduplex WAVE trace of test mutation 1, TT 
deletion in the IFR1 promoter and normal sequence, showing 
the different conformation determined elution times: 
homozygous TT deletion (green), heterozygote TT deletion 




Figure 3.4: Heteroduplex WAVE traces of test mutation 2, CT 
SNP in the IL12R2 gene in two patients and normal sequence, 
showing the different conformation determined elution times: 
Patient 1 homozygous T/T (purple), patient 2 homozygous T/T 
(yellow), patient 3 heterozygote C/T (green), patient 4 










Figure 3.5: Heteroduplex WAVE traces of test mutation 3, CT 
SNP in the TNFR1 gene and normal sequence, showing the 
different conformation determined elution times: homozygous 
T/T (blue), normal sequence C/C (red). 
3.4.2 Screening of study samples 
After successful validation of the method, screening for DNA changes 
in the IL12p40 promoter was carried out by the WAVE method.  
Because of limited resources and the longer processing time of WAVE 
compared to MDGA, screening of a limited number of randomly 
selected paediatric samples was completed first, followed by ARMS-
PCR to screen for any SNPS identified in the remaining paediatric 
cohort and healthy adult control samples.  




Figure 3.6: Algorithm showing screening of IL12p40 promoter 
by WAVE and ARMS-PCR. 
The categories of the paediatric TB cases screened by WAVE are shown 
in table 3.4. 
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 Active TB Past History TB Total 
Definite 12 13 25 
Highly Probable 6 0 6 
Probable 29 5 34 
Possible 18 11 29 
Total 65 29 94 
Table 3.4: Categories of paediatric TB cases screened by WAVE 
The categories of all paediatric TB cases screened by ARMS-PCR are 
shown in table 3.5. 
 Active TB Past History TB Total 
Definite 27 23 49 
Highly Probable 0 3 3 
Probable 61 13 74 
Possible 15 16 31 
Total 103 55 158 
Table 3.5: Categories of all paediatric TB cases screened by 
ARMS-PCR 
3.4.2.1 WAVE screening of study samples 
3.4.2.2 Amplification of IL12p40 promoter for WAVE 
screening 
The section of the IL12p40 promoter chosen for study extended from 
+73 to -1949 (2022bp).  This section of the promoter sequence was 
used as it encompassed the following transcription factor binding sites: 
TATAbox at -28, C/EBP at -80, NFkB at -115, PU.1 at -126, GA-12 at -
162, ets at -211, AP-1 at -232, SP-1 at -350, NF-IL6 at -510, IRF-1 at 
-728, as shown in figure 2.1 and described in chapter 2. 
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The fragment of the IL12p40 promoter was amplified using eight 
overlapping pairs of primers.  The eight primer pairs were designed by 
Dr Suzanne Anderson to generate amplicons of 300-400bp, the 
optimum size for WAVE screening.  These are listed with the respective 
melting points in table 3.6.   
   





IL12BP1F AAGCTTCTTTTGCATAACTGGC   300 55,57,60.5 
IL12BP1R CAACTGGGGGAGGGGCTTT   
IL12BP2F AACTACTTCACGTCAATTTCTG 339 56,58.5,61.5 
IL12BP2R CTGGCCGTGGGTGGAGAC   
IL12BP3F AGGCCTAGAGGACACAGGG 344 65.1 
IL12BP3R CGCAGGTCCACTTCTCCATC   
IL12BP4F TAAAACCCGGCCTGGTCCC 337 65.5 
IL12BP4R GGAATTTCAAGTTGCTAAGAGG   
IL12BP5F ACATGTTCCTGTTCACGTGCA 291 60.8 
IL12BP5R GTGCTCATAGGTACTCGCTC   
IL12BP6F CTGTATGCCTCCCTGAGGG 332 58.1, 59.5 
IL12BP6R CCTGGTTCTTCCCAAGTCAG   
IL12BP7F CCTTTGCCCTTCATCTCATCCT 389 57,61 
IL12BP7R TTGCAACATTGAAAACAACTCTC   
IL12BP8F TTTTGATGTCTATGTTCCCTCC 259 57.3,59.1,60.8 
IL12BP8R TTGGGAAGTGCTTACCTTGCT   
Table 3.6: Amplicon melting temperatures and primers for 
amplification of the IL12p40 promoter for WAVE 
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For WAVE screening, eight PCR products of each test DNA were 
prepared.  At the same time, eight PCR products of a normal sample 
from a healthy control were prepared for generation of heteroduplexes.  
PCR products were visualized on a 1% agarose gel to check for clarity 
and intensity prior to WAVE analysis.   
Heteroduplexes were prepared by mixing equal volumes of “normal” 
PCR product with “test” PCR product (for example 12l+12l of 
equivalent gel intensity PCR product), incubating at 95oC for 5 minutes 
in a thermal cycler and then switching the cycler off, allowing gradual 
cooling for 45 minutes. 
After running on the WAVE instrument, migration patterns were 
compared and all samples with abberant patterns were sequenced for 
DNA changes.   
3.4.2.3 WAVE screening results 
Potential sequence changes were identified in several of the PCR 
products amplified using the second of the overlapping primer pairs 
BP2F and BP2R shown in table 3.6.   
This region of genomic DNA of all these samples was PCR amplified 
and sequenced for identification of the mutations.  
3.4.2.4 Sequencing for identification of mutations detected 
by WAVE 
Sequencing reaction was done using the Big Dye® Terminator Cycle 
Sequencing kit by myself and electrophoresis of sequenced samples 
carried out at the Department of Human Genetics, UCT.  
In total, only two heterozygous SNPs, 42 bp apart, were identified by 
the WAVE screening, 6 samples had an adenine for guanine 
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substitution at position -1523 (-1523 AG) and 8 samples had a 
cytosine for thymine substitution at position -1564 (-1564 CT). 
Wave migration patterns of the PCR heteroduplex samples are shown 
in figures 3.7 and 3.8. 
 
Figure 3.7: Heteroduplex WAVE trace of normal DNA and SNP -
1523 A/G showing the differing conformation determined 





Figure 3.8: Heteroduplex WAVE trace of normal DNA and SNP -
1564 C/T showing the differing conformation determined 
elution times:  heterozygote C/T (yellow), normal sequence 
C/C (red). 
Sequence traces of the genomic DNA SNP -1523 A/G and SNP -1564 
C/T heterozygotes are shown in figures 3.9 and 3.10. 
 
Figure 3.9: Sequence trace of genomic DNA, showing the SNP -




Figure 3.10: Sequence trace of genomic DNA, showing the SNP 
-1564 C/T in the heterozygous state. 
3.5 ARMS-PCR screening of the larger cohort for the -1523 
A/G and -1564 C/T SNPs  
As these two SNPs were initially identified in a subset of the cohort, 
the remainder of the samples therefore required screening.  
Screening for the presence of the two SNPs in the remaining samples 
was completed using Amplification Refractory Mutation System PCR 
(ARMS-PCR).  This methodology is used for detection of heterozygotes 
by amplifying both alleles in one PCR tube.  These unique ARMS-PCR 
assays were designed and optimized by myself for this wider 
screening.  
3.5.1 Methods and results 
Two allele specific, mismatched forward primers and one reverse 
primer were used for each of the ARMS-PCR assays.  For the SNP -
1523 A/G and SNP -1564 C/T ARMS-PCR reactions, the WAVE primer 
pair IL12BP2F, IL12BP2R was used with additional allele specific, 
forward mismatched primers, ARMS-Fg  and ARMS-Ft  that would 
amplify only the G and T alleles respectively.  Primer positions and 




Figure 3.11: Schematic representation of primer annealing 
areas and amplicons generated by the ARMS-PCR assay, 
showing allele specific mismatched primers Fg and Ft for 
detection of G and T alleles. 
Amplification of the A/A genotype resulted in two identical PCR 
fragments 339bp long, while amplification of the A/G genotype 
resulted in two PCR products of 339 and 217bp respectively.  
Amplification of the C/C genotype resulted in two identical PCR 
fragments 339bp long while amplification of the C/T genotype resulted 
in two PCR products of 339 and 176bp respectively.   
Unique additional forward primers used for the novel ARMS-PCR 
assays were designed.  The ARMS-Fg primer ends in G for detection of 
G allele and ARMS-Ft primer ends in T for detection of T allele.  These 
primers have single base mismatches near the 3’ end, highlighted in 
Table 3.7.  As three primers are used in one tube in the ARMS-PCRs, 
the primer sequences were designed to have similar thermodynamic 
temperatures (Tms).  PCR conditions were optimized and the 
concentrations of the two forward primers and common reverse primer 
adjusted for the single tube assay.  The concentrations of the two 
forward primers were optimized to yield bands of similar 
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intensities.  The common reverse primer was used at a higher 
concentration than that of the forward primers.  
Primer Sequence 5’ to 3’ – mismatched bases in bold 
ARMS-Fg AATCTGCTTTGTCCACTTAATTCTG  (-1523 A/G) 
ARMS-Ft CACCCCACAAATGGTATCAGAT  (-1564C/T) 
IL12BP2F AACTACTTCACGTCAATTTCTG 
IL12BP2R CTGGCCGTGGGTGGAGAC 
Table 3.7: Allele specific mismatched primers for ARMS-PCR for 
detection of -1523 A/G and -1564 C/T SNPs 
3.5.1.1 ARMS-PCR optimization 
The ARMS-PCR was first optimized using different concentrations of 
primers, until intensities of all amplified alleles were similar.  Ethidium 
bromide stained agarose gels (3%) of PCR products of the two assays 
are shown in figure 3.12. 
If no amplicons were seen on the agarose gel, the ARMS-PCR was 





Figure 3.12:  Agarose gel (3%) electrophoresis of ARMS-PCR 
products. 
a: Lane 1, Marker 339bp; lane 2, homozygous A/A genotype 339bp; lane 3, 
heterozygous A/G genotype 339bp and 217bp  
b: Lane 1, Marker 339bp; lanes 2,4, 6 homozygous C/C genotype 339bp; lanes 3, 5, 
7 heterozygous C/T genotype 339bp and 176bp 
Further screening was then done for the two SNPs in the remaining 
paediatric sample (cases n = 158 and controls n = 95) (total n = 426) 
and adult control samples (n = 756). 
Large scale screening for the SNPs -1523 A/G and -1564 C/T was done 
using 96 well plates.  PCR products were electrophoresed on large 3% 
agarose gels, ethidium bromide stained and visualized under UV light 




Figure 3.13: Agarose gel (3%) electrophoresis of ARMS-PCR 
products for detection of -1523 A/G SNP.  Upper comb shows 
21226bp marker and three DNA samples heterozygous for both 
A and G alleles.  Lower comb shows 21226bp marker and one 





Figure 3.14: Agarose gel (3%) electrophoresis of ARMS-PCR 
products for detection of -1564 C/T SNP.  Upper comb shows 
21226bp marker and one DNA sample heterozygosous for both 
C and T alleles.  Lower comb shows 21226bp marker and two 
DNA samples heterozygosous for both C and T alleles. 
After the extended screening, in total, 61 samples (cases n=12, 
controls n=49) were found to have the adenine for guanine 
substitution at position -1523 (-1523 AG) and 60 samples (cases 
n=20, controls n=40) were found to have the cytosine for thymine 
substitution at position -1564 (-1564 CT). 
3.6 Submission to SNP database 
The two SNPs were submitted to the SNP database and given the 





3.7 Statistical Analysis 
Statistical analysis was done using STATA 9 
Initially, comparisons of frequencies of the two SNPs between cases 
and controls was carried out on the subcohort of children screened by 
WAVE, results shown in tables 3.8 and 3.9.  Thereafter, the expanded 
paediatric group screened by WAVE and ARMS-PCR was analysed.   
To increase the power of the study, ARMS-PCR was done on an 
expanded group, using adult control samples. 
Results were not stratified using ethnicity since the majority of 
paediatric subjects screened were 90% Xhosa and 10% Coloured 
(paediatric subjects) and 80% Xhosa and 20% Coloured (adult 
subjects). 
Differences between cases and controls combining Xhosa and Coloured 
groups into one group were investigated for each SNP by Fischer’s 
exact and Pearson chi-square tests. 
124 
 
3.7.1 Statistical analysis of the small paediatric cohort 
screened by WAVE 
Genotype TB Cases (%) Controls (%) Total (%) 
A/G 1 (1.1%) 5 (10.0%) 6 (4.2%) 
A/A 93 (98.9%) 45 (90.0%) 138 (95.8%) 
Total 94 (100.0%) 50 (100.0%) 144 (100.0%) 
Table 3.8: Frequencies of the SNP -1523 A/G and SNP -1523 
A/A  genotypes in the paediatric subcohort screened by WAVE 
Notes: 
Fischer’s exact p = 0.02 
-1523 A/G Odds Ratio (OR) 0.1 (0.002 – 0.92) 
Genotype TB Cases (%) Controls (%) Total (%) 
C/T 5 (5.3%) 3 (6.0%) 8 (5.6%) 
C/C 89 (94.7%) 47 (94.0% 136 (94.4%) 
Total 94 (100.0%) 50 (100.0%) 144 (100.0%) 
Table 3.9: Frequencies of the SNP -1564 C/T and SNP -1564 
C/C genotypes in the paediatric subcohort screened by WAVE. 
Notes: 
Fischer’s exact p = 1.0 
-1564 C/T Odds Ratio 0.9 (0.16 – 5.91) 
The frequencies of the A/G and A/A genotypes recorded in table 3.8 
showed the A/G SNP to be significantly less prevalent in TB cases 
compared to controls [1.1% vs 10%]; (Fischer’s exact p=0.02; n=94 
and 50 respectively]. 
The statistically significant p value of 0.02 for the A/G and A/A 
genotypes in this small paediatric group, suggested that the risk of TB 
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disease is significantly reduced in those subjects with the -1523 A/G 
genotype compared to those with the -1523 A/A genotype. 
3.7.2 Statistical analysis of larger paediatric cohort of 
children screened by WAVE and ARMS-PCR 
The number of children screened for these promoter SNP frequencies 
was increased to test the resilience of the earlier findings.  The results 
are shown in tables 3.10 and 3.11. 
Genotype TB Cases (%) Controls (%) Total (%) 
A/G 12 (4.8%) 10 (6.9%) 22 (5.5%) 
A/A 240 (95.2%) 135 (93.1%) 375 (94.5%) 
Total 252 (100%) 145 (100%) 397 (100%) 
Table 3.10: Frequencies of the SNP -1523 A/G and SNP -1523 
A/A genotypes in the larger group of paediatric subjects 
screened by WAVE and ARMS-PCR 
Notes: 
Pearson chi-square = 0.801  p = 0.4 
-1523 A/G Odds Ratio 0.7 (0.26 -1.80) 
Genotype TB Cases (%) Controls (%) Total (%) 
C/T 20 (7.9%) 9 (6.2%) 29 (7.3%) 
C/C 232 (92.1%) 136 (93.8%) 368 (92.7%) 
Total 252 (100%) 145 (100%) 397 (100%) 
Table 3.11: Frequencies of the SNP -1564 C/T and SNP -1564 
C/C genotypes in the larger group of paediatric subjects 
screened by WAVE and ARMS-PCR 
Note: 
Pearson chi-square = 0.407  p = 0.5 
-1564 C/T Odds Ratio 1.3 (0.55 – 3.34) 
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In this expanded cohort, neither the frequencies of A/G and A/A 
genotypes nor those of the C/T and C/C genotypes in paediatric TB 
cases and controls, recorded in tables 3.10 and 3.11 respectively, 
were significantly different.  
3.7.3 Statistical analysis of all paediatric cases and controls, 
including adult controls 
Because of the small number of paediatric controls, healthy adult 
controls were added to the control group.  Results are shown in tables 
3.12 and 3.13. 
Genotype TB Cases (%) Controls (%) Total (%) 
A/G 12 (4.8%) 49 (5.4%) 61 (5.3%) 
A/A 240 (95.2%) 852 (94.6%) 1092 (94.7%) 
Total 252 (100%) 901 (100%) 1153 (100%) 
Table 3.12: Frequencies of the SNP -1523 A/G and SNP -1523 
A/A genotypes in the expanded group of paediatric subjects 
and healthy controls (paediatric and adult) 
Notes: 
Pearson chi-square = 0.180  p = 0.7 
-1523 A/G Odds Ratio 0.9 (0.41 - 1.69) 
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Genotype TB Cases (%) Controls (%) Total (%) 
C/T 20 (7.9%) 40 (4.4%) 60 (5.2%) 
C/C 232 (92.1%) 861 (95.6%) 1093 (94.8%) 
Total 252 (100%) 901 (100%) 1182 (100%) 
Table 3.13: Frequencies of the SNP -1564 C/T and SNP -1564 
C/C genotypes in the expanded group of paediatric cases and 
healthy controls (paediatric and adult) 
Notes:  
Pearson chi-square = 4.882 p = 0.03   
-1564 C/T Odds Ratio (OR) 1.9 (1.0 – 3.3) 
In this expanded cohort, the frequencies of A/G and A/A genotypes in 
paediatric TB cases and controls recorded in table 3.12 were not 
significantly different. 
However, the frequencies of C/T and C/C genotypes recorded in table 
3.13, showed that the -1564 C/T SNP was significantly more prevalent 
in TB cases compared to controls [7.9% vs 4.4%; (Fischer’s exact p = 
0.03); n = 252 and 901 respectively]. 
The p value of 0.03 in the expanded group suggested that the C/T 
genotype may be associated with susceptibility to TB, as it was 
observed at a significantly higher frequency in TB cases.  
Analysis was repeated on SNP frequencies, excluding the category of 
“Possible TB” cases, but this did not show any significance differences 
between cases and controls. 
3.7.4 Concluding statement 
Screening the IL12p40 promoter for sequence variants among a cohort 
of paediatric TB cases and healthy controls identified two SNPs.  This 
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finding suggests that the IL12p40 promoter is highly conserved.  
However, a number of methodological reasons may have accounted for 
this apparent lack of genetic variation. The initial WAVE screening was 
restricted to 144 DNA samples, a subset of the whole cohort that was 
chosen randomly.  The rationale for this approach was logistical since 
the method is very time consuming and does not lend itself to the high 
throughput screening of a large number of samples. If the entire 
cohort had been screened by this method more SNPs may have been 
identified. However, given the time and financial constraint this was 
not feasible. 
An alternative approach that could have been used would have been to 
complete the initial screening on an enriched cohort of cases with 
severe disease, including TBM, miliary TB or those with low IL12/IFNγ 
responses, on the basis that these cases were more likely to harbour 
functional mutations.   
Another significant limitation was related to the small size of the 
paediatric cohort and especially the number of culture confirmed, 
‘definite’ TB cases. One of the challenges of completing work on 
paediatric TB is that the gold-standard of culture confirmed disease is 
rarely achieved, adding a level of uncertainty to the categorisation of 
cases. This is probably the main reasons why so few genetic studies of 
paediatric TB are reported in the literature.  It is therefore possible 
that some of the cases categorised as probable and possible TB, and 
included in this analysis, had another disease. 
The paediatric control group was also small and for this reason a 
healthy adult control cohort, with no history of TB disease, was 
recruited and included in this study. Controls were recruited from the 
same communities as cases and, because all were living in a TB 
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endemic environment, it was assumed that all were infected with M. 
tb.  When the adult control group was included, analysis of the -1523 
A/G and -1564 C/T SNPs showed that there was a significant 
difference between cases and controls for the -1564 C/T SNP, which 
was more prevalent in the cases. 
Increasing the control group with adult samples has the advantage of 
detecting the effect of a weak SNP.  However, detrimental mutations 
may also have been lost in the adult population, due to death earlier in 
life, resulting in a falsely significant difference between paediatric 
cases and adult controls.  
The -1523 A/G SNP occurred within a pentanucleotide sequence 
(GTATA), reported to bind nuclear factors.  A previous report of the 
GTATA sequence in the HLA-DR gene, showed that by gel retardation 
assays, a synthetic double stranded oligonucleotide containing both 
GTATA and IFN consensus sequences was able to form specific 
complexes with nuclear factors from cell lines of different histotypes 
(Barbieri et al. in 1990).  Amaya et al. 2001 studied promoter 
recognition in vegetative bacteria and reported the GTATA consensus 
sequences were recognized by sporulation associated  factors.  These 
observations are unrelated to the IL12p40 promoter, but there was 
nevertheless the possibility of this rare pentanucleotide being 
important in the expression of the IL12p40 gene.   
This was the rationale for testing for a functional role in determining 




CHAPTER 4: Functional assessment of IL12p40 
promoter SNPs  
4.1 Introduction 
The functional consequences of promoter sequence variations, on gene 
expression, are commonly evaluated by reporter assay systems. 
The reporter system of choice for this thesis was the Dual-Luciferase 
Reporter assay, where the activities of firefly (Photinus pyralis) and 
sea pansy (Renilla reniformis) luciferases are measured sequentially in 
a single test sample.  It is possible to selectively discriminate between 
their respective bioluminescent reactions as the enzymes have 
differing substrate requirements. 
Reporter assays are carried out on cell homogenates that have been 
transfected with DNA constructs.   The DNA is ligated into the cloning 
site of an expression vector that carries the gene for firefly luciferase, 
with the cloned DNA insert acting as the promoter for the luciferase 
gene.  Cells are co-transfected with an expression vector that carries 
the promoter and coding sequence of the sea pansy luciferase.  The 
latter high copy number construct, used as an internal control, serves 
as a baseline response. 
The mouse macrophage cell line, RAW 264.7, was chosen for this 
study as good results have been obtained by other groups using the 
Dual-Luciferase Reporter Assay System.  For limited comparative 
purposes, the human monocyte THP-1 and human fibroblast HT1080 
cell lines, were also used.  The expression vectors used for the 
reporter assay were the pGL3-Basic vector (firefly luciferase) and the 
pRL-TK vector with the thymidine kinase promoter (sea pansy 
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luciferase), gifts from Dr. Sharon Prince, Department of Human 
Biology, Medical School, University of Cape Town.  
This chapter describes the cloning of the PCR amplified promoter 
inserts into the pGEM®-T vector and sub-cloning into the pGL3-Basic 
expression vector.  The following strategy was used for the preparation 
and cloning of the normal, SNP -1523 G, SNP -1564 T promoter 
fragments and two truncation/deletion promoter control fragments. 
4.2 Methods and Results 
4.2.1  The IL12p40 promoter constructs 
The section of the IL12p40 promoter chosen for investigation extended 
from +73 to -1949 (2022bp).  This section was selected as it 
encompassed the following transcription factor binding sites:  TATAbox 
at -28, c/EBP at -80, NFkB at -115, Pu.1 at -126, GA-12 at -162, ets 
at -211, AP-1 at -232, SP-1 at -350, NF-IL6 at -510, IRF-1 at -728.  
Several  early publications defined the existence and importance of 
these transcription factor binding sequences, shown in figure 4.1 as 
discussed in chapter 2 (Murphy et al. 1995, Ma et al. 1996, Ma et al. 
1997, Gri et al. 1998 and Becker et al. 2001). 
 
Figure 4.1: Transcription factor binding sites of the human 
IL12p40 gene promoter. 
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As detailed in chapter 3, two heterozygous promoter SNPs were 
detected in the patient cohort studied, these being an AG 
substitution at nucleotide position -1523 (-1523 A/G) and a CT 
substitution at -1564 (-1564 C/T).  Three 2022bp long, full sequence 
promoter constructs were therefore required for the reporter assay.  1) 
A promoter section carrying the normal sequence at positions -1523 
(A) and -1564 (C), 2) A section carrying the -1523 (G) SNP with the 
normal -1564 (C) sequence and 3) a section carrying the normal -
1523 (A) sequence and the -1564 (T) SNP sequence.  Two negative or 
null controls were also needed for the reporter assay.  It was thus 
decided to prepare two promoter segments missing critical regulatory 
sequences.  This was achieved through truncation and deletion of 
sequence.   
4.2.2 Preparation of the Normal, SNP -1523 G and SNP -1564 
T promoter constructs 
The promoter variants were prepared by PCR using uniquely adapted 
primers.  In order to clone PCR products it is necessary to include 
vector compatible restriction enzyme cutting sites into the forward and 
reverse primers used to generate the PCR fragments.  The 5’ SacI and 
3’ XhoI cutting sites of the pGL3-Basic expression vector were chosen 
for sub-cloning in this study.   
The adapted PCR primers used for RE cutting site inclusion were the 
forward primer IL12BP1F (SacI) and reverse primer IL12BP8R (XhoI).  
These primers were adapted from those previously used for the WAVE 
screening described in chapter 3. 
To facilitate digestion of the 5’ ends of the PCR products, the tagged 
on 6bp cutting sequences were extended by 3 random bases to allow 
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for RE binding.  The respective 9bp 5’ sequences incorporated into the 
IL12BP1F and IL12BP8R primers, are shown in table 4.1.  
Primer Sequences with 9bp 5’ extensions 
Incorporated 
restriction site 
Original P1F AAGCTTCTTTTGCATAACTGGC  
Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Original P8R TTGGGAAGTGCTTACCTTGCT  
Adapted P8R ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 4.1: Adapted primers used for PCR of normal, SNP -1523 
G and SNP -1564 T promoter sequences 
4.2.3 Cloning of promoter variants into T vector system 
The normal and SNP -1523 G and SNP -1564 T promoter sequences 
were first cloned into a T vector system.  This is necessary as Taq 
polymerase adds an A base onto the 3’ end of the amplicons.  The 5’ T 
vector system thus facilitates ligation and cloning through A=T 
complementary binding. 
Several tubes of PCR product of each of the three promoter fragments 
to be cloned (normal, SNP -1523 G and SNP -1564 T), were pooled 
respectively and cleaned on a spin column. 
These three promoter fragments were ligated into the pGEM®–T Easy 
Vector (figure 4.2), (supplied linearized) and used to transform 
competent cells.  The transformation cultures were grown on 
LB/amp/IPTG/Xgal agar plates and screened for inserts through 




Figure 4.2: pGEM®-T Easy Vector circle map and multiple 
cloning site. 
The pGEM®-T vector used in blue/white colony screening, contains the 
 lactamase gene, which confers ampicillin resistance on the plasmid, 
thereby permitting only the growth of competent cells transformed 
with plasmids on medium supplemented with the antibiotic.  The F1 
origin of replication and the lacZ gene in the pGEM®-T vector allow for 
plasmid replication and lacZ gene expression.  The lacZ gene specifies 
synthesis of part of the -galactosidase enzyme and this gene is very 
near the multiple cloning site of the plasmid.  Cells harbouring normal 
plasmids would be ampicillin resistant and able to synthesize -
galactosidase.  Cells harbouring recombinant plasmids, with DNA 
cloned into them, would be ampicillin resistant, but unable to 
synthesize -galactosidase, due to the disruption of the lacZ gene 
sequence by the inserted DNA fragment.  IPTG (isopropyl-
thiogalactoside) is an inducer of the lac genes and ensures that the 
lacZ expression is not repressed.  X-gal (5-bromo-4-chloro-3-indolyl--
D-galactopyranoside) is a substrate for -galactosidase and is broken 
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down by the enzyme into a blue coloured product.  By plating bacterial 
cells transformed with plasmids onto agar containing ampicillin, IPTG 
and X-gal, the recombinant colonies containing the inserted DNA are 
distinguishable by their white colour. 
White colonies were picked and screened for the presence of inserts by 
PCR, using any pair of the original WAVE oligonucleotides, generating 
amplicons of approximately 300bp in size.  Master plates of colonies 
with inserts were prepared.  Overnight cultures were grown and 
plasmid DNA extracted from colonies with inserts of the correct size. 
Colonies with inserts were checked for any PCR errors by sequencing 
of plasmid DNA minipreps.  This was done to ensure that any results 
observed from the functional assays would be solely as a result of the 
variant DNA changes and not PCR errors.  DNA changes were 
interpreted as true mutations when identified in more than one 
sequenced clone. 
An ethidium bromide agarose gel of PCR screening of white colonies is 




Figure 4.3: Agarose gel (1%) gel electrophoresis of PCR 
screening of colonies for cloned inserts. 
Notes: 
Comb A: Lane 1 H/E markers (21226bp-560bp); lane 2, marker (339bp)(slightly 
degraded); lanes 3 and 6, inserts; lanes 4, 5, 7, no inserts. 
Comb B: Lane 1 H/E markers (21226bp-300bp); lane 2, marker (339bp)(slightly 
degraded); lane 6, insert; lanes 4, 5, 7, no inserts. 
An amplicon of 339bp generated from the WAVE screening was used 
as a low molecular weight marker.  Due to extensive use, it became 
slightly degraded over time. 
In spite of using Hi Fidelity Taq polymerase, PCR errors were observed 
in many of the cloned inserts.  Sequencing showed that about 90% of 
clones had 1 or 2 PCR errors, which occurred randomly.  PCR errors 
are a well- recognized occurrence.  Reports on the fidelity of several 
thermostable DNA polymerases has shown that mononucleotide and 
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dinucleotide repeats are not faithfully reproduced by PCR and that 
most commercially available Taq polymerases introduce errors at a 
rate of approximately 10-5 to 10-7 point mutations/bp/duplication.  
High fidelity polymerases generate up to eight times fewer errors 
(Cline et al. 1996, Clarke et al. 2001). 
Eventually normal and SNP -1564 T clones, free of PCR errors, were 
confirmed.  Overnight cultures were grown for storage at -80oC and 
plasmid DNA minipreps prepared. 
All sequence traces were compared to normal genomic sequences 
lodged in the genome database.  Comparisons were generated by the 
National Centre for Biotechnology Information (NCBI) blast alignment 
search tool. 
A sequence trace and NCBI blast alignment of the cloned normal 




Figure 4.4: A section of the cloned normal promoter DNA 
sequence, showing normal C and A sequences. 
 
Figure 4.5: Comparison of normal cloned fragment and normal 
genomic sequence on NCBI blast alignment search tool.  Boxes 
show C and A bases of normal sequence.  Boxes in this figure 
correspond to arrows in figure 4.4 above. 
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A sequence trace and NCBI blast alignment of the cloned SNP -1564 T 
fragment are shown in figures 4.6 and 4.7. 
 
Figure 4.6: A section of the sequence trace of cloned SNP -1564 
T fragment. 
 
Figure 4.7: Comparison of cloned SNP -1564 T and normal 
sequences on NCBI blast alignment search tool.  Box shows 
SNP -1564 T.  Box in this figure corresponds with arrow in 
figure 4.6 above. 
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4.2.4 Digestion of normal and SNP -1564 T fragments out of T 
vector plasmid 
The normal and SNP -1564 T fragments were digested out of the 
pGEM®T vector plasmid using SacI and XhoI restriction enzymes.  
After double digestion, the fragments were electrophoresed on an 
agarose gel, viewed under long wave UV, excised and extracted.  An 
ethidium bromide stained agarose gel of a cloned fragment released 
from the T vector is shown in figure 4.8. 
 
Figure 4.8: Agarose gel (1%) electrophoresis showing T vector 
with cloned fragment and released fragment.  Lane 1 H/E 
markers (21226bp-560bp); lane 2, vector with cloned 
fragment; lane 3, fragment released by digestion. 
Unfortunately, after extensive screening, no PCR error free SNP -1523 




4.2.5 New approach to SNP -1523 G fragment generation.   
The problem of PCR errors in the SNP -1523 G clones was 
circumvented by ligating the PCR error free fragment from a normal 
clone (AG4) with that from the flawed SNP -1523 G clone (AG44) 
which carried an error T-511C.  These individual PCR error free 
sections were generated by digesting both purified inserts with SmaI, 
which cut the promoter at one restriction site only, at nt -1287.  This 
gave selective fragments of 663bp and 1359bp free of PCR error.  
These fragments were purified by electrophoresis and gel extraction.  
The 1359bp fragment from the PCR error free normal clone (AG4) was 
ligated to the 663bp fragment from the SNP -1523 G clone (AG44) 
creating a SNP -1523 G fragment free of any PCR errors.  This strategy 
is depicted in figure 4.9. 
 
Figure 4.9: Schematic representation of the generation of the 
SNP -1523 G fragment through ligation of PCR error free 
sequences from AG44 (663bp) and AG4 (1359bp) after 
digestion with SmaI CCCGGG at nt -1287. 
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An ethidium bromide stained agarose gel of the SmaI digests of the 
AG44 and AG4 fragments is shown in figure 4.10.   
 
Figure 4.10: Agarose gel (1%) electrophoresis of SmaI digests 
of AG4 (normal) and AG44 (SNP -1523 G clone with PCR error 
at nt -511).  Lane 1 H/E markers (21226bp-560bp); lane 2, 
marker (339bp marker, slightly degraded); lane 3, digested 
AG4 (1359bp fragment); lane 4, digested AG44 (663bp 
fragment). 
The 663bp fragment in lane 4 is faint, as only a small amount was 
available for electrophoresis.  Most was used for ligation and cloning. 
These two fragments were ligated to create a PCR error free SNP -
1523 G promoter fragment and sub-cloned directly into the pGL3-Basic 
expression vector as described later. 
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4.2.6 Creation of the truncated and deletion IL12p40 
promoter constructs.  
Two additional constructs were created as negative controls for the 
reporter assay. One was a truncated promoter with the TATAbox, 
c/EBP, NFkB, Pu.1 and GA-12 response elements missing and the 
other was a promoter with essential elements TATAbox, c/EBP, NFkB, 
Pu.1, GA-12 and ets deleted. 
4.2.6.1 Creation of the truncated construct 
The truncated promoter was created by amplifying 1744bp of the 
plasmid DNA minipreparation of the normal promoter from -1949 
(1952 with adapted primer) to -208.  In order to enable this construct 
to be cloned into the pGL3-Basic expression vector, the initial adapted 
forward primer with SacI restriction site and overhang was used and a 
new reverse primer with the Xho1 restriction site and overhang 
designed for the amplification by PCR.  These primers are listed in 
table 4.2. 
Primer Sequence with 9bp 5’ extension  
Incorporated 
restriction site 
Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Adapted R 
truncated 
ATACTCGAGGGTTTACATCATGGCCA C’TCGAG XhoI 
Table 4.2: Primers used for creation of truncated promoter 
The truncated 1744bp construct was missing the TATAbox, c/EBP, 




Figure 4.11: Truncated promoter construct 1744bp in length, 
showing the absence of TATAbox, c/EBP, NFkB, Pu.1 and GA-12 
transcription factor binding sequences. 
Several tubes of PCR product of the amplified truncated promoter were 
pooled and cleaned on a spin column. 
An ethidium bromide stained agarose gel of the PCR product of the 
truncated promoter is shown in figure 4.12. 
 
Figure 4.12:  Agarose (1%) gel electrophoresis of PCR product 
of truncated promoter.  Lane 1 H/E markers (21226bp-
560bp); lane 2, marker (339bp marker, slightly degraded); 
lanes 3-5, truncated promoter (1744bp) from 3 PCR reactions. 
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4.2.6.2 Creation of the deletion construct 
The full length 2031bp normal promoter from +73 (+79 with adapted 
primer) to -1949 (1952 with adapted primer) was amplified and 
digested with Bal1, at a single site, nt -275.  This generated two 
fragments of 1673bp and 358bp in length.  This strategy was used as 
Bal1 was a blunt cutter which allows for ligation of PCR fragments.  
The 1673bp fragment was then ligated to the 3’ end of the 173bp 
fragment, which had been created by amplification of the normal 
promoter from -94 to +73 (+79 with adapted primer).  This resulted in 
a deletion construct of 1848bp in length with transcription factors 
TATAbox, c/EBP, NFkB, Pu.1, GA-12 and ets deleted.  The strategy for 
creation of the deletion construct is shown in figure 4.13 
 
Figure 4.13: Schematic representation of the generation of the 
deletion construct through ligation of 1673bp fragment 
(created by digestion of full length promoter by BalI TGGCCA 
at nt-275) to 173bp fragment (created by PCR).  Deletion 
construct of 1848bp in length is shown with transcription 
factors TATAbox, c/EBP, NFkB, Pu.1, GA-12 and ets deleted. 
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The primers used for generation of full length fragments (to be 
digested with BalI) and 173bp fragment are shown in tables 4.3 and 
4.4. 
Primer 




Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Adapted P8R  ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 4.3: Primers used for generation of full length promoter -
1952 to +79 (to be digested with BalI, creating 1673bp 
fragment of deletion construct) 
Primer 
Sequence with 9bp 5’ extension and 
new forward primer 
Incorporated 
restriction site 
New F  GAGAGTTGTTTTCAATGTTGCAACAAGTC  
Adapted P8R  ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 4.4: Primers used for generation of the -94 to +79 region 
creating 173bp fragment of the deletion construct 
Several tubes of each PCR preparation were pooled, electrophoresed 
on agarose, excised and extracted to ensure that no original template 
was present.  The eluate of the full length (2031bp) fragment was 
digested with BalI, generating two fragments of 1673bp and 358bp 
with blunt ends.  The digest was electrophoresed on agarose and the 
larger 1673bp fragment of the digest excised, extracted and then 
digested with SacI, to create the cloning site at the 5’ end.  The 
digested product was cleaned on a spin column.  The 173bp fragment 
was digested with XhoI, to create the cutting site at the 3’ end and 
cleaned on a spin column. 
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On this occasion PCR amplicons were not treated with T4 DNA 
polymerase to remove the 3’ A addition by Taq polymerase. 
An ethidium bromide stained agarose gel of the PCR products of the 
full length (2031bp) and 173bp fragments are shown in figures 4.14 
and 4.15. 
 
Figure 4.14: Lane 1, H/E markers (21226bp-560bp); lanes 2-
5, full length fragment (2031bp) (to be digested with BalI) 




Figure 4.15: Lane 1, H/E markers (21226bp-560bp); lane 2, 
marker (339bp); lanes 3-7, the 173bp fragment (for creation of 
deletion construct) from 5 PCR reactions. 
4.3 Cloning into pGL3-Basic expression vector 
As preparation for the reporter assay, the five promoter fragments 
normal, SNP -1523 G, SNP -1564T (2022bp), truncated (1744bp) and 
deletion (1848bp) were sub-cloned into the pGL3-Basic expression 




Figure 4.16: pGL3-Basic expression vector circle map and 
multiple cloning site. 
4.3.1 Cloning of normal and SNP -1564 T fragments into 
pGL3-Basic expression vector 
The pGL3-Basic expression vector was linearized by digestion with 
SacI and XhoI restriction enzymes and then cleaned on a spin column. 
The digested normal and SNP -1564 T inserts were subcloned into the 
linearized, cleaned pGL3-Basic expression vector by ligation and 
transformation of competent cells.  Master plates of white colonies 
were prepared and colonies checked for inserts by PCR.   Overnight 
cultures of colonies with confirmed inserts of the correct size were 
grown for storage at -80oC and plasmid DNA extractions done, as 
previously described, using the pGEM®-T vector system.   
4.3.2 Ligation of fragments for SNP -1523 G fragment and 
cloning into pGL3-Basic expression vector 
When the generation of the correct SNP -1523 G fragment was 
completed, the pGL3-Basic expression vector had been obtained, so 
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this fragment was ligated and cloned directly into the expression 
vector in a single step.  Prior to this step, each fragment was digested 
with SacI and XhoI respectively to remove the added overhangs, 
creating the complementary cloning site for ligation into the expression 
vector. 
An overnight culture of the SNP -1523 G clone was grown for storage 
at -80oC, plasmid DNA preparation and sequencing to confirm the 
correct construct sequence.  As clones AG4 and AG44 had been 
previously sequenced, only the sequence of the area of ligation was 
checked.  Sequence traces of the SNP -1523 G and ligation point of the 
663bp and 1359bp fragments are shown in figures 4.17 and 4.18.  
These are depicted separately due to the 236bp distance between  
 
Figure 4.17: A section of the sequence trace of cloned SNP -




Figure 4.18: Sequence trace of cloned SNP -1523 G fragment 
showing ligation point of the 663bp and 1359bp fragments at 
SmaI cutting site CCCGGG. 
The NCBI blast alignment of the cloned SNP -1523 G and normal 




Figure 4.19: Comparison of cloned SNP -1523 G fragment and 
normal sequences on NCBI blast alignment search tool, 
showing correct sequence across region of ligation of 663bp 
and 1359bp fragments.  Boxes show SNP -1523 G and ligation 
point at SmaI cutting site CCCGGG.  Boxes in this figure 
correspond with arrows in figures 4.17. and 4.18 above. 
4.3.3 Cloning of truncated promoter into pGL3-Basic 
expression vector 
The truncated promoter construct was also cloned directly into the 
pGL3-Basic vector.  Several tubes of PCR product of amplified 
truncated promoter were prepared, digested with SacI and XhoI, 
creating the cloning site for ligation, cleaned on a spin column and 
cloned as previously described.  Sequencing was done to verify that 
the fragment was correct.  Sequencing trace and NCBI blast alignment 





Figure 4.20: Sequencing trace of cloned truncated promoter, 
showing truncation of sequence at promoter-vector junction. 
 
Figure 4.21: Comparison of cloned truncated promoter and 
normal sequences on NCBI blast alignment search tool, 
showing end truncated sequence.  Box shows termination point 
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of promoter sequence.  Box in this figure corresponds with 
arrow in figure 4.20 above. 
4.3.4 Ligation of fragments for creation of deletion construct 
and cloning into pGL3-Basic expression vector 
The 1675bp and 173bp were also ligated together in a single step and 
cloned into the pGL3-Basic expression vector as previously described.  
Overnight cultures were grown and plasmid DNA extractions prepared 
on clones with confirmed inserts.  Sequencing was done to verify that 
the sequence spanning the deletion/ligation site was correct.  
Sequence trace and blast alignments are shown in figures 4.22 and 
4.23.   
 
Figure 4.22: Sequence trace showing ligation point of 1675bp 





Figure 4.23: Comparison of cloned deletion promoter and 
normal sequences on NCBI blast alignment search tool, 
showing ligation point of the 1673bp and 173bp fragments.  
Comparison alignments are shown in two sections due to the 
deleted area between them, where the normal sequence did 
not align.  Boxes show the BalI cutting site TGGCCA in larger 
1675bp fragment and correct sequence after ligation to smaller 
173bp fragment.  Boxes in this figure correspond to arrow in 
figure 4.22 above, showing correct ligation of two fragments. 
The normal, SNP -1523 G and SNP -1564 T IL12p40 promoter 
fragments were successfully cloned into the pGL3-Basic expression 
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vector.  A truncated IL12p40 promoter of 1744bp and one of 1848bp 
with essential elements deleted were created and cloned into the 
pGL3-Basic expression vector, providing two negative control 
constructs for the reporter assay. 
Plasmid DNA extractions of five clones containing each of the five 
fragments were prepared from overnight cultures (20ml of each) and 
checked by visualization on an agarose gel, and concentrations 
measured, for the reporter assay.  The concentrations of the plasmid 
DNA preparations were: normal fragment 296ng/l, SNP -1523 G 
fragment 343.6 ng/l, SNP -1564 T fragment 335.3ng/l, truncated 
promoter fragment 422.2ng/l, promoter fragment with deletion 
310.1ng/l.  This provided sufficient plasmid DNA for all transfection 
experiments. 
Plasmid DNA minipreps of clones with the five promoter inserts 
(normal, SNP -1523 G, SNP -1564 T, truncated and deletion 
constructs) in the pGL3-Basic expression vector are shown in figure 
4.24.  The size of the vector (4818bp) prevents the size differences of 




Figure 4.24: Agarose gel (1%) of plasmid DNA 
minipreparations of the 5 cloned promoter fragments in the 
pGL3-Basic expression vector.  Lane 1, H/E markers 
(21226bp-560bp); lane 2 , normal promoter; lane 3, SNP -1523 
G; lane 4, SNP -1564 T; lane 5, truncated promoter; lane 6, 
promoter with deletion.  
4.4 Transfection experiments 
4.4.1 Background 
Transfection is the delivery of DNA, RNA, proteins or other 
macromolecules into the interior of cultured cells.  Without 
intervention, mammalian cells take up and express externally applied 
DNA with very low efficiency, due to the lipid bilayer of the eukaryotic 
cell membrane which acts as a barrier.  Transfection methods increase 
the efficiency of uptake and are based largely on three different 
strategies that rely on 1) carrier molecules, 2) liposomes and 3) 
encapsulation with viral proteins (Sambrook, Fritsch and Maniatis 
1989).  In the case of nucleic acid transfection, carrier molecules 
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utilize the fact that negatively charged nucleic acids can readily adsorb 
to positively charged carrier molecules through electrostatic 
interaction.  The carrier/nucleic acid complex is taken up by the cells 
and the nucleic acid is released within the cytoplasm or nucleus of the 
cell.  The first method that used this principle was the calcium 
phosphate or DEAE-dextran method, described by Graham and van 
der Eb in 1973.  This method is pH dependent and can be toxic to 
cells, so today transfection reagents usually belong to the 
lipid/liposome group (Current Protocols in Molecular Biology Volume 1 
[Eds Asubel et al] John Wiley and sons 1989). 
Cationic liposomal reagents have improved DNA transfection methods.  
If a cationic lipid is mixed with a neutral lipid, unilamellar liposome 
vesicles are formed, carrying a net positive charge.  Nucleic acids can 
adsorb to these vesicles, gaining access to the interior of cells, by 
fusion of the liposome either with the plasma membrane or the 
membrane of an endocytic vesicle.  The next generation of these 
transfection reagents has been the multicomponent reagents 
consisting of lipids and proprietary components.  This new type of 
transfection reagent exhibits lower cytotoxicity and more transfection 
efficiency.   
More forceful, direct methods of delivery include electroporation, which 
generates short lived pores in the cell membrane and bombardment 
with nucleic acid coated carrier particles by eg a gene gun and 
microinjection.  These methods may be used when working with plant 
cells, bacteria or transgenic mice, but are not generally suitable for 
transfection of cultured mammalian cells. 
Nucleic acid transfection can be done by using viral vectors such as 
recombinant vaccinia viruses, retroviruses and adenoviruses. 
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Transfected nucleic acids can be transiently expressed, permanently 
expressed or not expressed at all.  DNA that has crossed the 
membrane barrier will be transported to the nucleus of the eukaryotic 
cell, where it will be transcribed if it contains a suitable promoter.  
Expression usually ceases after two to four days since episomal DNA is 
degraded by the cells (Sambrook, Fritsch and Maniatis 1989).  
Permanently expressing cell lines can be generated by incorporating 
the foreign DNA/gene into the genome of the transfected cells.  This is 
readily achieved through use of retroviral vectors. 
Several factors need to be considered when planning a transfection 
experiment as results of expression studies may be critically influenced 
by several factors.  
Correct choices of cell line and culture conditions are vitally important.  
Dividing cells tend to be more accessible for the uptake and expression 
of foreign DNA compared to quiescent cells.  Transfection efficiencies 
can differ between adherent and suspension cells.  Passage number 
can affect transfection efficiency as cell features may change over time 
in culture.  Other important factors include choice of vector, 
appropriate transfection reagent, ratio of transfection reagent to DNA 
in the transfection complex (charge ratio), time allowed for 
transfection complex to form, volume of transfection complex added, 
transfection medium and cell density at the time of transfection. 
For the work of this thesis, the Dual-Luciferase Reporter Assay 
System  was used to assess the functional relevance of the SNP -1523 
A/G and SNP -1564 C/T heterozygous changes found in the IL12p40 
promoter in the subjects screened. 
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The term “dual reporter” refers to the simultaneous expression and 
measurement of two individual reporter enzymes within a single 
system.  The experimental reporter is correlated with the effect of 
specific experimental conditions, while the activity of the co-
transfected control reporter provides an internal control that serves as 
the baseline response.  Normalizing the activity of the experimental 
reporter to the activity of the internal control minimizes experimental 
variability caused by differences in cell viability, transfection efficiency, 
or lysis efficiency.  In this way, dual reporter assays reduce extraneous 
influences, allowing more reliable interpretation of results.  
4.4.2 Methods and results 
4.4.2.1 Optimization 
In optimizing experiments, three cell lines, two internal controls, three 
transfection reagents and different DNA:transfection reagent ratios 
were used.  Two incubation times of 34 hours and 48 hours were used. 
The mouse macrophage RAW 264.7, human monocyte THP-1 and 
human fibroblast HT1080 cell lines were used.  In the optimization 
experiments, only the RAW 264.7 cell line showed an increase of fold 
induction on stimulation with IFN and LPS.  Very low readings were 
obtained with the THP-1 and HT1080 cell lines with RLUs measuring 




Figure 4.25: RLU readings from triplicate experiments 
[experiment 1 =blue, experiment 2 = red and experiment 3 = 
green] using three different cell lines i.e. 1) mouse 
macrophage RAW 264.7, 2) human monocyte THP-1 and 3) 
human fibroblast HT1080, transfected with normal L12p40 
promoter construct and stimulated with IFN (final 
concentration 1ug/ml) and LPS (final concentration 1ug/ml). 
Two concentrations of two internal controls pRL-TK (with thymidine 
kinase promoter 50ng) and pRL-CMV (with cytomegalovirus promoter 
10ng) were used.  The pRL-TK was the internal control vector of choice 
as no advantage was seen with pRL-CMV and there was more stock of 




Figure 4.26: RLU readings from RAW 264.7 cells transfected 
with normal IL12p40 promoter construct using internal 
controls:  
1) pRL-TK [blue] 2) pRL-CMV [red]. 
The three transfection reagents gave similar results, but X-tremeGene 
HP DNA Transfection Reagent, the recommended agent for cells known 




Figure 4.27: RLU readings from RAW 264.7 cells transfected 
with normal IL12p40 promoter construct using transfection 
reagents: 1) Fu Gene HD [green] 2) X-tremeGene HP [blue] 3) 
X-tremeGene 9 [purple]. 
The recommended incubation time of 48 hours was used, for 
convenient and timely addition of stimulants, as no advantage was 
observed with the shorter time of 34 hours.  
4.4.2.2 Transfection experiments 
A typical transfection experiment took 5 days.  The following is a brief 
summary as detailed methods are described in chapter 6, General 
Methods.    
On day 1, cells were plated into a 12 well tissue culture plate and 
grown overnight to a confluency of 60-70%.   
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On days 2 and 3, the DNA mixes of five cloned promoter fragments 
(normal, SNP -1523 G, SNP -1564 T, truncated, deletion) in pGL3-
Basic expression vector and pRL-TK internal control vector were 
prepared.  This was followed by preparation of the transfection reagent 
and subsequent DNA transfection into the RAW 264.7 cells.  The cells 
were incubated at 37oC in 5% CO2 for a total of 48 hours, with the 
addition of DMSO, IFN and LPS at specific allotted times according to 
experimental design.  IFN primes the IL12p40 gene promoter for 
response to LPS and DMSO has been reported to enhance the effect 
(Ma et al. 1996, Gri et al. 1998, Becker et al. 2001). 
On day 4 the cells were lysed, harvested and frozen overnight at -
80oC. 
On day 5, the Relative Light Units (RLUs) were determined by 
luminometry 
A transfection control (transfection control construct was kindly 
donated by the South African Aids Vaccine Institute laboratory, 
Institute of Infectious Disease and Molecular Medicine, UCT) was 
included in each experiment by transfecting the RAW 264.7 cells with 
the normal promoter fragment together with the control construct 
LucZ/SV40 in the pGL4-Basic expression vector.  This control 
construct, containing the strong SV40 promoter, was a measure of 
transfection efficiency.  It gave similar or higher readings than the 
experimental transfection constructs on the luminometer.   
4.4.2.3 Transfection Results  
Test results were normalized as follows:  background readings (empty 
vector and/or unstimulated) were subtracted from all readings.  The 
firefly readings were normalized against the internal control pRL-TK 
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readings which were taken as 1.  The fold induction values for the 
normal, SNP -1523 G, SNP -1564 T and truncated promoter were 
calculated as normalized firefly value/normalized deletion promoter.  
No fold induction was observed for the truncated promoter construct, p 
values were not significant. (p = 0.49 G vs T; p = 0.74 Normal vs G; p 
= 0.35 Normal vs T) (p value is for Kruskal Wallis one-way analysis of 
variance). 
The relative luciferase activity (fold induction above deletion promoter 
construct) of the stimulated RAW 264.7 cells transfected with the 
normal, SNP -1523 G and -1564 T promoter constructs is shown in 
figure 4.28. 
 
Figure 4.28: Relative luciferase activity in RAW264.7 cells 
transfected with normal, SNP -1523 G and SNP -1564 T 
promoter constructs in pGL3-Basic expression vector and 
stimulated with DMSO (1.2%), IFN (1µg/ml) and LPS 




The functional effect of any mutation, particularly a heterozygous 
mutation where the effect is diluted, may be subtle in a clinical 
condition. 
In a reporter assay, effects of single alleles are tested.  In this series 
of experiments, a functional effect of the promoter SNPs was not 
demonstrated and no gross differences were observed between the 
normal and SNP -1523 G or SNP -1564 T readings. 
Unless the functional effect is marked, a reporter assay of this kind 
may not be sensitive enough to show subtle functional differences. 
To further evaluate whether the SNPs had any effect on the 
immunological phenotype of paediatric patients and controls 
measurement of functional phenotype was done by measurement of 




CHAPTER 5: Immune Testing 
5.1 Introduction 
Cytokines are humoral proteins or glycoproteins with 
immunomodulatory functions.  The clinical outcome of many infections 
appears to be influenced by the overall balance of production of pro-
inflammatory and anti-inflammatory cytokines (Hassig et al. 1998, 
Bidwell et al. 1999a). 
Cytokines modulate the activities of target cells, binding to specific 
cytokine receptor ligands, resulting in gene activation.  Cytokine 
production by cells of the immune system may occur through non-
antigen specific and antigen specific stimuli.  An example of a non-
antigen specific response would be when monocytes are exposed to 
bacterial cell wall products such as LPS, resulting in production of IL12 
and other cytokines.  Antigen specific responses are generated by B 
and T cells through immunoglobulin and T cell receptors respectively. 
Cytokine and cytokine receptor genes are generally highly conserved 
in terms of exon sequences, but even silent mutations may influence 
protein expression by altering mRNA splicing, mRNA stability and gene 
transcription.  A single base change can increase or decrease the 
binding of a transcription factor.  Polymorphisms within the 5’ to 3’ 
regulatory sequences or introns of genes may have a significant effect 
on transcription.  In several cytokine genes, polymorphisms within 
promoter regions, mostly single nucleotide polymorphisms (SNPs) or 
microsatellites which affect gene transcriptions causing inter individual 
variations in cytokine production have been described (Bidwell et al. 
1999a, Bidwell et al. 1999b). 
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Many of the reported polymorphisms within cytokine genes occur 
within known or putative regulatory regions (Bidwell et al. 1999a, 
Bidwell et al. 2001).  These changes may have a significant effect on 
transcription, since they may alter the structure of transcription factor 
binding sites within gene promoters, or the structure of enhancers and 
silencers within introns or at more remote regulatory sites. 
In the first early studies, cytokine gene polymorphisms were shown to 
be involved in the susceptibility, severity and clinical outcome of 
several infectious diseases (Bidwell et al. 1999a, Bidwell et al. 2001, 
Hill 1998) and may play a role in mortality in children and the elderly 
(Pawelec et al. 1999).   
The influence of cytokine gene polymorphisms on gene expression and 
disease has been addressed by two approaches in research, namely, 
studies using in vitro gene expression and studies looking at in vivo 
disease association. 
The in vitro gene expression studies examine the relationship between 
individual polymorphic alleles of cytokine genes and the expression of 
the transcript or cytokine in vitro.  The approach has usually included 
measuring the level of cytokine or cytokine receptor mRNA, or of 
cytokine or receptor protein, expressed as a result of in vitro 
stimulation of cells in culture with a mitogen and isolation of individual 
alleles of gene promoters by cloning them adjacent to a reporter gene 
in an expression vector. 
The in vivo association studies have attempted to identify genetic 
markers for a given disease.  The genetic analysis of cytokines in 
human disease has focused on case-control association studies in 
which the frequencies of marker alleles in groups of patients and 
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healthy controls are compared and the difference is subjected to 
statistical analysis.  One of the limitations of this approach is the 
difficulty in identifying a perfectly matched control group. 
5.2  Immune phenotype 
An immune phenotype which is defined by cytokine and cytokine 
receptor measurements, can predict genetic defects.  Following is a 
description of some phenotypes that present with genetic defects 
within and outside of the IL12/IL23/IFN pathway, shown in table 5.1. 
Deficiency Immune phenotype Reference 
IFNR1   
Complete 
recessive 
No response to IFN, ratio of 
TNF production in response to 
LPS+IFN/LPS low.  Reduced in 
vivo production of IFN, IL12 
and TNF.  High levels of 
plasma IFN. 
Absent receptor expression. 
Newport et al. 1995, 
Holland 2001, 




Diminished response to IFN.  
Response increased by using 
high concentrations of IFN. 
Expression of non-functional 
receptor. 




Diminished response to IFN.  
Response increased by using 
high concentrations of IFN. 
Over-expression of non-
functional receptor. 
Jouanguy et al. 
1999, Villela et al. 
2002 




No response to IFN, ratio of 
TNF production in response to 
LPS+IFN/LPS low.  High levels 
of plasma IFN. 
Absent receptor expression 
Dorman and Holland 
1998, Jouanguy et 








Diminished response to IFN.  
Response increased by using 
high concentrations of IFN. 
Reduced expression of non-
functional protein. 
Doffinger et al.  
2000a, Doffinger et 
al. 2001. 
IFN   
Acquired 
autoantibodies 
Undetectable IFN in whole 
blood.  
In absence of autologous 
plasma, detectable IFN levels 
secreted by PBMCs. 
Kampmann et al. 
2005 







No response to IL12.  IFN 
production impaired. 
Absent receptor expression.  
Sakai et al. 2000, 




Diminished response to IL12.  
Internal receptor measured. 
Lichtenauer-Kaligis 
et al. 2003 




Undetectable or low IL12. 
Normal receptor expression. 
Altare et al. 1998c 




Undetectable or low IL12, TNF, 
IFN levels. 
 
Doughty et al. 





Low IFN levels, undetectable 
IL12p40 production. 
Chapgier et al. 
2006b 




Undetectable or low IFN and 
IL12 levels.  
Filipe-Santos et al. 
2006 
CYBB   
Partial X-
linked 
Impaired CYBB dependent 
NADPH respiratory burst. 









Impaired IL12 production. Hambleton et al. 





Impaired IL12 production. Hambleton et al. 
2011, Salem et al. 
2013 




Low IFN levels produced by 
PBMCs and NK. 
Bogunovic et al. 
2012 
Table 5.1: Immune phenotypes of deficiencies causing MSMD 
5.3 Immunological Investigations 
Cytokine assays can be used to probe the site of defects in patients 
with single gene mutations in the IL12/IL23/IFN pathway (Lammas et 
al. 2000). 
Cytokines do not function in isolation, but operate within a complex 
network.  IL12 plays a pivotal role in cell mediated immunity, 
enhancing the cytotoxic activity of NK and T cells and stimulating IFN 
production.  The effects and responses of TNF, IL12 and IFN all 
interact within this cytokine network.  
Immunological investigations for genetic defects include whole blood 
assays followed by ELISA for the measurement several cytokines, 
including TNF, IL12p70, IFN and flow cytometry for measurement of 
the cytokine receptors.   
Known primary and secondary immunodeficiencies, including HIV 
infection need to be excluded before investigating patients for possible 




For TNF measurement, whole blood is stimulated with LPS and LPS + 
IFN.   The ratio of TNF levels secreted in response to LPS +IFN/LPS 
is a reflection of the ability of cells to respond to IFN.  Typically a 
patient with an IFNR defect that abolished function, preventing 
binding of the ligand to its receptor, would have a low ratio, close to 1.   
5.3.2 IL12p70 
For IL12 (IL12p70) measurement, whole blood is stimulated with 
LPS+IFN as IFN augments production of IL12.  The IL12 levels 
secreted in response to this stimulation are a reflection of the ability of 
cells in the blood to produce IL12.   
5.3.3 IFN  
For IFN measurement, whole blood is stimulated with PHA, a 
nonspecific T cell stimulant, PHA+IL12 and PPD.   
PHA is a non-specific T cell mitogen that cross links T cell receptors.  It 
is commonly used as a positive control to measure the capacity of cells 
to produce IFN in general, rather than to a specific stimulus. 
As IL12 is important for optimal IFN production, the additive effect of 
exogenous IL12 on IFN responses to PHA is used as an indicator of 
functional response to IL12 (Altare et al. 1998d).  The ratio of IFN 
levels produced in response to PHA+IL12/PHA can be used as an 
indicator of the ability to respond to IL12.  Typically a patient with an 
IL12R defect that affected function, preventing binding of the ligand to 
the receptor, would have a low ratio. 
The IFN levels secreted in response to PPD, an extract of M. tb, 
indicate a memory response to mycobacterial antigens.  Thus, children 
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who have been infected with M. tb, would be expected to produce IFN 
in response to PPD irrespective of whether they have clinical or latent 
disease. 
Details of assays for probing defects in cytokine production described 
above are shown in figures 5.1 and 5.2. 
 
Figure 5.1: Diagrammatic representation of the diluted WBA for 
measuring TNF and IL12p70.   
E.coli LPS binds to the CD14 receptor on the antigen presenting 
cell/monocyte and stimulates TNF production.  Pre-incubation with 
IFN enhances production in the presence of functional IFNR.  
IL12p70 is produced by the activated monocyte.  Yellow boxes indicate 
cytokines measured (TNF and IL12p70) in assay supernatant and 





Figure 5.2: Diagrammatic representation of the diluted WBA for 
measuring IFN. 
Mycobacterial antigen is processed by the macrophage and presented, 
with MHC Class II receptor, to the T cell that produces IFN.  Addition 
of IL12p70 enhances IFN production if IL12R1 receptors are 
functional.  The yellow box indicates cytokine measured (IFN) in 
assay supernatant and turquoise boxes indicate stimulatory reagents 
(PHA, IL12 and PPD) added in the WBA. 
5.3.4 Cell surface receptors 
The surface cell expression of the cytokine receptors are measured by 
flow cytometry.   
5.4 Methods and results 
As a screen, a quantitative immune phenotype was measured on TB 
cases and healthy controls in the paediatric cohort.  The screen 
included measurement of TNF, IL12p70 and IFN cytokines and the 
expression of the IL12R1 receptor. 
175 
 
Following is a summary of the methods, which are fully described in 
chapter 6, General Methods. 
5.4.1 Sample Collection 
For cytokine measurement, venous blood was collected into 
preservative free heparin and whole blood assays set up within a 
maximum of 4 hours of collection.  IL12Rβ1 expression was measured 
on stimulated PBMCs. 
5.4.2 WBAs for measurement of TNF, IL12p70 and IFN. 
WBAs were done by diluting heparinized blood 1 in 10 in RPMI medium 
and then stimulating with specific anitigens, viz LPS and IFN for TNF 
and IL12p70; PHA, IL12 and PPD for IFN.  
These whole blood assays were optimized using small blood volumes 
and set up on 96 well plates for large scale screening. 
To reduce the potential effect of diurnal variation in cytokine response 
(Petrovsky and Harrison 1997b), patients were always bled in the 
mornings. 
Many factors can influence the expression of cytokine genes, for 
example the diurnal immune variation (Petrovsky and Harrison 
1997b), linkage disequilibrium with MHC alleles (Petrovsky and 
Harrison 1997a), as well as the age of donors of blood samples, due to 
age affecting T cell activation (Lio et al. 1996, Pawelec et al. 1999). 
Active TB patients were bled at recruitment and then at 6 and 12 
months after commencing TB treatment to ensure that the disease 
itself was not influencing cytokine responsiveness.  Children with a 
past medical history of TB and healthy controls were bled twice at an 
interval of 2 to 4 weeks 
176 
 
to ensure that the measured functional phenotype was stable. 
5.4.3 ELISAs 
Cytokine levels in the harvested supernatants from the WBAs were 
measured by in house ELISAs optimized for use in the Burroughs-
Wellcome funded collaborative study by Dr Suzanne Anderson.  Colour 
development was then read in a Versamax ELISA plate reader.  
Cytokine concentrations were calculated using ELISA software from a 
standard curve run in duplicate on every plate.   
The standard curves used for the TNF, IL12p70 and IFN ELISAs are 
shown in figures 5.3, 5.4, 5.5.  Samples readings were read from the 
linear part of the standard curve. 
 
Figure 5.3: TNF ELISA standard curve generated by nine 




Figure 5.4: IL12p70 ELISA standard curve generated by nine 




Figure 5.5: IFN ELISA standard generated by nine standards 
40pg/ml – 5000pg/ml. 
The lower and upper detection limits were 30pg/ml to 2000pg/ml for 
TNF, 15pg/ml to 2000pg/ml for IL12p40 and 40pg/ml to 5000pg/ml 
for IFN (second lowest to second highest standards on the standard 
curve). 
5.4.3.1 Cytokine measurement 
For patients with active TB, bloods for cytokine testing were taken at 
baseline (pre commencement of TB treatment), 6, 12 and 24 months 
later. 
For evaluation of cytokine production between groups, levels 
measured in acute cases collected at least 12 months after diagnosis 
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and commencement of TB treatment were used for comparison with 
Past History TB cases and healthy controls.  
5.4.3.2 TNF responses 
The ability to produce TNF in response to E. coli LPS and respond to 
IFN was assessed by measuring the ratio of TNF produced to LPS 
alone and following the addition of exonegous IFN.  This was 
expressed as a ratio of TNF production (LPS+IFN/LPS).  Responses 
of all TB cases, Active and Past History combined, were significantly 
lower than those of the healthy controls (p<0.0001), shown in figure 
5.6 (a).   
To evaluate if the lower TNF ratios in TB cases were due to the effect 
of the active disease process itself, TB cases were stratified into Active 
and Past History and compared with healthy controls, shown in figure 
5.6 (b).  There was a gradient of responses, with Active TB cases 
having lower values compared with Past History cases and controls.  
There was no significant difference in TNF ratios between Past History 




Figure 5.6: TNF ratios (stimulation with LPS +IFN/LPS) 
indicative of response to IFN, in TB cases and healthy controls. 
Notes: 
a: Values shown for Cases: (n= 123) median 2.3 IQR (1.8-3); Controls: (n=127) 
median 3.1 IQR (2.6-3.9).  p value is for Mann-Whitney U test.  
b: Values shown for Cases Active: (n=55) median 1.9 IQR (1.6-2.4); Cases Past 
History: (n=68) median 2.5 IQR (2.15-3.35); Controls: (n=127) median 3.1 IQR 
(2.6-3.9).  p value is for Kruskal Wallis one-way analysis for variance of ranks. 
5.4.3.3 IL12p70 responses 
IL12p70 responses of all TB cases, Active and Past History cases 
combined, were significantly lower than those of the healthy controls 
(p<0.0001), shown in figure 5.7 (a).  To evaluate if the lower IL12 
responses in TB cases were due to the effect of the active disease 
process itself, TB cases were stratified into Active and Past History and 
compared with controls, shown in figure 5.7 (b).  A significant 
difference between stratified cases and controls was observed 
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(p<0.0001), suggesting that patients with TB were phenotypically 
different from healthy controls in their ability to upregulate IL12.  
 
Figure 5.7: IL12p70 responses (pg/ml) to LPS+IFN indicative 
of ability to produce IL12, in TB cases and healthy controls. 
Note: 
a:  Values shown for Cases: (n=127) median 641 IQR (388-962); Controls: (n=124) 
median 1092 IQR (680-1577).  p value is for Mann-Whitney U test.  
b:  Values shown for Cases Active: (n=58) median 715 IQR (486-983); Cases Past 
History: (n=69) median 540 IQR (318-883); Controls: (n=124) median 1092 IQR 
(680-1577).   p value is for Kruskal Wallis one-way analysis for variance of ranks. 
Surprisingly, a significant difference was seen in IL12p70 production 





Figure 5.8: IL12p70 responses (pg/ml) to LPS+IFN, indicative 
of ability to produce IL12, in TB cases (active and past history).    
Note:  
c:  Values shown for Cases Active: (n=58) median 715 IQR (486-983); Cases Past 
History: (n=69) median 540 IQR (318-883).   p value is for Mann-Whitney U test. 
5.4.3.4 IFN responses 
For analysis of IFN responses to PHA, TB cases were compared with 
healthy controls with evidence of TB infection. Healthy controls were 
therefore stratified by TST response and only those with 
measurements of ≥10mm used. 
5.4.3.4.1  IFN responses to PHA in TB cases and healthy 
controls 
There was no significant difference in IFN responses to PHA between 
all TB cases and healthy controls, but on stratifying cases into Active 
and Past History and comparing with controls, the Active cases had 




Figure 5.9: IFN responses (pg/ml) to PHA in TB cases and 
healthy controls.   
Notes:  
a:  Values shown for Cases: (n=136) median 11320 IQR (3502-24414); Controls: 
(n=52) median 6066 IQR (2523-15052).   p value is for Mann-Whitney U test.  
b:  Values shown for Cases Active: (n=59) median 14396 IQR (5903-32577); Cases 
Past History: (n=77) median 6719 IQR (2300-21387); Controls: (n=52) median 
6066 IQR (2523-15052).  p value is for Kruskal Wallis one-way analysis for variance 
of ranks. 
When comparing Active and Past History TB cases, each with healthy 
controls, the Active cases were again seen to have higher IFN levels 
than the healthy controls (p=0.002), shown in figure 5.10 (c).  No 
difference was seen with comparison of Past History cases and healthy 




Figure 5.10: IFN responses (pg/ml) to PHA in TB cases (active 
and past history) and healthy controls.   
Notes:  
c:  Values shown for Cases Active: (n=59) median 14396 IQR (5903-32677); 
Controls: (n=52) median 6066 IQR (2523-15052).  p value is for Mann-Whitney U 
test.  
d:  Values shown for Cases Past History: (n=77) median 6719 IQR (2300-21387); 
Controls: (n=52) median 6066 IQR (2523-15052).  p value is for Mann-Whitney U 
test.  
To test the responsiveness to IFN production to IL12, the additive 
effect of IL12 with PHA was used as stimulus for IFN.  This was 
expressed as a ratio of IFN in response to PHA+IL12/PHA, shown in 





Figure 5.11: Ratios of IFN responses to PHA+IL12/PHA, 
indicative of ability to respond to IL12, in TB cases and healthy 
controls.   
Notes:  
e:  Values shown for Cases: (n=85) median 1.84 IQR (1.31-2.57); Controls: (n=14) 
median 2.09 IQR (1.35-3.0).  p value is for Mann-Whitney U test. 
f:  Values shown for Cases Active: (n=58) median 2.03 IQR (1.33-2.81); Cases Past 
History: (n=27) median 1.54 IQR (1.22-2.14); Controls: (n=14) median 2.09 IQR 
(1.35-3.0).  p value is for Kruskal Wallis one-way analysis for variance of ranks. 
5.4.3.4.2 IFN responses to PPD in TB cases and healthy 
controls 
Predictably, all TST positive healthy controls produced IFN in response 
to PPD.  On comparison with TB cases, the TST positive controls had 
significantly higher values than the cases (p=0.002) shown in figure 
5.12 (a). When TB cases were stratified into Active and Past History 
cases, similar IFN responses to PPD were observed, with controls 




Figure 5.12: IFN responses (pg/ml) to PPD in TB cases and 
healthy controls.   
Note:  
a:  Values shown for Cases: (n=135) median 8856 IQR (2624-13923); Controls: 
(n=52) median 15402 IQR (6360-27747).  p value is for Mann-Whitney U test.  
b:  Values shown for Cases Active: (n=58) median 10313 IQR (3916-17547); Cases 
Past History: (n=77) median 7744  IQR (1797-12160); Controls (n=52) median 
15402 IQR (6360-27747).  p value is for Kruskal Wallis one-way analysis for 
variance of ranks. 
Stratifying TB cases into Active and Past history and comparing with 
healthy controls demonstrated significantly higher IFN responses in 
controls compared with Past History cases (p=0.0004).  While there 
was a trend for lower values in Active cases, this did not reach 




Figure 5.13: IFN responses (pg/ml) to PPD in TB cases (active 
and past history) and healthy controls.   
Notes: 
c:  Values shown for Cases Active: (n=58) median  10313 IQR (3916-17547); 
Controls (n=52) median 15402 IQR (6360-27747).  p value is for Mann-Whitney U 
test.  
d:  Values shown for Cases Active: (n=58) median  10313 IQR (3916-17547); 
Controls (n=52) median 15402 IQR (6360-27747).  p value is for Mann-Whitney U 
test.   
5.4.3.5 Role of SNPs on cytokine responses 
To determine if the identified SNPs in the IL12p40 promoter had a 
functional effect on cytokine production, comparison was made of 
cytokine responses in TB cases with SNP genotypes and wildtype 
healthy controls and of cytokine responses in healthy controls with 
SNP genotypes and wildtype TB cases. 
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5.4.3.5.1 Effect of SNPs on IL12p70 responses  
Comparison of IL12p70 responses in wildtype healthy controls and TB 
cases with SNP genotypes showed no significant difference between 
genotypes, as shown in figure 5.14 (a and b). 
 
Figure 5.14: IL12p70 responses (pg/ml) wildtype healthy 
controls and TB cases with SNP genotype.   
Note: 
a:  Values shown for Wildtype Controls: (n=65) median 522 IQR (329-893); 
Genotype -1523 A/G Cases: (n=12) median 367 IQR (281-621).  p value is for 
Mann-Whitney U test.  
 b:  Values shown for Wildtype Controls: (n=65) median 522 IQR (329-893); 
Genotype -1564 C/T Cases: (n=20) median 507 IQR (346-790).  p value is for 
Mann-Whitney U test. 
Comparisons of IL12p70 responses in wildtype TB cases and healthy 
controls with SNP genotypes showed no significant difference between 
genotypes, as shown in figure 5.15 (c and d).  The number of controls 
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with SNP genotype that had IL12 levels measured was less than that 
for other cytokines, resulting in lower numbers for analysis.   
 
Figure 5.15: IL12p70 responses (pg/ml) in wildtype TB cases 
and healthy controls with SNP genotype.   
Notes:  
c:  Values shown for Wildtype Cases: (n=117) median 601 IQR (324-928); Genotype 
-1523 A/G Controls: (n=5) median 342 IQR (342-355).  p value is for Mann-Whitney 
U test.  
d:  Values shown for Wildtype Cases: (n=117) median 601 IQR (324-928); Genotype 
-1564 C/T Controls: (n=8) median 529 IQR (211-790).  p value is for Mann-Whitney 
U test. 
5.4.3.5.2 Effect of SNP on IFN responses to PHA 
Comparison IFN responses to PHA in wildtype healthy controls and TB 
cases with SNP genotypes showed no significant differences between 




Figure 5.16: IFN responses (pg/ml) to PHA in wildtype healthy 
controls and TB cases with SNP genotype.   
Notes:  
a:  Values shown for  Wildtype Controls: (n=52) median 5810 IQR (2362-13289); 
Genotype -1523 A/G Cases: (n=12) median 2156 IQR (556-13746).  p value is for 
Mann-Whitney U test. 
b:  Values shown for Wildtype Controls: (n=52) median 5810 IQR (2362-13289); 
Genotype -1564 C/T Cases: (n=20) median 8022 IQR (3138-22246).  p value is for 
Mann-Whitney U test. 
Comparison of IFN responses to PHA in wildtype TB cases and healthy 
controls with SNP genotypes and showed no significant difference 
between genotypes for the -1523 A/G SNP, shown in figure 5.17 (c).  
However, wildtype TB cases were shown to have higher IFN levels 
than the healthy controls with -1564 C/T genotype (p=0.01), shown in 




Figure 5.17: IFN responses (pg/ml) to PHA in wildtype TB 
cases and healthy controls with SNP genotype.   
Notes: 
c:  Values shown for Wildtype Cases (n=136) median 11320 IQR (3502-2441); 
Genotype -1523 A/G Controls (n=10) median 5226 IQR (2760-14082).  p value is for 
Mann-Whitney U test. 
d:  Values shown for Wildtype Cases: (n=136) median  11320 IQR (3502-24414); 
Genotype -1564 C/T Controls: (n=9) median 2488 IQR (1503-8145).  p value is for 
Mann-Whitney U test. 
5.4.3.5.3 Effect of SNPs on IFN responses to PPD 
Comparison of IFN responses to PPD in wildtype healthy controls and 
TB cases with SNP genotypes showed no difference for the -1523 A/G 
SNP, but TB cases with -1564 C/T genotype were shown to have lower 
IFN levels than the wildtype healthy controls (p=0.002), shown in 




Figure 5.18: IFN responses (pg/ml) to PPD in wildtype healthy 
controls and TB cases with SNP genotype.   
Notes:  
a:  Values shown for Wildtype Controls: (n=52) median 15417 IQR (7090-29279); 
Genotype -1523 A/G Cases: (n=12) median 9360 IQR (112-23619).  p value is for 
Mann-Whitney U test. 
b:  Values shown for Wildtype Controls: (n=52) median 15417 IQR (7090-29279); 
Genotype -1564 C/T Cases: (n=20) median 5429 IQR (1876-11691).  p value is for 
Mann-Whitney U test. 
Comparison of IFN responses to PPD in wildtype TB cases and healthy 
controls with SNP genotypes showed no differences for the -1523 A/G 
SNP, but healthy controls with -1564 C/T genotype were seen to have 
lower levels than wildtype TB cases (p=0.0005), shown in figure 5.19 




Figure 5.19: IFN responses (pg/ml) to PPD in wildtype TB 
cases and healthy controls with SNP genotype.   
Notes: 
c:  Values shown for Wildtype Cases: (n=135) median 8856 IQR (2624-13923); 
Genotype -1523 A/G Controls (n=10) median 3962 IQR (92-14620).  p value is for 
Mann-Whitney U test. 
d:  Values shown for Wildtype Cases: (n=135) median 8856 IQR (2624-13923); 
Genotype -1564 C/T Controls: (n=9) median 300 IQR (94-1526).  p value is for 
Mann-Whitney U test. 
5.5 Measurement of IL12R1 expression by Flow Cytometry. 
IL12R1 cell surface expression was measured by flow cytometry, 
using PBMCs isolated from heparinized blood, stimulated with PHA and 
labelled with a fluorescent IL12R1 antibody (Ozenci et al. 2001, Zaki 
et al. 2001) as detailed in methods, section 6.4. 
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5.5.1 IL12R1 expression  
Cell surface expression of the IL12Rβ1 cytokine receptor is shown in 
figure 5.20. 
 
Figure 5.20: IL12R1 expression (percentage) in TB cases and 
healthy adult controls.   
Note: 
Values shown for Cases: (n=31) median 81 IQR (32-86); Adult Controls: (n=10) 
median 72 IQR (60-84).   Value is for Mann-Whitney U test. 
5.6 Discussion 
Diagnosis of Mendelian susceptibility to mycobacterial infection 
remains challenging.  At the time of completing this work, the 
technology for rapid sequencing of genes and whole exome sequencing 
was not available in Cape Town nor developed to the extent that it is 
today (2013). 
To help tease out the site of a genetic mutation in  patients suspected 
to have this disorder, WB cytokine stimulation assays and 
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measurement of receptor expression can be used to probe the site of a 
suspected defect.  Thereafter, screening for mutations in a suspected 
gene or genes can be completed making it a rapid and relatively 
inexpensive screening tool. 
In this chapter I have described the screening process for defects in 
the IFN pathway, by measurement of TNF, IL12p70 and IFN after 
stimulation in WB assays and measurement of IL12Rβ1 by flow 
cytometry.  Cytokines do not function in isolation, but operate within a 
complex network.  IL12 plays a pivotal role in cell mediated immunity, 
enhancing the cytotoxic activity of NK and T cells and stimulating IFN 
production.  The effects and responses of TNF, IL12 and IFN all 
interact within this cytokine network.  
Because of small numbers of children recruited from the Cape 
Coloured population, stratification by ethnicity was not carried out. 
Stratification by age and gender were also not done, as the aim of this 
work was to identify an immune phenotype resulting in susceptibility 
to TB, not affected by age or gender. 
On the immune testing of this paediatric cohort screened, various 
cytokine profiles were seen.  Overall responses were heterogeneous 
for both TB cases and healthy controls. 
The lower TNF ratios seen in all TB cases compared to higher ratios 
seen healthy controls (p<0.0001), is probably due to the 
mycobacterial infection.  When the TB cases were stratified into Active 
and Past History cases and compared to the healthy controls, this 
lower response in cases was still evident.  The reason for this was due 
to the fact that TB cases (both Active and Past History) produced 
higher levels of TNF to LPS alone, compared to healthy controls (data 
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not shown).  The reasons for this are unclear, but may relate to the 
fact that TB disease has switched on a more profound inflammatory 
response in cases compared to healthy controls and that this effect 
persists even after completion of TB treatment. 
The lower IL12 levels seen in all TB cases as a combined group and 
when stratified into Active and Past History cases, compared to healthy 
controls (p<0.0001), is also probably due to the clinical disease, 
evident even 12 months after diagnosis.  In retrospect, it would have 
been best to measure IL12p40, but at the time, antibodies to the 
heterodimer IL12p70 were readily available, so this was measured. 
Analysis of IFN production in response to PHA, showed no significant 
difference between TB cases as a combined group and controls.  This 
was not unexpected and is likely due to the fact that PHA is a T cell 
mitogen, used to assess non specific responsiveness to IFN.  
However, on stratifying into groups, Active TB cases were shown to 
have higher levels of IFN (p=0.003).  Comparisons of IFN responses 
to PHA in Active and Past History TB cases, each with healthy controls, 
showed this difference still to be evident (p=0.002).  This is likely to 
be due to an enhanced immune response in the Active TB cases. 
PPD is used to specifically look at IFN responses to mycobacterial 
antigens.  Analysis of IFN production in response to PPD, showed a 
significant difference between TB cases as a combined group 
(p=0.002), or stratified into Active and Past History cases (p=0.0009), 
compared to healthy controls.  The healthy controls had higher 
responses compared to the cases.  This was likely due to the fact that 
all IFN producing cells are at the site of disease in the lung and not in 
peripheral circulation (Sutherland et al. 2012).  Another reason for this 
result could be that patients with TB are phenotypically different to 
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healthy controls and less able to upregulate IFN and are therefore 
more susceptible to TB.   
Analysis of IL12R1 expression showed no absence of receptor 
expression.  However, there was a clear bimodal distribution of 
receptor expression with a cluster of seven patients seen to have very 
low expression following stimulation with PHA.  In contrast, among the 
10 healthy controls screened, only one individual was found to have 
low expression.  There are a number of reasons that may have 
accounted for this finding.  First, this may be a normal variant with no 
functional effect.  Very few controls were screened, all of whom were 
healthy adult lab volunteers with no past history of mycobacterial 
disease.  With larger numbers, more individuals with low expression 
may have been found.  Second, low expression may be associated with 
a functional inability to effectively upregulate IFN.  One way to 
evaluate absent or abnormally responsive IL12R1 expression is to 
measure IFN production to PHA in the presence and absence of 
exogenous IL12 (section 6.2.1.2.1).  Unfortunately assays for both 
IL12RB1 expression and IL12 ratio were set up at different time points 
and as a result there were very few patients with both sets of data for 
comparison.   Correlation of larger numbers would be an opportunity 
for future work. 
Comparison of IFN responses to PHA, expressed as a ratio of 
PHA+IL12/PHA, showed no difference between cases and healthy 
controls. 
Analysis of the role of the SNPs on cytokine responses showed varied 
results.   
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No differences between wildtype and SNP genotypes were seen on 
analysis of IL12 levels.   
On analysis of the functional effects of the SNPs with respect to IFN 
production, results were varied.   Analysis of IFN production in 
response to PHA showed the wildtype TB cases to have higher IFN 
levels than the healthy controls with -1564 C/T genotype (p=0.01). 
Analysis of IFN production in response to PPD showed significant 
differences between genotypes.  The TB cases with -1564 C/T 
genotype were seen to have lower IFN levels than the wildtype 
healthy controls (p=0.002) and the healthy controls with -1564 C/T 
genotype were also found to have lower levels than the wildtype TB 
cases (p=0.0005). 
These results are to be interpreted with caution as this variation of 
results is likely to be due to the very small numbers of individuals with 
SNPs, resulting in a lack of power for accurate statistical analysis. 
In conclusion, an immune phenotype correlating with the SNPs found 
in the IL12p40 gene promoter was not observed.  The reasons for this 
may be due to a number of reasons: the small numbers of subjects 
identified with SNPs and associations may have arisen by chance. 




CHAPTER 6: General Methods 
The study group and ethics are discussed in chapter 3. 
6.1  Clinical Methods 
6.1.1 Mantoux testing 
6.1.1.1 Method 
Purified protein derivative of M. tb (PPD), batch RT-23, (Statens 
Serum Institute, Copenhagen, Denmark) was used.  Two tuberculin 
units (0.1ml) were injected intradermally on the volar surface of the 
left forearm.  PPD was injected using a tuberculin syringe (Beckton 
Dickenson, Oxford UK). This procedure was done by one experienced 
nurse. 
6.1.1.2 Measurement of Mantoux reactions 
Induration diameters were measured 48-72 hours later using the 
ballpoint pen technique to determine the borders of the indurated 
area.  This was completed by one nurse who administered the 
tuberculin and the measurement was verified by her co-worker.  The 
widest transverse diameter of the induration was recorded in mm.  
Where no palpable induration was detectable, the result was recorded 
as ‘0’.  Mantoux responses of 15 mm or greater were categorized as 
positive, while those of less than 10 mm were categorized as negative.  
Any child with an induration diameter of 15 mm or greater was 
referred to the local TB clinic for a chest X-ray and assessment in 
accordance with national guidelines (The South African Tuberculosis 
Control Program Guidelines, 2000). 
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6.2  Cellular Methods  
6.2.1  Measurement of immunological phenotype in cases and 
controls 
Blood samples were handled under strict tissue culture conditions in a 
class II bio-safety cabinet to avoid contamination.  For all whole blood 
assays (WBA), venous blood was collected into a sterile syringe 
containing preservative free sodium heparin (Sigma Cat. No. H3149) 
(10ul/ml blood = 10 U/ml blood) and transferred into a sterile tube 
(10ml Falcon Cat. No. 128B). 
For the cytokine assays, bloods were diluted 1:10 in sterile plastic 
tubes (7ml Bijou Cat. No. DA275046024) in tissue culture medium 
(6.3ml tissue culture medium + 0.7ml blood) composed of: 
RPMI 1640 with 1% L-glutamine (200mM) (Gibco Cat. No. 72400-
021), penicillin (100IU/ml) and streptomycin (100mg/ml) (Pen-
Strep)(Gibco Cat. No. 15140-114).  
A blood sample from a pool of healthy adult volunteers was included in 
every upregulation experiment.  
6.2.1.1 Production of TNF and IL12p70 in whole blood  
A WBA for TNF upregulation using LPS of E. Coli and IFN together to 
enhance TNF production, was used to screen for IFN responsiveness.  
This was an adaptation of the method developed and used by Levin 
and colleagues (Levin et al. 1995) to investigate children for defects in 
the IFNR1 gene.  This was reoptimized to enable harvesting of 
supernatants following an overnight incubation and the reproducibility 
verified on a group of healthy laboratory controls.  The concentration 
of assay reagents and time point for aspiration of supernatants was 
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chosen following experiments adapting a WBA tube method into a 96 
well plate assay and assessing the time course of peak TNF 
production following stimulation with LPS and IFN.   
6.2.1.1.1 Reagents 
For the TNF assay, E. coli 0111:B4 LPS (Sigma Cat. No. L2630) was 
supplied as 10mg lyophilised powder and reconstituted in 1ml RPMI to 
give a final concentration of 10mg/ml.  This was further diluted 1:1000 
in RPMI to give a stock concentration of 10µg/ml which was stored in 
100µl aliquots at –80C.  A working solution of LPS was freshly 
prepared from frozen stock on the day of WBA by diluting stock LPS 
1:2000 in RPMI to give a final concentration of 5ng/ml.  Recombinant 
Human IFNγ (rHu IFN) (Immukin, Boehringer Ingelheim Cat. No. 
PL00015/0154) was prepared from stock at 100µg/0.5ml diluted 1:100 
in PBS to give a final concentration of 2000ng/ml).  The working 
solution was stored at 4C for a maximum of one month.  
A similar WBA for IL12 upregulation using LPS of E. coli and IFN was 
used to screen for production of IL12p70.  For the IL12p70 assay a 
working solution of LPS was freshly prepared from frozen stock on the 
day of WBA by diluting stock LPS 1:100 in RPMI to give a final 
concentration of 100ng/ml.  Stock IFN (100µg/0.5 ml) was diluted 
1:10 in PBS to give a final concentration of 20µg/ml.  The working 
solution was stored at 4C for a maximum of one month. 
6.2.1.1.2 Method for TNF and IL12p70 upregulation TNF 
upregulation 
Diluted blood (180l) was placed into 12 wells of a 96 well, round-
bottomed tissue culture plates (Greiner Cat. No. 163320).  IFN at a 
final concentration of 100ng/ml was added to the first four wells and 
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an equivalent volume of RPMI added to a further 6 wells.  The plates 
were then incubated at 37C in 5% CO2 for two hours.  LPS at a final 
concentration of 0.5ng/ml was added to four wells 1-4 containing IFN 
or RPMI and the wells mixed 5 times with a multi-channel pipette.  
Control wells contained RPMI alone.  Incubation was continued for a 
further 18 hours at 37C in 5% CO2.  Supernatants from quadtriplicate 
wells were harvested, pooled and stored at –80C in two aliquots until 
analysis by ELISA.  A summary of this procedure is shown in table 6.1. 
TNF plate plan Wells 1-4 Wells 5-8 Wells 9-12 
 Unstimulated LPS IFN + LPS 
RPMI 30ul 10ul - 
IFN 1:100 - - 10ul 
Blood 1:10 180ul 180ul 180ul 
LPS 1:2000 - 20ul 20ul 
NB: TNF plate was incubated for 2 hours before the addition of LPS 
Table 6.1: Summary of loading volumes for TNF upregulation 
in microtitre plate IL12p70 upregulation 
The TNF method was adapted for measuring IL12 up-regulation using 
IFN and LPS at final concentrations of 1g/ml and 10ng/ml 
respectively.  Control wells contained RPMI alone.  Supernatants from 
quadtriplicate wells were harvested, pooled and stored at –80C as two 
duplicate aliquots until analysis by ELISA.  The final concentration of 
assay reagents and the time course of peak IL12 production were 
chosen following optimisation experiments.  A summary of this 
procedure is shown in table 6.2. 
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IL12p70 plate plan Wells 1-4 Wells 5-8 Wells 9-12 
RPMI -   
IFN 1:10 10ul   
Blood 1:10 180ul   
LPS 1:100 20ul   
NB: IL12 plate was incubated for 2 hours before the addition of LPS 
Table 6.2: Summary of loading volumes for IL12 upregulation 
in microtitre plate 
6.2.1.2 IFN production in whole blood  
6.2.1.2.1 Reagents 
Preparations of 100,000 units of PPD per ml (Evans Medical Limited, 
Leatherhead, UK) were diluted in RPMI to a final concentration of 
10µg/ml ready for use.  Aliquots were stored at –20C and defrosted 
prior to use.  PHA (Sigma Cat. No L-1668) was diluted in RPMI to a 
final concentration of 5µg/ml and used for WBA stimulation of IFN 
production.  The solution was stored in aliquots at –20C and defrosted 
immediately before use. 
6.2.1.2.2 Method for IFN upregulation 
Twenty microlitres of solution containing either PHA at 5µg/ml, PPD 
10µg/ml or phosphate buffered saline (PBS) as unstimulated control 
were pipetted into 96 well, round-bottom tissue culture wells (Greiner 
Cat. No 163320).  Four wells were set up for each stimulant with each 
blood sample.  An additional 4 wells containing both PHA at 5µg/mL 
and recombinant human (rHu) IL12p70 (BD Pharmingen, Becton-
Dickinson, Oxford, UK) at a final concentration of 50pg/ml were also 
included, as a screen for IL12 responsiveness.  Diluted blood (180 l) 
was pipetted into each well.  The plates were incubated at 37C in a 
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5% CO2 incubator.  On day three, supernatants were harvested from 
the wells containing PHA/blood and the unstimulated control.  On day 
six, supernatants were harvested from the wells containing PPD/blood 
and the unstimulated controls.  Quadruplicate wells were harvested, 
pooled and stored as two duplicate aliquots at -80C until analysis by 
ELISA. 
Separate plates were used for PHA and PPD stimulation, due to their 
different incubation periods.   
Optimal time for upregulation of IFN with PHA and PHA/IL12 was 3 
days 
Optimal time for upregulation of IFN with PPD was 6 days 
Summaries of these procedures are shown in tables 6.3 and 6.4. 





RPMI 20ul - - 
PHA 1:100 - 20ul 20ul 
IL12 1:12500 - - 10ul 
Blood 1:10 180ul 180ul 180ul 
Table 6.3: Summary of loading volumes for 3 day IFN 
upregulation with PHA in microtitre plate 
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IFN PPD Plate Plan Wells 1-4 Wells 5-8 
 Unstimulated Control PPD 
RPMI 20ul - 
PPD 1:20 - 20ul 
Blood 1:10 180ul 180ul 
Table 6.4: Summary of loading volumes for 6 day IFN 
upregulation with PPD in microtitre plate 
Note: Rows A and H of the 96-well plate were not used to avoid excess evaporation 
during the long incubation periods. 
Summary of loading volumes for 6 day IFN upregulation with 
PPD in microtitre plate 
6.2.1.3 Production of pooled TNF and IFN internal 
biological controls for ELISA 
Using the TNF and IFN upregulation assays described above, two 
batches of supernatant were collected for use as an internal quality 
control (QC) for measurement of inter-assay variation.  In summary, 
20ml of heparinized blood was collected from a single donor, diluted 1 
in 10 with RPMI and 180µl aliquots pipetted into 96 well tissue plates.  
The blood was stimulated with either 5ng/ml of LPS plus 20ng of IFNγ 
or 5µg of PHA.  TNF and IFN supernatants were harvested and 
pooled after incubation at 37oC in 5% CO2 for 18 hours and 3 days 
respectively.  These were stored at -80oC in aliquots for use as ELISA 
controls. 
6.3 Cytokine Measurement using ELISA technique 
Concentrations of TNF, IL12p70 and IFN in supernatants, collected at 
specific time points during WBA experiments, were measured using 
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sandwich ELISA antibody pairs according to manufacturer's 
recommendations.   
6.3.1 Reagents 
Coating buffer 
ELISA plate coating buffer consisted of bicarbonate buffer (0.1 M 
Na2HCO3 pH 8.4) for TNF and IFN and sodium phosphate buffer 
(0.1M Na2HPO4 pH9.0) for IL12p70 assays. 
Cytokine standards, purified mouse anti-human monoclonal capture 
and biotinylated detection antibodies were obtained from BD 








TNF 19761T 18631D 18642D 
IL12p70 19721V 23271D 55466O 
IFN 19751N 18891D 18902D 
Table 6.5: Details of cytokine standards, capture and detection 
antibodies 
PBS  
This was prepared from 11.6g Na2HPO4, 2.0g KH2PO4, 2.0g KCl, 80.0g 
NaCl made up to 10L in Milli-Q H2O (Invitrogen Cat. No. 10270), 
filtered with a 0.22 mm filter (Separations Inc. USA).  
Blocker 
10% Fetal Calf Serum (FCS) (Invitrogen Cat. No. 10270) was filtered 
with a 0.22 mm filter (Separations Inc. USA) prior to mixing with PBS.    
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Washing solution - PBS with 0.5% Tween 20 
5.0ml Tween 20 was added to 10L  of prepared PBS. 
Diluent for samples, detection antibody and avidin peroxidase 
10% FCS in PBS without Tween. 
Avidin Peroxidase 
Avidin peroxidase (Sigma A-3151) was stored at 1 mg/ml in sterile 
PBS at -80C and diluted 1:1000 in 10% FCS/PBS for use.  Aliquots 
were stored at -20C and defrosted immediately prior to use.   
Dilutions were made and final concentrations of 1.25g/ml for TNF, 
3.3g/ml for IL12 and 5g/ml for IFN ELISA assays used. 
Substrate 
Substrate consisted of O-phenylenediamine dihydrochloride (OPD) 
(Sigma P-1526) dissolved in citric acid buffer (citric acid 5.19g/L, 
Na2HPO4.2H20 9g/L, pH 5.0 plus 10 ml of 30% H2O2) 
4mg OPD was used per 10ml citric acid buffer. 
Stop Solution 
Stopping solution consisted of 2M H2SO4. 
6.3.2 Method  
Measurement of the TNF, IL12p70 and IFN cytokines was a three 
day assay.  
Day 1 – capture antibody  
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On day one, flat bottomed, 96-well high binding ELISA plates (Nunc 
442404) were coated with 50l per well of the capture antibody diluted 
in sodium bicarbonate buffer to a final concentration of 2µg/ml for 
TNF and IFN and in sodium phosphate buffer at 5µg/ml for IL12p70.  
Plates were covered and kept at 4C overnight.   
Day 2 – blocking and loading with standards, samples and 
controls 
Plates were washed twice in PBS with 0.5% Tween 20. Plates were 
blocked for 1-2 hours using 200 µl/well of PBS/10% FCS without 
Tween.  After blocking, they were washed twice more with PBS/0.5% 
Tween 20 before application of samples and standards.    
6.3.2.1 Preparation of cytokine standards for ELISA assay 
Recombinant human cytokines (rHu) were used as reference 
standards.  
Prior to use, the TNF standard was diluted to 1µg/ml, IFN to 
25µg/ml, and IL12p70 to 12.5µg/ml in 10mg/ml Bovine Serum 
Albumin in PBS, aliquoted and stored at -80C. 
For each experiment, one vial of each reconstituted, rHu cytokine was 
defrosted and diluted further for use.   
One hundred microlitres of standard were applied in duplicate and 
serially diluted between 5000pg/ml and 19.5pg/ml for TNF, 
2000pg/ml and 7.8pg/ml for IL12 and 5000pg/ml and 19.5pg/ml for 
IFN across the ELISA plate.  Where possible the same batch of 
standard was used for all experiments for the duration of the study. 
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6.3.2.2 Preparation of harvested supernatants 
Frozen supernatants, generated during WBA experiments, were 
thawed at room temperature (RT), mixed by vortexing and 100 µl 
serially diluted in 100 µl volumes of PBS/10% FCS in duplicate.   




















1 in 2 
1 in 4 
1 in 4 
1 in 8 
1 in 2 
1 in 16 
1 in 32 
1 in 64 
1 in 8 
1 in 16 
1 in 32 
Table 6.6: Sample dilutions of supernatants used for cytokine 
measurement by ELISA 
6.3.2.3 ELISA controls 
6.3.2.3.1 WHO reference control 
In order to control for any plate to plate as well as inter-assay 
variability WHO cytokine standards were used for each cytokine 
assayed. Recombinant human TNF and IL12p70 standards were 
obtained from the National Institute for Biological Standards and 
Control (NIBSC) Potters Bar, Herts, UK (rHu TNF: 87/650; rHu 
IL12p70: 95/544) and rHu IFN standard was obtained from the 
National Institute of Allergy and Infectious Diseases (NIAID) Reference 
Reagent Repository, Atlanta, USA (rHu IFN: Gxy01-902-535).   
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Prior to use, the TNF reference control was diluted to 1µg/ml, IFN to 
1µg/ml, and IL12p70 to 0.5µg/ml in sterile water, aliquoted and stored 
at -80C. 
A single dilution of the WHO reference standard was applied to two 
wells on each plate per ELISA assay, to enable intra-plate variation to 
be quantified.  The WHO standards were serially diluted on the plate to 
cover the following dilutions: 
TNF and IFN: 2000pg/ml to 62.5pg/ml.  For IL12p70: 2000 pg/ml to 
15pg/ml.   
One concentration was applied to each plate per batch. 
6.3.2.3.2 Internal biological controls 
An in-house, pooled cytokine control supernatant, as described in 
Section 7.4.1.3 was also applied to two wells per ELISA batch for 
quantitation of inter-assay variation.  These were used to ensure that 
results were comparable over an extended period of time. 
ELISA plates were then sealed and incubated over night at 4C.   
Day 3 – completion of ELISA assay. 
After 4 washes with PBS/0.5% Tween20, biotin labeled detection 
antibodies were diluted in 10% FCS in PBS with 0.5% Tween 20 to a 
final concentration of 1µg/ml for TNF and IFN and at 2.5µg/ml for 
IL12p70, and 100ul applied/well.   After 45 minutes incubation at RT, 
the plates were washed 6 times and avidin peroxidase, at 
concentrations of 1.25g/ml for TNF, 3.3g/ml for IL12 and 5g/ml 
for IFN, applied in a volume of 100µl to all wells and the plates 
incubated at RT for 30 minutes.  After 8 further washes, ELISAs were 
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developed using 4mg of OPD per 10ml of citrate buffer with 10µl of 
30% hydrogen peroxide, (pH5) as substrate in volumes of 100µl/well.  
Plates were incubated at RT for 20 minutes for IFN, 15 minutes for 
TNF and 40 minutes for IL12p70.  The reaction was stopped using 
100µl/well of H2SO4.  Colour development was then read in a 
Versamax ELISA plate reader (Molecular Devices, Menlo Park, UK) and 
absorbance measured at OD 492 nm with a reference optical density of 
620nm. 













Figure 6.1: Flow chart depicting ELISA method. 
Day 1 
Coat with capture antibody 
Incubate O/N at 40C 
Day 2 
Wash 2X 
Block 2 hours 
Wash 2X 
Load Standard, Supernatants, WHO control, Internal control 
Incubate O/N at 40C 
Day 3 
Wash 4X 
Apply biotinylated detection antibody - incubate for 45 minutes 
Wash 6X 
Apply avidin peroxidise – incubate for 30 minutes 
Wash 8X 
Apply substrate – incubate at times specific for cytokines 
Apply stop solution 
Read optical density on ELISA plate reader 
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6.3.3 Interpretation of ELISA results 
Cytokine concentrations were calculated using ELISA software 
(Softmax, Molecular Devices, Menlo Park, UK) from a standard curve 
run in duplicate on every plate.  Results were calculated from the 
linear part of the standard curve using a four parameter curve fit.  
Cytokine concentrations were reported as the concentration with the 
background (PBS/Tween) subtracted.  Using the antibody pairs and 
standards as detailed, the lower and upper ranges of detection for 
each cytokine were as follows:   
TNF: 30 - 2000pg/ml; IL12p70: 15 - 2000pg/ml.; IFN: 40 - 
5000pg/ml 
The low cutoff value was that of the least concentrated standard and 
the high cutoff value was that of the second most concentrated.   
For the TNF assay, a ratio was calculated from the level obtained 
from stimulation with LPS + IFN, divided by the level obtained from 
stimulation with LPS alone.  If this ratio was <2, the result was 
considered to be low.  An IFN result of <1000 pg/ml was considered 
to be low.  All low results were retested to eliminate laboratory error 
and to confirm or eliminate immunological differences between 
samples. 
The results were accepted if the optical density read within range of 
the standard curve, the WHO standard external control and internal 
control values were within the acceptable range and the duplicates had 
a CV of less than 15%.  If required, the ELISA was repeated on the 
frozen duplicate sample. 
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6.4 Flow Cytometry 
All FACS analysis was carried out on a Beckton Dickinson FACS Calibur 
Flow Cytometer (Beckton Dickinson Immunocytometry Systems, San 
Jose, USA) using the CellQuest analysis program. 
6.4.1 Measurement of IL12Rβ1 
A 2 tube (unstimulated and stimulated) 2 colour (PE-FL2, APC-FL4) 
flow cytometric method was set up to measure IL12Rβ1  expression on 
stimulated lymphocytes in order to quantitate differentiate receptor 
expression between TB patients and healthy controls.  This was 
optimized by Dr Suzanne Anderson and myself as part of the 
collaborative study.  A normal control was always set up for 
measurement of receptor expression when testing a patient. 
6.4.1.1 Reagents 
Fluorescently labeled antibodies obtained from Pharmingen were as 
follows:  Anti-IL12R1 (PE) (Cat. No. 556065) and Anti-CD3 (APC) 
(Cat No 345767). 
6.4.1.2 Method 
PBMCs were separated from heparinized blood by Ficol according to 
standard procedure and the cell concentration adjusted to 1 X 106/ml.  
PBMCs were pipetted into 2 Falcon 2052 polystyrene tubes for 
stimulated and unstimulated samples. 
1ml of 1 X 106/ml cells was added to each tube for unstimulated cells 
and cells stimulated with PHA, final concentration 2ug/ml for 72 hours.  
Note that both tubes are incubated at 37oC in a humidified atmosphere 
of 5% CO2 for 72 hours.  Tubes were centrifuged at 300g for 5 
minutes and supernatant decanted leaving a residual volume of 
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approximately 50µl of cell suspension in the tube.  5l IL12R1 and 5l 
CD3 were added to both tubes, samples mixed briefly by vortexing and 
incubated in the dark at RT for 30 minutes.  1 ml BD FACSTM lysing 
solution, diluted 1:10 in ddH2O, was added to each tube and samples 
incubated for a further 30 minutes in the dark.  Tubes were then 
centrifuged at 300g for 5 minutes.  Supernatants were decanted and 
the pellet resuspended in 1ml sterile PBS prior to assay on a Beckton 
Dickinson FACS Calibur Flow Cytometer (Beckton Dickinson 
Immunocytometry Systems, San Gates were drawn around the specific 
fluorescent populations and the median fluorescent intensity (MdX) 
and percent fluorescence analyzed in proportion to a total of 5000 
events counted.  Histogram and quadrant statistics were applied. 
6.5  Molecular Methods 
Unless stated otherwise, all PCR primers were designed and optimized 
by myself. 
All PCR procedures were carried out on a Perkin Elmer Applied 
Biosystems, GeneAmp® PCR System 9700 thermal cycler. 
6.5.1 DNA extraction and quantitation 
6.5.1.1 DNA extraction 
Blood (2ml) was collected into EDTA tubes and DNA extracted using 
the QIAamp® DNA Blood Mini Kit (Qiagen Cat No 51183) according to 
manufacturer’s instructions.  In summary, 200µl of Qiagen protease, 
stored at 4oC was pipetted into a 15ml centrifuge tube containing 2ml 
of EDTA whole blood and the sample vortexed.  Buffer AL (2.4ml) was 
added, mixed thoroughly by inverting tube 15 times, followed by 
additional vigorous shaking for at least 1 minute and the sample then 
incubated for 10 minutes in a 70oC water bath.  Absolute ethanol (2ml) 
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was added to the sample and mixed thoroughly by inverting tube 10 
times, followed by additional vigorous shaking.  Half the solution was 
transferred onto a QIAamp® Midi column placed in a 15ml centrifuge 
tube and the sample centrifuged at 1850g for 3 minutes.  The filtrate 
was discarded into bleach (Exitol) diluted to a final concentration of 
10000ppm of chlorine, and the remaining solution applied to the 
column and centrifuged again at 1850g for 3 minutes.  The filtrate was 
discarded into the bleach, 2ml buffer AW1 added to the Midi column 
and the sample centrifuged at 4500g for 1 minute.  Buffer AW2 (2ml) 
was then loaded onto the column and the sample centrifuged at 4500g 
for 15 minutes.  The Midi column was then placed into a clean 15ml 
centrifuge tube and the original tube with its contents discarded.  DNA 
was eluted by adding 300µ TE buffer (Tris HCl 1M pH7.6, EDTA 0.5M 
pH8.0 in 100ml ddH2O) directly onto the membrane of the Midi 
column, incubated at RT for 5 minutes and then centrifuged at 4500g 
for 5 minutes.  Eluted DNA was stored in 1.5ml Eppendorf tubes. 
6.5.1.2 DNA quantitation 
Extracted DNA was quantified prior to storage and use by the 
PicoGreen®ds DNA Quantification Reagent (Molecular Probes, Cat No  
P-7581) according to manufacturer’s instructions.  In summary, a 
standard curve was prepared from calf thymus DNA (Sigma Cat No D-
3663).  Lyophilized calf thymus DNA was reconstituted in 2ml TE 
buffer giving a concentration of 1mg/ml.  This was stored in aliquots at 
-20oC.  Immediately prior to use, Picogreen Solution A was prepared 
by diluting 1:200 in TE buffer and Picogreen Solution B was prepared 
by diluting 1:380 in TE buffer.  The tubes containing prepared 
solutions A and B were covered with aluminium foil.  To prepare the 
STD curve 20µl of stock DNA solution was diluted with 1540µl of TE 
buffer in a Bijou tube (Sterilin, UK) and serial dilutions prepared in 
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buffer to give standards with a range of concentrations 6400ng/ml to 
12.5ng/ml.  Each prepared standard (50µl) was applied in duplicate 
across a 96 well, flat bottomed microwell plate (Nunc Cat. No. 442404) 
and 5µl of each DNA sample, diluted 1:10 in TE buffer, prior to assay, 
placed in the remaining wells.  Picogreen solution A was then added to 
each of the STD wells to give final working concentrations of 
3200ng/ml to 6.25ng/ml and 95µl of Picogreen solution B added to 
wells containing DNA samples, to give a final dilution of 1:200.  The 
plate was covered with aluminium foil and incubated at RT for 5 
minutes.  Fluorescence was measured using an excitation wavelength 
of 488nm and an emission wavelength of 530nm on a Spectramax 
Microplate Reader (Molecular Devices).  DNA concentrations were 
calculated relative to that of the standards using the Spectramax 
software, SOFTmax PRO. 
6.6 DNA amplification 
6.6.1 WAVE screening 
6.6.1.2 PCR amplification of IL12p40 promoter for WAVE 
screening 
Using eight overlapping pairs of primers and genomic DNA, the 
IL12p40 promoter fragment amplified was 2022bp long, from +73 to -
1949.  
The oligonucleotide primers used are listed in table 6.7.   
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Primer  Sequence 5’ to 3’ 
















Table 6.7: Primers for amplification of the IL12p40 promoter 
for WAVE 
Note: These primers were designed by Dr Suzanne Anderson as part of the 
Burroughs-Wellcome funded collaborative study. 
PCR amplification of fragments was performed in 25l volumes 
containing 200ng genomic DNA template, 0.5M of each primer, 
1.5mM MgCl2, 200M dATP, dCTP, dGTP, dTTP; 0.5 units of Taq DNA 
polymerase (Red Hot Taq, ABGene Cat. No. AB 0406).   
Amplications were carried out as follows: 1 cycle of 95oC for 90 
seconds; 10 cycles of 95oC for 30 seconds, 56oC for 50 seconds, 72oC 
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for 40 seconds; 23 cycles of 95oC for 20 seconds, 56oC for 50 seconds, 
72oC for 50 seconds.   
6.6.1.3 Preparation of heteroduplexes 
Heteroduplexes were prepared by mixing small, equal volumes of 
“normal” PCR product with “subject” PCR product (for example 
12l+12l), incubating at 95oC for 5 minutes in a thermal cycler and 
then switching the cycler off, allowing gradual cooling for 45 minutes.  
This allowed the formation of homoduplexes and heteroduplexes.  
When running the heteroduplex samples on the WAVE instrument, a 
normal homoduplex sample was always loaded, in addition to the test 
samples and the elution patterns compared.  Any pattern different 
from the normal sample was analyzed and considered as a possible 
DNA sequence change. 
The melting domains of the PCR product fragments were calculated by 
computation prior to running the samples.  If a fragment contained 
different melting domains, it was run through the WAVE instrument at 
the respective melting temperatures.   
6.6.1.4 Running on WAVE instrument 
Heteroduplexes were pipetted into microtubes (ABgene Cat. No. AB-
0620), fitted into a 96 well plate and run on the WAVE instrument 
(WAVE nucleic Acid Fragment Analysis System, Model No 3500 HT, 
Transgenomic, Inc. Omaha, NE.) at the Department of Human 
Genetics, according to their procedure. 
6.6.2 ARMS-PCR screening for -1523 A/G and -1564 C/T SNPs 
For screening of the A/G and C/T heterozygotes, novel ARMS-PCR 
assays were designed, using primers IL12BP2F, IL12BP2R and an 
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additional forward mismatch primer, ARMS-Fg or ARMS-Ft that would 
amplify only the G and T alleles respectively.  Amplification of the 
normal AA and CC genotypes resulted in 2 identical PCR fragments of 
269 bp long for each of the two reactions.  Amplification of the 
heterozygous A/G genotype resulted in 2 PCR products of 269bp and 
217bp and amplification of the heterozygous C/T genotype resulted in 
2 PCR products of 269bp and 176bp.  The oligonucleotide primers used 
are listed in table 6.8. 
Primer Sequence 5’ to 3’ - mismatches in bold 
ARMS-Fg AATCTGCTTTGTCCACTTAATTCTG   C mismatch 
ARMS-Ft CACCCCACAAATGGTATCAGAT  G mismatch 
IL12BP2F AACTACTTCACGTCAATTTCTG 
IL12BP2R CTGGCCGTGGGTGGAGAC 
Table 6.8: Mismatched Allele Specific Primers for ARMS-PCR for 
detection of -1523 A/G and -1564 C/T SNPs 
Notes: 
The ARMS-Fg primer ends in G for detection of G allele 
The ARMS-Ft primer ends in T for detection of T allele  
The amplification conditions used were the same as for the WAVE 
screening, except for the primer concentrations, where 0.3M of 
IL12BP2F, 0.8M of ARMS-Fg, 0.8M of ARMS-Ft and 0.6M of 
IL12BP2R were used and Go Taq® polymerase (Promega Cat No 
M3001) was used. 
Amplications were carried out as follows: 1 cycle of 94oC for 2 
minutes; 33 cycles of 94oC for 15 seconds, 59oC for 30 seconds, 72oC 




6.7.1 PCR Amplification of the IL12p40 promoter for cloning 
The original oligonucleotides used in WAVE screening were adapted as 
shown in table 6.9, resulting in a PCR product of 2031bp. 
Primer 




Original P1F        AAGCTTCTTTTGCATAACTGGC  
Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Original P8R TTGGGAAGTGCTTACCTTGCT  
Adapter P8R ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 6.9: Uniquely adapted primers for cloning 
PCR amplification of fragments was performed in 25l volumes 
containing 200ng genomic DNA template; 0.5M of each primer; 
1.5mM MgCl2; 200M dATP, dCTP, dGTP, dTTP; 0.5 units of Expand Hi 
Fidelity PCR system Taq polymerase (Roche Cat No 011 504 4600).   
Amplications were carried out as follows: 1 cycle of 94oC for 2 
minutes; 33 cycles of 94oC for 15 seconds, 59oC for 30 seconds, 72oC 
for 2 minutes; 1 cycle of 72oC for 7 minutes, 25oC for 2 minutes.   
For this amplification, using the Expand Taq polymerse, the elongation 
time was extended according the manufacturer’s instructions. 
6.7.2 Purification of PCR product 
Several tubes of PCR product of each of the fragments to be cloned 
were pooled respectively and cleaned up using a QIAquick® PCR 
purification kit (Qiagen Cat No 28104).  All centrifugations were 
carried out at 13000 rpm.  In summary, 5 X volume of lysis buffer PB 
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was added to PCR product and mixed by vortexing.  Each sample was 
applied to a spin column placed in a collection tube, centrifuged for 
one minute, the flow-through discarded and the column placed back 
into the collection tube.  For the washing step, 750l of buffer PE was 
added to the columns which were centrifuged for 1 minute, the flow-
through discarded and the column placed back in to the collection tube 
and samples centrifuged for an additional minute.  For the elution 
step, the columns were placed in sterile 1.5ml Eppendorf tubes, 30l 
of buffer EB added to the centre of each column, left to stand for one 
minute and then centrifuged for one minute. 
6.7.3 Cloning into T vector system 
The purified PCR products (normal promoter, SNP -1523 G and SNP -
1564 T promoter fragments) were cloned into a T vector, using the 
pGEM®-T Easy Vector System II (Promega A1380).  The purified insert 
DNA was ligated into the vector at 4oC overnight, using a 1:1 molar 
ratio of vector:insert.  A positive control and background control were 
included.  A transformation control, using uncut plasmid, was not done 
as the T vector was supplied linearized.  Transformation was done by 
adding 2µl of each ligation reaction to 50µl JM109 competent cells, 
leaving on ice for 20 minutes, heat shocking at 42oC for 50 seconds, 
again leaving on ice for two minutes, adding 950µl of SOC medium 
kept at RT and then incubating shaking at 37oC for 1.5 hours.  Then 
20µl of each transformation culture was plated onto duplicate Luria 
Bertoni (LB) plates containing 100µg/ml ampicillin, 0.5mM IPTG and 
80µg/ml X-Gal and incubated overnight at 37oC.  After this incubation, 
the white colonies were screened for inserts by PCR.  A blue colony 
was screened as a negative control.   
222 
 
6.7.3.1 Ligation of normal, SNP -1523 G and SNP -1564 T 
promoter fragments into T vector system 
The ligation mix used for ligating the three promoter fragments into 
the T vector are shown in table 6.10. 
2X rapid ligation buffer 5l 
pGEM®T easy vector, linearized, cleaned 1l (50ng) 
PCR product, digested, cleaned 1l (50ng) 
T4 DNA ligase 1l 
Sterile water 2l 
Total volume 10l 
Table 6.10: Ligation mix used for cloning into T vector system 
6.7.3.2 Transformation of competent cells 
LB agar plates were prepared by dissolving 2.5g bactotryptone, 1.25g 
yeast extract, 1.25g sodium chloride and 3.75g agar in 250ml water 
and autoclaving.  The agar was allowed to cool to 55oC and 250l of 
100mg/ml ampicillin added, giving a final concentration of 100g/ml 
ampicillin, poured into sterile petri dishes and allowed to set.  The 
plates were checked for sterility by incubating at 37oC overnight. 
Onto each LB ampicillin plate was spread 100l of 100mM IPTG and 
20l of 50mg/ml Xgal.  This was allowed to absorb onto the plates at 
37oC for 30 minutes. 
Working on ice, 2l of each ligation reaction was added to a sterile 
tube and 50l competent cells, just thawed, added. 
For a transformation control, uncut plasmid is required.  This control 
was not done as the vector from the kit was supplied linearized. 
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A background control was done by transforming with linearized vector 
without an insert  
The tubes were kept on ice for 20 minutes, heat shocked at 42oC in a 
waterbath for 45-50 seconds, kept on ice for two minutes and then 
950l SOC medium equilibrated to room temperature added.   
The SOC medium was prepared by dissolving 1g bactotryptone, 0.25g 
yeast extract, 0.5ml 1M NaCl and 0.125ml KCl in 47ml distilled H20, 
autoclaving and then adding 0.5ml filter sterilized 2M Mg2+ and 0.5ml 
filter sterilized 2M glucose.  The volume was then made up to 50ml, 
pH checked (required to be 7.0), aliquoted and stored at -80oC. 
The tubes were incubated at 37oC for 1.5 hours with shaking. 
A volume of 25l from each tube was plated onto two 
LB/ampicillin/IPTG/Xgal plates and incubated at 37oC overnight. 
6.7.3.3 Screening of colonies for inserts 
For the screening, a small part of the culture was scraped with a sterile 
tip and placed into 50µl sterile water.  This bacterial suspension was 
heated to 95oC for 5 minutes to destroy DNAses and then 10µl used 
for the PCR reaction.  The internal primers designed for the WAVE 
technique were used for this screening. 
The following morning white colonies were then picked off the plates 
with sterile tips, master plates prepared and incubated at 37oC 
overnight.  Colonies that remained white were dipped into volumes of 
50l sterile water in tubes, heated to 95oC for 5 minutes to degrade 
DNAses and then placed on ice.  PCR as previously described using any 
pair of the WAVE primers was done on 10l of the water containing 
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heat treated colony.  The PCR product was run on a 1% agarose gel 
for visualization for confirmation of insert in colony. 
6.7.3.4 Sequencing   
The sequencing reaction was carried out using the Big Dye®  
Terminator Cycle Sequencing kit (Applied Biosystems Cat No 4336915) 
by PCR. 
PCR amplification of cloned promoter fragments was performed in 20ul 
volumes containing  3l miniprep DNA (300ng); 10l water; 3.3M of 
primer (1l) [10m diluted 1:3]); 2l Big Dye Terminator Mix; 4l 5X 
buffer. 
Amplication was carried out as follows: 1 cycle of 96oC for 10 seconds; 
25 cycles of 96oC for 10 seconds, 52oC for 15 seconds, 60oC for 4 
minutes; 1 cycle of 60oC for 4 minutes, 4oC till taken out of machine.   
6.7.3.5 Overnight cultures, freezing and storage of colonies 
with inserts 
Single colonies were scraped from the master plates into 5ml LB 
medium with 5ul of 100mg/ml ampicillin, giving a final concentration 
of 100g/ml ampicillin and incubated at 37oC overnight with shaking. 
The following morning 2 tubes each of 1ml culture was mixed with 1ml 
freezing solution, snap frozen in liquid nitrogen and stored at -70oC for 
future resources of material. 
A 1ml volume of saturated culture from a 16 hour culture was added 
to 1ml glycerol solution in a cryostat vial, snap frozen in liquid N2 and 
stored at -70oC.  When it was necessary to reculture the clone, the 
culture was revived by scraping frozen splinters onto an agar plate.  
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The glycerol stock was never thawed completely as freeze/thaw cycles 
reduce viability. 
6.7.3.6 Plasmid minprep DNA extraction 
The plasmid DNA was isolated using the Qiaprep®Spin Miniprep Kit 
(Qiagen Cat No 27104).  All centrifugations were carried out at 
13000rpm in a microcentrifuge.  In summary, overnight cultures were 
done by incubating at 37oC and shaking at 150rpm, 4ml volumes of LB 
medium containing 100ug/ml ampicillin and a single colony.  Bacterial 
cells were harvested by centrifugation.  Supernatant was taken off, the 
pelleted bacterial cells resuspended in 250µl Buffer P1 and transferred 
to a microfuge tube.  A 250µl volume of buffer P2 was added, the tube 
mixed by inverting, 350µl buffer N3 added and the tube again mixed 
by inverting.  The tube was centrifuged for 10 minutes and the 
supernatant applied to a spin column.  The spin column was 
centrifuged for 1 minute, flow through discarded, 500µl wash buffer PB 
added, centrifuged for 1 minute, flow through discarded, 750µl PE 
added, centrifuged for 1 minute, flow through discarded and 
centrifuged for an additional minute.  The plasmid DNA was then 
eluted by adding 50µl buffer PE, allowed to stand for 1 minute and 
then centrifuged for 1 minute.   
6.7.4 Cloning of promoter fragments into pGL3-Basic vector 
6.7.4.1 Linearization of pGL3-Basic vector by double 
digestion 
As preparation for the ligation reaction, the pGL3-Basic was double 
digested to make the restriction sites in the multiple cloning site 
available for the inserts to be cloned. 
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The digestion mix used for linearization of the pGL3-Basic vector is 
shown in table 6.11. 
pGL3-Basic vector 2l (1200ng)  
XhoI 2.0l 
10 X Buffer D 1.0l 
BSA 10mg/ml 1.0l 
Casein 10mg/ml 1.0l 
Sterile water 3.0l 
Total Volume 10.0l 
Incubation  37oC for 90 mins 
Followed by 
SacI 2.0l 
10 X Buffer J 2.0l 
10 X Buffer D 2.0l 
Sterile water 4.0l 
Total Volume 20.0l 
Incubation  37oC for 90 mins 
Table 6.11: Double digestion mix for linearization of pGL3-Basic 
vector 
6.7.4.2 Release of promoter fragments from T vector by 
double digestion 
As preparation for the ligation reaction, the normal and SNP -1564 T 
promoter fragments were double digested, releasing them from the T 




The digestion mix used for double digestion of the promoter fragments 
is shown in table 6.12. 
Plasmid DNA miniprep 8l (100ng) 
XhoI 1.0l 
10 X Buffer D 1.5l 
BSA 10mg/ml 1.5l 
Casein 10mg/ml 1.0l 
Sterile water 2.0l 
Total Volume 15.0l 
Incubation  37oC for 90 mins 
Followed by 
SacI 1.0l 
10 X Buffer J 2.0l 
10 X Buffer D 1.5l 
Sterile water 1.5l 
Total Volume 20.0l 
Incubation  37oC for 90 mins 
Table 6.12: Digestion mix used for releasing normal and SNP -
1564 T fragments from T vector 
6.7.4.3 Gel extraction of DNA fragments 
In order to ensure integrity of the DNA, 40% sucrose was used as 
loading buffer for electrophoresis and fragments viewed under long 
wave UV light. 
After electrophoresis and viewing, the appropriate fragments were 
excised out of the gel. 
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The DNA was extracted from the agarose using the QIAEX II Gel 
Extraction kit (Qiagen Cat No 20021). 
In summary, the following procedure was carried out. 
All centrifugations were carried out at 13000 rpm. 
Gel slices were weighed, 3 X volume of QIAEXI buffer added and 
vortexed for 30 seconds.  The QIAEXII beads were resuspended by 
vortexing and 30l added to each gel slice in QIAEXI buffer.  The gel 
slices were incubated at 50oC for 10 minutes, vortexing every 2 
minutes to solubilize the agarose and bind DNA to the beads.  Samples 
were centrifuged for 30 seconds, supernatants removed, pellets 
washed once in 500l QIAEXI buffer and twice in 500l PE buffer.  
Pellets were air dried for at least 30 minutes till white.  DNA was 
eluted by adding 20l sterile water, resuspended by vortexing, 
incubated at room temperature for 5 minutes, centrifuged and eluate 
taken off into a sterile Eppendorf tube.  The elution procedure was 
repeated one more time. 
6.7.4.4 Creation of SNP -1523 G promoter fragment 
6.7.4.4.1 Digestion of AG4 and AG44 clones with SmaI for  
creation of the SNP -1523 G fragment. 
The digestion mixes used for creating correct fragments from AG4 and 
AG44 clones are shown in table 6.13.  Separate digestion mixes were 
set up for each of the AG4 and AG44 clones. 
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AG4 and AG44 60l (total ng extracted from gel) 
SmaI 2.0l 
10 X Buffer J 8.0l 
Sterile water 2.0l 
Total Volume 80.0l 
Incubation  25oC for 60 mins 
Table 6.13: Digestion mix for creation of fragments for the SNP 
-1523 G promoter fragment 
6.7.4.4.2 Ligation of AG4 and AG44 fragments for creation of 
SNP -1523 G fragment and cloning into pGL3-Basic vector 
in single step 
The ligation mix for creation and cloning of mutant -1523 G fragment 
into pGL3-Basic vector is shown in table 6.14. 
2 X ligation buffer 8l 
pGL3-Basic linearized, cleaned 1.0l (50ng) 
AG44 (663bp fragment) 3.0l (20ng) 
AG4 (1359bp fragment) 1.0l (20ng) 
*T4 DNA ligase 3l 
Total volume 16l 
Table 6.14: Ligation mix for creation and cloning of fragments 
for SNP -1523 G into pGL3-Basic vector 




6.7.4.5 Creation of truncated promoter fragment 
6.7.4.5.1 PCR amplification for creation of truncated promoter 
Uniquely adapted primers shown in table 6.15 were designed, resulting 
in a truncated promoter fragment of 1744bp in length. 
Primer Sequence 9bp 5’ extension 
Incorporated 
restriction site 
Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Adapted R 
truncated 
ATACTCGAGGGTTTACATCATGGCCA C’TCGAG XhoI 
Table 6.15: Uniquely adapted primers for creation of truncated 
promoter 
PCR conditions were as previously described for WAVE screening. 
6.7.4.5.2 Ligation mix for cloning truncated construct into 
pGL3-Basic vector 
The ligation mix for cloning the truncated promoter fragment into the 
pGL3-Basic vector is shown in table 6.16. 
2 X rapid ligation buffer 5l 
pGL3-Basic linearized, cleaned 1l (50ng) 
PCR product digested, cleaned 3l (50ng) 
T4 DNA ligase 1l 
Total volume 10l 




6.7.4.6  Creation of deletion promoter construct 
6.7.4.6.1 PCR amplication of fragments 1 and 2 for creation of 
deletion construct 
Uniquely designed primers used for generation of fragments 1 and 2 
for creation of the deletion construct are shown in tables 6.17 and 
6.18. 
Primer Sequence 9bp 5’ extensions Incorporated 
restriction site 
Adapted P1F ACAGAGCTCCTTTTGCATAACTGGC GAGCT’C SacI 
Adapted 8R  ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 6.17: Primers used for generation of full length promoter 
-1952 to +79 (to be digested with BalI), creating 1673bp of 
deletion construct 
Primer Sequence with 9bp 5’ extension 
and new forward primer 
Incorporated 
restriction site 
New F  GAGAGTTGTTTTCAATGTTGCAACAAGTC  
Adapted 8R  ATACTCGAGGGAAGTGCTTACCTTGCT C’TCGAG XhoI 
Table 6.18: Primers used for creation of the -94 to +79 
promoter region creating 173bp fragment of deletion construct 
6.7.4.6.2 Digestion of full length fragment for creation of 
deletion construct 
The digestion mix used for fragment 1 is shown in table 6.19. 
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Eluate of normal construct 40l  
BalI 2.0l 
10 X Buffer G 6.0l 
BSA 10mg/ml 6.0l 
Sterile water 6.0l 
Total Volume 60.0l 
Incubation  37oC for 60 mins 
Table 6.19: Digestion mix for fragment 1 
6.7.4.7 Ligation and cloning of deletion construct into pGL3-
Basic vector in single step 
The ligation mix used for ligating of 1675bp and 173bp fragments  and 
cloning into the pGL3-Basic vector in a single step is shown in table 
6.20. 
2 X rapid ligation buffer 8l 
pGL3-Basic linearized, cleaned 1l (50ng) 
Digested, large fragment (1675bp) 2l (50ng) 
Small fragment (173bp) 2l (50ng) 
*T4 DNA ligase 3l 
Total volume 16l 
Table 6.20: Ligation mix for cloning of 1675bp and 173bp 
fragments   into the pGL3-Basic vector in a single step 
*Additional T4 DNA ligase was used in this reaction, as two fragments were ligated 
together. 
6.8 Visualization of PCR products by agarose gel 
electrophoresis 
10l of the PCR reactions was mixed with 2l of 6 X DNA loading buffer 
and electrophoresed in 1 X TAE buffer, at 80V on an agarose gel 
prepared in 50ml of 1 X TAE containing 2l of 10mg/ml ethidium 
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bromide.  For visualization of the PCR products a 1 or 2% agarose gel 
was used.  For visualization of the ARMS-PCR products, a 3% gel was 
used for separation of the two bands similar in size. 
An appropriate molecular weight marker was run on the gel for 
comparison with the PCR product.  DNA was visualized using a 
transilluminator. 
When the Go Taq® polymerase was used, the green reaction buffer 
used in the PCR reaction, had a dual purpose, being the loading buffer 
as well.  For samples amplified using this system, the PCR product was 
loaded directly onto the gel. 
6.9 Dual Luciferase Reporter Assay 
6.9.1 Optimization 
Optimizing experiments were done as follows:  
Transfection experiments were done using the mouse macrophage 
RAW 264.7 cell line, the human monocytic THP-1 cell line and the 
human HT1080 cell line. 
Two internal controls pRL-TK (50ng) and pRL-CMV (10ng) were used. 
Three transfection reagents, FuGENE HD Transfection Reagent (Roche 
Cat. No. 04709713001), X-tremeGene HP DNA Transfection Reagent 
(Roche Cat. No.  06365752001) and X-tremeGene 9 DNA Transfection 
Reagent (Roche Cat. No. 0636651100) were used. 
Total incubation times of 34 and 48 hours were used. 
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After optimization experiments, X-tremeGene HP DNA Transfection 
Reagent was used to transfect the mouse macrophage RAW 264.7 
cells, with internal control pRLTK in a total incubation time of 48 hours. 
6.9.2 Method 
The Dual Luciferase Reporter Assay was a four day assay. In summary 
the following procedure was carried out. 
Day 1 
Cells were plated into a 12 well tissue culture plate.  Cells grown in 
complete medium (RPMI + 10% FCS) in at atmosphere of 5% CO2, 
passaged every 2 days were used.  These were harvested from two 
10cm tissue culture dishes by washing with complete medium.  The 
cell suspension was collected into a 50ml tube and centrifuged at 
10000 rpm for 3 minutes and the cell pellet resuspended in 10ml 
complete medium.  A cell count was done by loading 10ul of the cell 
suspension onto a counting chamber, 4 squares counted and the mean 
calculated.  The cell concentration was adjusted to 6 X 10 4 cells/ml.  
Cells (1ml) at a concentration of 6 X 10 4 cells/ml were pipetted into 
each well of the 12 well plate and grown overnight to a confluency of 
60-70%.   
Day 2 
Transfection was done on day 2.  First the DNA to be transfected was 
prepared.  Five constructs, the normal promoter, SNP -1523 G and 
SNP -1564 T promoters, a truncated promoter and promoter with 
essential elements deleted, all in the pGL3-Basic vector were used.  
Miniprep plasmid DNA extractions of these promoter constructs in the 
pGL3-Basic vector had been previously prepared and stocks of known 
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concentration frozen.  500ng DNA of the cloned normal, SNP -1523 G, 
SNP -1564 T, truncated and deletion promoters, as well as the empty 
pGL3 vector were mixed with 10ng of pRL-TK, the internal control 
Renilla reniformis Luciferase Reporter vector.  These samples were 
prepared in duplicate in 12 Eppendorf tubes.  Serum free medium was 
prewarmed to room temperature and transfection reagent equilibrated 
to room temperature and mixed well before use.   
Using FuGENE®HD transfection reagent, for each transfection, 48l 
serum-free medium and 2l FugGENE were added to an Eppendorf 
tube.  FuGENE must be added directly into medium and not come into 
contact with the plastic tube.  This was incubated at room temperature 
for 15 minutes. 
A master mix of this was prepared as follows: 
13 X 48l = 624l medium 
13 X 2l = 26l FuGENE 
After incubation at room temperature, 50l of this master mix was 
added to each Eppendorf tube containing the DNA transfected (500ng 
plasmid DNA + 10ng pRL-CMV).  Duplicates for each reaction were 
prepared.  The DNA with FuGENE mixes were mixed and incubated at 
room temperature for 15 minutes. 
Using the X-tremeGENE and X-tremeGENE 9 DNA transfection 
reagents, the DNA mixes were diluted to a minimum volume of 100l 
with serum free RPMI and the transfection reagent was added directly 
to the tubes containing DNA. 
4:1 ratio of transfection reagent:g DNA was used (4.2l XtremeGENE 
added to 1050g DNA [1000ng + 50ng]) 
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A transfection control, kindly donated by the South African Aids 
Vaccine Institute laboratory, IIDMM, was included in each experiment.  
The DNA mix for this was 1000ng of normal promoter + 100ng 
LucZ/SV40 in pGL4 basic vector.  
The transfection Reagent/DNA complex was added dropwise onto the 
cells in a 12 well plate and immediately mixed gently to ensure equal 
distribution over entire plate surface.  The plate was incubated at 37oC 
in 5% CO2.  Thirteen or 16 hours after transfection, 1.2% DMSO was 
added to each well (12l to 1000l) except the unstimulated well.  Five 
or 16 hours later a final concentration of 1g/ml IFN was added to 
each well (50µl of 20g/ml) except the unstimulated well.  Eight hours 
later a final concentration of 1g/ml LPS was added to each well 
(100µl of 10g/ml) except the unstimulated well.  Eight hours later, 
cells were harvested. 
Day 3 
On day 3, cells were harvested as follows: passive lysis buffer was 
equilibrated to room temperature.  The plate was centrifuged at 
3000rpm for 5 minutes, medium was gently taken off all wells and 
cells washed 2 X with 1ml of sterile PBS with a sterile squeeze pipette, 
centrifuging as before after each wash.  After the PBS had been 
removed, 100l of passive lysis buffer was added to each well and the 
plate shaken on a plate shaker for 15 minutes at room temperature.  
All the cell lysate from each well was taken into an Eppendorf tube and 
stored at -80oC for one hour or overnight. 
The following time sequences were carried out: 
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Transfection  16 hours, 1.2% DMSO added  16 hours, IFN 1g/ml 
added  8 hours, LPS 1g/ml added 8 hours, cells harvested.  Total 
incubation time 48 hours. 
Transfection  13 hours, 1.2% DMSO added  5 hours, IFN 1g/ml 
added  8 hours, LPS 1g/ml added  8 hours, cells harvested.  Total 
incubation time 34 hours (Optimization). 
Day 4 
The Relative Light Units (RLUs) of the cell lysates were read on the 
luminometer (Luminoskan Ascent luminimeter (Thermo Labsystems).  
Eppendorf tubes containing cell lysates were centrifuged at 10000 rpm 
for 1 minute and the supernatant taken off into clean tubes, leaving a 
pellet of cell debris behind.  Four samples were read on the 
luminometer at a time.  10l of each sample was pipetted into a 96 
well plate and 50l of LARII reagent added.  On addition of the LARII 
reagent, the firefly luciferase activity was measured.  An aliquot (50l) 
of the STOP & GLO Reagent (50 X substrate diluted in buffer) was 
added to each sample in well.  On addition of the Stop & Glo Reagent, 
the firefly luciferase activity was quenched and the Renilla reniformis 
luciferase activity (internal control) measured. 
6.10 Statistical Analysis 




CHAPTER 7: Final Discussion 
Expansion of our understanding of the IL12/IL23/IFN pathway came 
about with the identification of mutations in the IFNR1, IFNR2, 
IL12R1, IL12p40 and STAT1 genes.  This resulted in a new area of 
research and clinical activity, adding to the understanding of 
mechanisms underlying human susceptibility to mycobacterial disease.  
Individuals with MSMD, caused by mutations in these genes, are 
usually affected with infections caused by poorly pathogenic 
mycobacteria and, less commonly, Salmonella.  However, following the 
initial description of these mutations, a subset of these patients were 
found to be infected with M. tb (Altare et al. 2001, Caragol et al. 2003, 
Ozbek et al. 2005, Tabarsi et al. 2011).  This raises the possibility that 
susceptibility to M. tb in the general population is a consequence of 
single gene defects in the IL12/IL23/IFN pathway and that TB in the 
general population is a Mendelian disorder (Alcais 2005). 
This work was part of a collaborative study that screened a well-
defined cohort of paediatric TB cases and healthy controls from the 
Western Cape region of South Africa, a TB-endemic area, for 
mutations in genes of the IL12/IL23/IFN pathway, associated with TB.  
When the study started, the IL12p40 promoter had not been 
extensively screened for mutations causing susceptibility to TB.  The 
gene is a good candidate for TB susceptibility, since IL12 is important 
for IFN signalling and the clinical phenotype of subjects with defects 
in the gene is relatively mild, with affected individuals surviving into 
adult life. There was therefore, a high likelihood of finding functional 
polymorphisms within the promoter region of the gene that were likely 
to affect disease susceptibility 
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The majority of published TB susceptibility studies have been carried 
out on adults since confirming disease with the gold standard of 
mycobacterial culture is more easily achieved in adults than children.  
However, paediatric studies are important since the mechanisms of 
susceptibility are likely to differ from adults, as children tend to 
develop primary progressive TB disease rather than reactivation of 
dormant infection that classically characterises adult disease. 
To investigate the role of gene defects in the IL12p40 promoter in TB 
susceptibility, a subset of the main paediatric cohort (total n=144, 
cases n=94, controls n=50) was first screened for DNA changes by the 
WAVE technique.  Two heterozygous SNPs -1523 A/G (total n=6, cases 
n=1, controls n=5) and -1564 C/T (total n=8, cases n=5, controls 
n=3) were identified.  Although numbers were small, analysis showed 
the -1523 A/G SNP to be more prevalent in controls (p=0.02) 
suggesting that it may have a role in protection from TB.  The 
observation that the -1523 A/G SNP occurred within a genetic 
sequence (GTATA), reported to be important for nuclear binding, also 
suggested that it may have a functional effect on IL12p40 production. 
In order to evaluate the role of these SNPs, further screening of the 
whole paediatric cohort was then done.  A cohort of healthy adult 
controls, from a TB-endemic area, none of whom had a history of TB 
disease, but had been exposed to TB, was also included to increase 
the numbers to add power to the analysis.  For the additional 
screening, a unique ARMS-PCR system with specifically designed 
mismatch primers was set up, a more cost effective method.  The 
additional screening of the larger cohort (total paediatric samples 
n=397, cases n=252, healthy controls n=145; total adult healthy 
controls n=756), increased the numbers with the -1523 A/G (total 
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n=61, cases n=12, controls n=49), and -1564 C/T (total n=60, cases 
n=20, controls n=40) SNPs.  Analysis showed that the -1564 C/T SNP 
may contribute to susceptibility to TB disease (p=0.03). 
Functional testing of these two SNPs was done, using a reporter assay.  
In preparation for this, uniquely adapted primers that included 
restriction sites corresponding to those in the multiple cloning site of 
the expression vector were designed.  The normal and two promoter 
fragments with the SNPs were PCR amplified with the adapted primers, 
facilitating cloning into the expression vector.  In addition, a truncated 
promoter and one with essential regions deleted, were created as 
negative controls.  The five promoter fragments were cloned into the 
expression vector and functional differences measured by reporter 
assay.  An increase was seen in stimulated promoter fragments over 
the deletion control, but no marked functional differences between the 
normal and variant promoter fragments were observed.  Reasons for 
this may have been a lack of sensitivity of the reporter assay for 
detecting subtle differences. 
Functional cytokine studies on patients with MSMD have demonstrated 
distinct immunological phenotypes, the type and severity of which 
correlate with gene defect.  To determine if patients with TB had a 
distinct immunological phenotype compared to healthy controls, 
immune testing was done by measurement of cytokines TNF, IL12p70 
and IFN after stimulation in WBAs and measurement of IL12Rβ1 by 
flow cytometry.  A very heterogeneous pattern of cytokine responses 
was seen. 
The TNF production in response to LPS with and without the addition 
of IFN showed ratios to be lower in TB cases than the healthy controls 
(p<0.0001), probably due to an enhanced inflammatory response to 
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LPS in both Active and Past History TB cases with high levels of TNF 
to LPS alone. 
IL12p70 levels were also lower in the cases compared to healthy 
controls (p<0.0001), likely due to the clinical disease. 
Responses to IFN were varied, with responses to PHA higher in Active 
TB cases, compared to healthy controls (p=0.002), probably to an 
enhanced immune response in the disease state.  IFN levels in 
response to PPD however, were seen to be higher in healthy controls, 
compared to TB cases.  This is probably due to the fact that most IFN 
producing cells are located at the site of active disease, a feature 
exploited by some researchers in developing TB diagnostic tests 
(Sutherland et al. 2012).  
Analysis of IL12R1 expression showed no individuals with absent 
receptor expression. However, there was a clear bimodal distribution 
of responses with a group of TB cases having low expression compared 
with controls.  It was not possible to determine if these individuals 
showed a reduced ability to reponse to IL12. 
The functional role of the SNPs was investigated by comparing 
cytokine responses in the different genotypes.  No differences were 
seen between wildtype and SNP genotypes in IL12 levels. 
Analysis of IFN responses to PHA showed no differences between 
genotypes for the -1523 A/G SNP.   
For the -1564 C/T SNP, IFN levels in response to PHA showed 
wildtype TB cases to have higher levels than healthy controls with SNP 
genotype (p=0.01).  TB cases with SNP genotype were seen to have 
lower IFN levels in response to PPD than wildtype healthy controls 
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(p=0.002).  Healthy controls with -1564 C/T genotype were found to 
have lower levels of IFN in response to PPD than the wildtype TB 
cases (p=0.0005). 
It is highly likley that the heterogenous results identified in this work 
are due to the very small numbers of individuals with SNP genotype.  
As a result, prediction of immune phenotype and correlation with the 
genotype could not be done.  For accurate statistical analysis, greater 
numbers of cases should be screened to increase the frequency of 
SNPs thereby adding power to the statistical analysis. 
One of the challenges of doing studies on children is recruiting enough 
numbers of TB cases with culture proven disease.  If a study like this 
were to be repeated, it would be possible to increase numbers by 
doing a multi-site study.  Sample size analysis should be used in order 
to calculate numbers for sufficient power for statistical analysis. 
There were a number of limitations to the work in this thesis.  First, 
because only a small sub-group of paediatric TB cases were screened 
by the WAVE technique it is possible that some additional promoter 
mutations were missed.  Had an enriched cohort been used, including 
patients with more severe clinical phenotypes (eg TB meningitis, 
miliary TB) in the initial WAVE screening, more mutations may have 
been identified.  However, at the time of completing this work the cost 
of the doing the WAVE technique prohibited the screening of more 
samples.   
Second this cohort was genetically heterogenous - a reflection on the 
mixed poulation that accessed the health services at RCWMCH and 
surrounding clinics. Due to the small numbers recruited overall, a 
decision was made not to stratify by ethnicity group and it is possible 
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that this will have further weakened the power to detect significant 
differences in both phenotype and SNP genotype between cases and 
controls. 
Third, because both TB infection and disease are on a continuous 
spectrum, it is possible that some of the tuberculin positive paediatric 
controls could themselves have become cases over time.  Similarly, 
because not all the TB cases had culture proven disease, but were 
diagnosed on the clinical likelihood of disease, there exists the 
possibility that some may have had another disease altogether and 
been incorrectly categorised at TB cases.   
Predisposition to TB is complex and while single gene mutations may 
play a role in disease susceptibility, it is likely that in the general 
population there are small effects from multiple interacting genes of 
the IL12/IL23/IFN pathway that have an effect.  Complex 
combinations of SNPs on many genes may have associations. 
The methodology used for this thesis, although scientifically sound, is 
now outdated, but could still be used for small scale screening.  During 
the extended time frame over which the work was done, methodology 
has rapidly expanded and advanced.  Today, screening can be done on 
a much larger scale, using techniques such as whole genome 
sequencing, with high throughput SNP platforms.  This way, 
associations between different SNPs in known candidate genes as well 
as novel association with, as yet, unidentified genes can be detected.  
Today many studies are also being done using gene expression 
patterns for identification of biomarkers (Mistry et al. 2007, Jacobsen 
et al. 2007, Berry et al. 2010, Lesho et al. 2011, Lu et al. 2011, Wang 
et al 2011, Maertzdorf et al. 2012, Ottenhof et al. 2012, Kaforou et al. 
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2013, Anderson et al. 2014). This methodology has the potential to 
distinguish between clinical TB groups such as active and latent 
disease and can identify subjects who are at risk of recurrent disease, 
as shown in a study by completed on South African adults (Mistry et 
al. 2007).  Other studies have shown it to be a powerful tool for 
discriminating between active TB, latent TB and uninfected individuals 
(Lu et al. 2011, Maertzdorf et al. 2012). 
Most of these studies have been done on adults, but a study done on a 
Warao Amerindian paediatric cohort identified a predictive 116 gene 
signature for discriminating active from latent TB disease (Verhagen et 
al. 2013).  Data from this study suggests that this signature be used 
as a biomarker for potential childhood TB diagnosis.  A recent study on 
childhood tuberculosis in Africa has identified tuberculosis-specific 
transcriptome signatures, capable of distinguishing tuberculosis from 
latent tuberculosis and other common infectious diseases that may 
mimic tuberculosis. Furthermore this study explored the diagnostic 
potential of these signatures and strongly suggested that gene 
expression signatures may have a future role in the diagnosis of 
childhood tuberculosis (Anderson et al. 2014). 
It would be informative to know which genetic defects may be 
associated with TB.  Today, rather than screening for single gene 
defects by association studies, whole genome sequencing may be 
performed to evaluate the effect of multiple gene polymorphisms and / 
or mutations on disease susceptibility to disease.  Furthermore, 
genetic expression studies are starting to yield insights about the 
pathogenesis of TB and the study of genetic polymorphisms in the 
context of these gene expression patterns has potential for providing 
greater understanding in this field. For example, in the recent study by 
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Berry, et al. 2010 showed that the TB signature identified in their 
study was dominated by a neutrophil-driven interferon inducible gene 
profile, suggesting that Type I IFN signalling may play an important 
role in TB pathogenesis.   
In conclusion, in this study two previously unreported polymorphisms 
within the IL12p40 promoter have been identified and documented in 
the SNP database for further studies  However, no significant 
differences were found between cases and controls for these variants 
and furthermore, it was not possible to demonstrate any functional 
effects of these sequence variants.  Thus, the IL12p40 promoter 
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